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Abstract 
Bronchiectasis is characterised by chronic cough productive of mucopurulent sputum 
and frequent exacerbations. We have aimed to validate clinical, biochemical and 
microbiological endpoints to aid planning of future interventional studies. We recruited 
fifty-eight subjects with bronchiectasis at the Lung Defence unit (Papworth Hospital, 
Cambridge) and studied them in stable state (no exacerbation in the preceding four 
weeks) and during an exacerbation over a period of two years. The results of our 
research are discussed in this study. Clinical symptoms: Cough chest pain, chest 
discomfort, colour and volume of sputum and fatigue measured by a visual analogue 
score are useful endpoints. Breathlessness is a reliable endpoint when measured using 
either a visual analogue score or modified Borg’s breathlessness score. Health related 
quality of life measured using the Euroqol questionnaire is a sensitive marker of 
change during an exacerbation. The St George’s respiratory questionnaire did not 
demonstrate a significant change during an exacerbation. Spirometry: Forced 
expiratory volume in the first second (actual and percentage predicted) and Forced 
vital capacity (percentage predicted) do not change during the course of an 
exacerbation. Forced vital capacity actual may be used as an endpoint. pH of exhaled 
breath condensate in bronchiectasis is lower than in healthy subjects but does not 
change during the course of an exacerbation. Sputum appearance is a valid endpoint 
while 24hour volume of sputum and microbial clearance and anti-pseudomonal 
antibody titres cannot be used. ESR and serum titres of IFN-γ, TNF-α IL-6, IL-8, IL-
10, IL-17 and IL-1β and titres in sputa of IFN-γ, IL-6, IL-17 do not change during an 
exacerbation. C-reactive protein and titres in sputa of TNF-α, IL-8 and IL-1β are 
effective indicators and can be recommended for use as end points in therapeutic 
interventional trials.  
iii 
 
Table of Contents 
Title          i 
Abstract         ii 
Table of contents        iii 
Tables and Figures        x 
Acknowledgements        xvi 
Chapter 1         1 
Introduction         1 
1.1 Non Cystic fibrosis bronchiectasis     1 
1.1.1 Background        1 
1.1.2 Prevalence of bronchiectasis      3 
1.1.3 Pathophysiology of bronchiectasis     4 
1.1.4 Aetiology of bronchiectasis      6 
1.1.5 Clinical features of bronchiectasis     8 
1.1.6 Diagnosis of bronchiectasis      12 
1.1.7 Therapeutics of bronchiectasis      12 
1.1.8 Prognosis of non CF bronchiectasis     17 
 
 
1.2 Acute infective exacerbations in bronchiectasis    19 
1.2.1 Defining an acute exacerbation in bronchiectasis    19 
1.2.2 Pathophysiology of an acute exacerbation in bronchiectasis              21 
1.2.3 Therapeutics of exacerbations in bronchiectasis    23 
 
1.3 Measuring outcome and setting end points for therapeutic trials                                
in bronchiectasis       24 
 
1.4 Quality of life in bronchiectasis                  28 
1.4.1 Background        28 
1.4.2 Determinants of quality of life in bronchiectasis    28 
iv 
 
1.4.3 HR-QoL and acute exacerbations in bronchiectasis   32 
 
 
1.5 Measuring lung function in bronchiectasis    33 
1.5.1 Background        33 
1.5.2 Spirometry in non CF bronchiectasis     34 
1.5.3 Use of spirometry as a biomarker in bronchiectasis   34 
1.5.4 Spirometry and prognosis in bronchiectasis    35 
1.5.5 Impulse Oscillometry (Forced Oscillation technique)         36                                    
and lung disease 
 
 
1.6 Exhaled breath condensate and bronchiectasis    38 
 
1.6.1 Exhaled breath condensate      38 
1.6.2 Exhaled breath condensate and lung disease    38 
1.6.3 Monitoring lung disease by measuring pH of exhaled        40                                                                                      
breath condensate 
1.6.4 Exhaled breath condensate and bronchiectasis    41 
 
 
1.7 The microbiology of bronchiectasis     41 
 
1.7.1 Background        41 
1.7.2 Potentially pathogenic microorganisms in bronchiectasis   42 
1.7.3 Bacterial colonisation of the lower respiratory tract in bronchiectasis 43 
1.7.4 Markers of infection in sputa      45 
1.7.5 Non tuberculous mycobacterial and bronchiectasis   46 
1.7.6 Anti-pseudomonal antibodies in bronchiectasis    47 
 
 
1.8 Cytokines and the lung in bronchiectasis     48 
 
1.8.1 Cytokines in bronchiectasis      48 
1.8.2 Lower airway inflammation and bronchiectasis    49 
1.8.3 Systemic evaluation of airways inflammation    52 
1.8.4 Cytokines as a marker of inflammation in therapeutic trials.  53 
 
 
 
 
Chapter 2         54 
 
The COBEX study        54 
 
 
2.1 Introduction        54 
2.2 Definition        55 
2.3  Objectives        55 
v 
 
2.4 Study design        57 
2.5 Ethical approval       57 
2.6 Funding        58 
2.7 Time frame        58 
2.8 Subjects        58 
2.9 Patient criteria        59 
2.10 Protocol        59 
 
 
Chapter 3         62 
 
Results          62 
Characteristics of patients in the COBEX study 
 
 
3.1 Study subjects        62 
3.2 Body mass index       63 
3.3 Smoking history       63 
3.4 Past medical history       65 
3.5 Diagnosis of bronchiectasis      65 
3.6 Aetiology of bronchiectasis      65 
3.7 Antibiotic therapy in bronchiectasis     67 
3.8 Domiciliary oxygen       68 
3.9 Mucolytic agents       68 
3.10 Vaccination history       68 
3.11 Chest physiotherapy       68 
3.12 Use of inhaled corticosteroid therapy     70 
3.13 Discussion        70 
 
 
 
Chapter 4         74 
 
Symptoms and clinical features in bronchiectasis    74 
 
4.1 Introduction        74 
 
4.1.1 Visual analogue score       74 
4.1.2 Borg’s breathlessness score      76 
 
4.2 Aims         78 
4.3 Methods        78 
4.4 Statistics        80 
4.5 Results         80 
 
4.5.1 Visual analogue scale       80 
4.5.2 Modified Borg’s breathlessness score     87 
 
4.5 Clinical examination       90 
4.6 Discussion        95 
vi 
 
 
 
Chapter 5         98 
 
Quality of life and bronchiectasis      98 
 
5.1 Background        98 
 
5.2 Measuring health related quality of life in bronchiectasis   99 
 
5.2.1 St George’s respiratory questionnaire     99 
5.2.2 Euroqol        100 
5.2.3 Assessment of HR-QoL during acute exacerbations in bronchiectasis 101 
 
5.3 Aims         102 
5.4 Methods        102 
5.5 Statistics        103 
 
5.6 Results         104 
 
5.6.1 St George’s respiratory questionnaire      104 
5.6.2  Euroqol        114 
 
5.7  Discussion        119 
 
 
 
Chapter 6         122 
 
Lung function tests 
Spirometry and Impulse Oscillometry in bronchiectasis   122 
 
6.1 Introduction        122 
6.2 Impulse Oscillometry (force oscillation technique)   123 
6.3 Aims         126 
 
6.4 Methods        127 
 
6.4.1 Spirometry        127 
6.4.2 IOS         127 
6.4.3 Equipment         128 
6.4.4 Statistical analysis       128 
 
6.5 Results         129 
 
6.5.1 FEV1         129 
6.5.2 FEV1 % predicted       131 
6.5.3 FVC         133 
6.5.4 FVC % predicted       135 
 
vii 
 
6.6 IOS         138 
6.7 Discussion        144 
 
 
 
Chapter 7         147 
 
Exhaled breath condensate and bronchiectasis    147 
 
7.1 Introduction        147 
 
7.1.1 Exhaled breath condensate      147 
7.1.2 pH of exhaled breath condensate     147 
7.1.3 Collection of exhaled breath condensate     149 
7.1.4 Markers of inflammation in exhaled breath condensate                              151 
and bronchiectasis 
 
7.2 Aims         152 
7.3 Methods        152 
 
7.4 Results         154 
 
7.4.1 Patient characteristics       154 
7.4.2 Stable state bronchiectasis      155 
7.4.3 Acute exacerbation of bronchiectasis     158 
 
7.5 Discussion        161 
 
 
 
Chapter 8         164 
 
The Microbiology of bronchiectasis 
Stable state and during exacerbations      164 
 
8.1 Introduction        164 
 
8.1.1 Use of qualitative analysis of sputum as an end point in        164                          
therapeutic trials of bronchiectasis 
8.1.2 Twenty-four hour sputum volume as a marker of infection  165 
8.1.3 Quantitative total bacterial counts as markers of infection  165 
8.1.4 Sputum appearance as a marker of infection.    166 
8.1.5 Non tuberculous mycobacterial analysis in bronchiectasis  166 
8.1.6 Obtaining sputum samples for analysis     167 
  
8.2 Aims         168 
8.3 Methods        169 
 
8.4 Results         171 
  
viii 
 
8.4.1 Sputum appearance       171 
8.4.2 24 hour sputum collection      173 
8.4.3 Qualitative analysis data      176 
8.4.4 Antibiotic prophylaxis and microbiological profile                                                
of the study cohort       181 
8.4.5 Quantitative analysis data      183 
8.4.6 Bacterial colonisation of lower airways in stable state bronchiectasis 184 
 
8.5 Discussion        186 
 
 
 
Chapter 9         190 
 
Anti-pseudomonal antibodies in bronchiectasis    190 
 
9.1 Background        190 
9.2 Aims          192 
9.3 Methods        193 
9.4 Results         193 
9.5 Discussion        198 
 
 
 
Chapter 10         216 
 
Serum inflammatory markers and capillary blood gas analysis                                      
in bronchiectasis        200 
 
10.1 Introduction        200 
 
10.1.1 C-reactive protein and bronchiectasis     201 
10.1.2 Erythrocyte sedimentation rate and bronchiectasis   202 
10.1.3 Total white cell count and bronchiectasis    203 
10.1.4 Serum albumin and bronchiectasis     204 
10.1.5 Capillary blood gas and bronchiectasis     205 
 
 
10.2 Aims         207 
10.3 Methods        207 
 
10.4 Results         209 
 
10.4.1 C-reactive protein       211 
10.4.2 Erythrocyte sedimentation rate      213 
10.4.3 Serum albumin        215 
10.4.4 Total white cell count       217 
10.4.5 Capillary blood gas       219 
 
10.5 Discussion        223 
ix 
 
Chapter 11         226 
 
Cytokines in sputa and sera of patients with bronchiectasis   226 
 
 
11.1 Introduction        226 
11.2 Tumour necrosis factor α (TNF α) and Interferon γ (IF γ)                                                                                               
and bronchiectasis       227 
11.3 IL-1β, IL-6, IL-8, IL-10, IL-17 and bronchiectasis   228 
11.4 Aims         231 
11.5 Methods        231 
11.6 Statistical analysis       232 
11.7 Results         233 
11.8 Discussion        238 
 
 
 
Chapter 12         240 
 
Summary and discussion for future work     240 
 
12.1 Summary        240 
12.2 Discussion for future work      241 
 
 
 
Chapter 13         246 
 
References         246 
 
 
 
Chapter 14         260 
 
Appendix         260 
 
14.1 Ethical approval notice (August 2006)     261 
14.2 Valid notice of substantial amendment     263 
14.3 Clinical record form       265 
14.4 Methodology of analysis of sputa     293 
 
 
 
 
x 
 
Tables and Figures 
 
Tables 
Table 2.1:  Summary of the visit schedule     61 
Table 3.1:  Demographic characteristics of patients and healthy                  64                                          
volunteers entered into the COBEX study    
Table 3.2:  Aetiology of bronchiectasis in subjects recruited to the    66            
COBEX study. 
Table 3.3:  Aetiology of bronchiectasis in the cohort that was            66           
followed through an acute exacerbation. 
Table 3.4:  Methods of physiotherapy employed by subjects    69                          
within the COBEX study. 
Table 3.5:   Frequency of physiotherapy techniques employed  69                                
by subjects within the COBEX study. 
Table 4.1:  The modified Borg’s breathlessness Score (MBS)  77 
Table 4.2:  VAS scores for symptoms for patients with   81                             
bronchiectasis at baseline  
Table 4.3:  VAS scores for symptoms for patients during   82                                      
an acute exacerbation of bronchiectasis. 
Table 4.4:  Mean (SD) values of Modified Borg’s score at        88                    
different time points during the exacerbation. 
Table 4.5:  Auscultatory findings in patients of the COBEX     94                                 
study in steady state bronchiectasis. 
Table 5.1:   Schedule of HR-QoL questionnaires employed               103                      
during an exacerbation of bronchiectasis. 
Table 5.2:  St Georges Respiratory Questionnaire      104                                                  
Outcome in stable state bronchiectasis  
Table 5.3:  Symptom score – St Georges respiratory questionnaire     105                      
scores during an exacerbation of bronchiectasis 
Table 5.4: Activity score – St George’s respiratory questionnaire                   107        
scores during an exacerbation of bronchiectasis 
xi 
 
Table 5.5:  Impacts score – St George’s respiratory questionnaire           110                 
scores during an exacerbation of bronchiectasis 
Table 5.6:  Total score – St George’s respiratory questionnaire                     112          
scores during an exacerbation of bronchiectasis 
Table 5.7: Euroqol scores in stable state and during an           115                         
exacerbation bronchiectasis 
Table 6.1:  Mean FEV1 during an exacerbation of bronchiectasis     129 
Table 6.2:  Mean FEV1% predicted during an exacerbation of                131     
bronchiectasis 
Table 6.3:  Mean FVC during an exacerbation of bronchiectasis     133 
Table 6.4:  Mean FVC% predicted during an exacerbation of                  135    
  bronchiectasis 
Table 6.5: Spirometry in patients colonised with bacteria      137 
Table 6.6:  Correlation between spirometric and IOS indices                             139        
in stable state bronchiectasis 
Table 6.7:  Correlation between spirometric and IOS indices             139                   
during an exacerbation of bronchiectasis 
Table 7.1:  Patient characteristics for the exhaled breath condensate                 154
   analysis arm of COBEX study 
Table 7.2:  Pearson’s correlation coefficient for                159                 
measured parameters and pH of EBC at baseline and                             
during the course of an exacerbation. 
Table 8.1:  Weight of sputa produced by patients at each visit of study.    174 
Table 8.2:  Microorganisms isolated in steady state and at onset of an               179         
exacerbation in patients followed through an exacerbation of 
bronchiectasis. 
Table 8.3:  Microorganisms isolated during the course of and on                 180           
recovery from an exacerbation of bronchiectasis. 
Table 8.4:  Key to Table 8.4                     180 
Table 8.5:  Antibiotic prophylaxis and microbiological profile of                      181                                               
the study cohort at baseline 
Table 8.6:  Total bacterial counts for all patients followed through          182                        
an exacerbation of bronchiectasis 
xii 
 
Table 8.7:  Mean (SD) log scale total bacterial counts of patients                      183                       
with PPM at all visits used for analysis of global test 
Table 9.1:  Antipseudomonal antibody titres at baseline                                     195 
Table 9.2: Key to Table 9.1         196 
Table 9.3:  Anti-pseudomonal antibody titres during the course          196                            
of an exacerbation. 
Table 10.1:  Systemic markers of inflammation in stable-state             209                   
bronchiectasis.  
Table 10.2  Pearson’s correlation coefficients between                                              
lung function measures and systemic markers                       210                                         
of inflammation  
Table 10.3:  CRP during the course of an exacerbation of bronchiectasis.     211 
Table 10.4:  ESR during the course of an exacerbation of bronchiectasis.            213 
Table 10.5:  Serum albumin levels during the course of an exacerbation             215             
of bronchiectasis.  
Table 10.6:  Total white cell counts during the course of an exacerbation           217            
of bronchiectasis  
Table 10.7:  Capillary blood PaO2 levels during the course of an                    219                  
exacerbation of bronchiectasis 
Table 10.8:  Capillary blood PaCO2 levels during the course of an                      221         
exacerbation of bronchiectasis 
Table 11.1:  Changes in cytokines levels in serum during the course                   235             
of an exacerbation of bronchiectasis 
Table 11.2:  Changes in cytokine levels in sputum between stable state              236            
and onset of an exacerbation 
Table 11.3:  Pearson’s correlation coefficient and significance levels                  237
  for sputum and serum cytokines. 
 
xiii 
 
Figures 
Figure 4.1: Visual analogue score for breathlessness during   83                           
an acute exacerbation of bronchiectasis 
Figure 4.2:  Visual analogue score for chest pain during        83                                     
an acute exacerbation of bronchiectasis.  
Figure 4.3:   Visual analogue score for chest tightness during              84                      
an acute exacerbation of bronchiectasis.  
Figure 4.4:  Visual analogue score for colour of sputum during    84                               
an acute exacerbation of bronchiectasis.   
Figure 4.5:  Visual analogue score for volume of sputum during       85                             
an acute exacerbation of bronchiectasis.   
Figure 4.6:  Visual analogue score for cough during                  85                               
an acute exacerbation of bronchiectasis.   
Figure 4.7:  Visual analogue score for fatigue during                                      86         
an acute exacerbation of bronchiectasis.  
Figure 4.8:  Change in modified Borg’s breathlessness score     89                         
during an acute exacerbation of bronchiectasis 
Figure 4.9:  Interval plot showing change in systolic blood pressure  91
  during an acute exacerbation of bronchiectasis    
Figure 4.10:  Interval plot showing change in diastolic blood pressure  91
  during an acute exacerbation of bronchiectasis    
Figure 4.11:  Interval plot showing change in oxygen saturations            92              
during an acute exacerbation of bronchiectasis 
Figure 5.1:  Symptom sub-score on the St George’s Respiratory         106      
questionnaire during an exacerbation of bronchiectasis. 
Figure 5.2:  Activities sub-score on the St George’s Respiratory           108      
questionnaire during an exacerbation of bronchiectasis. 
Figure 5.3:  Impacts sub-score on the St George’s Respiratory                 111    
questionnaire during an exacerbation of bronchiectasis. 
Figure 5.4:  Total score on the St George’s Respiratory questionnaire       113                   
during an exacerbation of bronchiectasis. 
Figure 5.5:  Total score on the Euroqol questionnaire during         116                           
an exacerbation of bronchiectasis. 
xiv 
 
Figure 5.6:  Correlation between Quality of life and total number of         117      
exacerbations experienced by patients in the preceding year.  
Figure 5.7:  Correlation between Quality of life and total daily         118                          
dose of inhaled corticosteroid being used by patients.     
 
Figure 6.1:  Interval Plot showing change in FEV 1 during an      130                      
exacerbation of bronchiectasis.  
Figure 6.2:  Interval Plot of FEV 1% predicted during an                   132         
exacerbation of bronchiectasis. 
Figure 6.3:  Interval Plot of FVC actual during an exacerbation       134                          
of bronchiectasis 
Figure 6.4:  Interval Plot of change in FVC% predicted during             136                            
an exacerbation of bronchiectasis. 
Figure 6.5:  Scatter plot depicting significant relationship between             140     
Resistance at 5Hz (R5) and FEV1 actual. 
Figure 6.6:  Scatter plot depicting significant relationship between     141                
Resistance at 5Hz (R5) and FEV1 %predicted. 
Figure 6.7:  Scatter plot depicting significant relationship between                   141 
Reactance at 5Hz (X5) and FEV1 actual. 
Figure 6.8:  Scatter plot depicting significant relationship between                  142     
Reactance at 5Hz (R5) and FEV1 %predicted. 
Figure 6.9:  Scatter plot depicting significant linear relationship     143                       
between resistance at 5Hz (R5) and RV/TLC. 
Figure 7.1:  Interval plot of depicting difference in EBC pH between  156                     
stable state bronchiectasis and healthy volunteers. 
Figure 7.2:  Interval plot of EBC pH when compared according               157              
to sputum appearance. 
Figure 7.3: Interval plot depicting change in EBC pH during        160                          
the course of an exacerbation. 
Figure 8.1:  Bar chart showing  change in appearance                                       172       
of sputa during an exacerbation of bronchiectasis 
Figure 8.2:  Interval plot demonstrating change in 24 hour sputum         175             
volume during the course of an exacerbation. 
Figure 8.3:  Interval plot demonstrating change in the mean bacterial count     185          
during the course of an exacerbation of bronchiectasis  
xv 
 
Figure 9.1:  Interval plots showing change in anti-pseudomonal                          197    
antibody titres in serum during the course of an exacerbation. 
Figure 10.1:  Box plot indicating change in C-reactive protein                             212           
during the course of an exacerbation. 
Figure 10.2  Box plot indicating change in ESR during the course of an             214 
exacerbation 
Figure 10.3:  Box plot indicating change in serum albumin during                       216        
the course of an exacerbation 
Figure 10.4:  Box plot indicating change in total white cell count during              218         
the course of an exacerbation 
Figure 10.5:  Interval plot indicating change in PaO2 during the course of an       220 
exacerbation 
Figure 10.6:  Interval plot indicating change in PaCO2 during the course of an     222 
exacerbation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xvi 
 
Acknowledgements 
 
 
I would like to thank Dr Diana Bilton for her help in formulating this project, support 
in acquiring the funding and her unconditional support at every stage. I would also like 
to thank Dr Juliet Foweraker for her advice and invaluable support in the 
microbiological aspects of this study. I am grateful to Dr Andrew Wilson for all his 
support. 
 
I am grateful to Mrs Christian Laughton for the laboratory training and guidance at all 
times. Mrs Jane French provided clinical support when required. Mrs Tracy Herod and 
Mrs Katrina Oates have been responsible for the lung functions tests carried out on all 
patients. Mrs Linda Sharples has provided invaluable help with the statistical analysis. 
 
This work has been funded by the Evelyn Trust (The Chequers, Preston, Hitchin 
Hertfordshire SG4 7TY) for the first year and by Papworth Hospital NHS Trust for the 
second year. 
1 
 
Chapter 1 
Introduction 
 
 
1.1 Non Cystic Fibrosis bronchiectasis 
 
1.1.1 Background 
 
This affection of the bronchia is always produced by chronic catarrh, or by some 
other disease attended by long, violent, and often repeated fits of coughing. 
R.T.H. Laënnec [1]  
Despite being regularly exposed to particulate matter containing bacteria from the 
environment, the healthy lung is kept “free of pathogens” by efficient defence 
mechanisms [2]. However structural abnormality of bronchi predisposes to recurrent 
infection. Bronchiectasis is a descriptive term for abnormal chronic dilatation of 
bronchi. Such damage is the end result of a vicious cycle of infection and inflammation 
arising from a number of causes either acquired or inherited [3, 4]. The age of 
presentation of bronchiectasis is 10-20 years after the causative incident. The initial 
insult results in structural damage to the airway. In time superimposition of chronic 
inflammation on the anatomic damage leads to further abnormalities and symptoms 
occur [5, 6]. This infection remains confined to the lung and has therefore also been 
referred to as ‘chronic bronchial suppuration’.  
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Bronchiectasis is the morphological definition of the disease characterised by 
permanent dilatation of the bronchi. It has been categorised according to the 
pathological appearance of the airways. This definition has remained for more than 
half a century. The more recent use of high resolution computed tomography (HRCT) 
has made the identification of this morphology only easier. Three distinct forms of 
bronchiectasis are described: Cylindrical or tubular, varicose and cystic bronchiectasis. 
Cylindrical bronchiectasis is dilatation of the airways alone, Varicose bronchiectasis is 
characterised by focal constrictive areas along these dilated airways. Cystic 
bronchiectasis is the term used for dilated airways that end in large cysts, saccules or 
grape like clusters [7, 8]. 
The disease itself can be focal and confined to a single lobe or segment of the lung. 
This may happen if bronchial luminal blockage occurs either due to a broncholith, 
foreign body [9] or a slow growing tumour.  A middle lobe syndrome may cause 
obstruction, collapse and consolidation of the distal lung and persistent suppuration 
[10]. Occasionally post-operative changes may result in a narrow bronchus that may 
cause distal bronchiectasis in time [11].  Diffuse disease is seen in more severe cases. 
This kind of disease is usually associated with a systemic aetiology such as cystic 
fibrosis (CF) [8, 12]. 
Bronchiectasis is generally classified into CF and non CF bronchiectasis. In this study 
we refer only to non CF bronchiectasis unless otherwise specified. 
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1.1.2 Prevalence of bronchiectasis 
 
Bronchiectasis unrelated to cystic fibrosis has been termed an “orphan disease”. There 
is little direct evidence for the incidence or prevalence of bronchiectasis. Hospital 
admissions and healthcare resource utilisation in the Finnish population has decreased 
by fifty per cent between 1972 and 1992 [13].  Following the introduction of antibiotic 
therapy, control of tuberculosis and effective vaccination for whooping cough and 
measles, there has been a decline in the incidence of bronchiectasis [3]. 
Currently it is estimated that more than 110,000 adults in the US have bronchiectasis 
[14]. This ranges from 4.2 per 100 000 persons aged 13-34 years to  271.8 per 100 000 
among those aged 75 years or older [4]. The annual death rate from bronchiectasis is 
estimated at 970 (NHLBI 1999). 
In the UK, in 2002-03, bronchiectasis accounted for 0.06% (7,605) of hospital 
consultant episodes. Seventy eight per cent of hospital consultant episodes for 
bronchiectasis required hospital admission. The mean length of stay in hospitals was 
10.5 days. For hospital consultant episodes for bronchiectasis, 15-59 year olds 
accounted for 37%, while over 75 years for 22% (Hospital Episode Statistics, 
Department of Health, England, 2002-03). In addition to this, up to 29% of patients 
with chronic obstructive airways disease may have evidence of bronchiectasis on high 
resolution computed tomography (HRCT) [15] . 
Bronchiectasis is more prevalent in developing countries but is not well characterised. 
Although with improved sanitation and nutrition, introduction of childhood 
immunization, and the early and frequent use of antibiotics a decline has been noted in 
its prevalence, the disease is still a problem in developing countries [16].  
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All reports from studies of adult patients confirm a predominance of women who are 
lifelong non-smokers. This is particularly notable in patients who have onset of 
symptoms in middle age and symmetrical lower lobe disease [16-21]. Mean age at 
presentation is between 57 and 67 years [17, 21, 22]. 
 
1.1.3 Pathophysiology of bronchiectasis 
 
Bronchiectasis is the irreversible dilatation of those airways that have a normal 
diameter of >2mm. This pathological dilatation is caused by the destruction of 
muscular and elastic components of the airways wall. This process of bronchial wall 
weakening is poorly understood. Rather than being a single process, it is accepted to be 
a result of a number of pathophysiological processes [23]. 
In health there are four possible outcomes for bacteria inhaled into the bronchial tree. 
Firstly there is immediate clearance by mucociliary apparatus [24]. Then there is 
asymptomatic carriage which occurs in some bronchitis patients between exacerbations 
[2, 25] and lastly this may be followed by either local mucosal inflammatory reaction 
or invasion of bronchial wall and lung parenchyma [2].  
The mucociliary system is the most important first line defence mechanism [26]. 
Anatomical or physiological dysfunction in the mucociliary apparatus results in 
impaired mucous clearance and retained secretions that are observed in bronchiectasis.  
Coordinated ciliary motion is essential to efficient bacterial clearance. In primary 
ciliary dyskinesia there is inherent ciliary dysfunction. Some bacteria also produce 
factors that slow and disorganise the beating of cilia. Ciliary dysfunction thus 
facilitates bacterial binding to the epithelial surface [26]. 
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Viscid secretions are commonly seen. The illness is related to thick retained secretions 
causing obstruction and mechanical distension of the airways. This distension may 
persist even when obstruction is cleared [8, 23]. Obstruction itself may cause 
parenchymal atelectasis perpetuating bronchial dilatation. Also fibrosis and scarring 
from parenchymal disease leads to traction on the bronchial walls [23]. 
The purulent secretions contain mucous glycoproteins and abundant amounts of DNA. 
DNA is an extremely viscous polymerised polyanion [27]. Variants of an amiloride 
sensitive epithelial sodium channel (ENaC) regulatory gene may also contribute to this 
effect [28]. 
The ionic content of secretions may also affect the mucociliary transport. Regulation of 
these features relies on active ion transport across a continuous epithelial layer and 
intact tight junctions. In animal studies Pseudomonas aeruginosa has been shown to 
disrupt these tight junctions. Separation of tight junctions has also been observed in 
human nasopharyngeal cultures infected with Haemophilus influenzae [29, 30]. 
Bacterial colonisation occurs in these secretions causing inflammation locally. This in 
turn causes bronchial wall damage and perpetuates infection. The most widely 
accepted theory is that of a vicious circle of trans mural infection and inflammation 
with mediator release This cyclical phenomenon is constant and results in significant 
morbidity [6, 31].  
The bacteria that cause bronchial infections possess a wide array of potential virulence 
factors. They may breakdown local immunoglobulin by cleaving protease antibodies or 
reduce viability of circulating macrophages [2]. Pseudomonas aeruginosa are seen to 
grow as continuous sheets over the mucous surface [32] and growth in such biofilms is 
resistant to opsonophagocytic killing by neutrophils [33]. Another interesting aspect in 
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the physiology of patients infected with Pseudomonas aeruginosa is that it is one of 
the limited bacteria that can synthesise hydrogen cyanide. This may be important in its 
pathogenicity. Cyanide is a highly toxic compound that diffuses rapidly into tissues 
and can inhibit aerobic respiration through its interaction with the terminal oxidases of 
aerobic respiratory chains. Pseudomonas aeruginosa can synthesise a respiratory chain 
terminated by a cyanide insensitive terminal oxidase [34]. It raises the issue of which 
symptoms of disease are related to prolonged exposure of lung tissue to cyanide. 
Many other mechanisms are implicated. Not all have been well studied to date. One 
such theory implicates Nitric oxide (NO) which has marked in vitro antimicrobial 
properties. Therefore a decrease in production of NO in bronchiectasis would result in 
reduced local bacterial killing, thus facilitating repeated infections and colonisation 
[35]. 
The relative contribution of host and microbial determinants need to be considered as 
this balance is the basis of the pathogenesis of bronchiectasis. Varied virulence factors, 
multiple adhesins on the bacterial surface and multiple mucosal receptors have been 
found for most pathogens. A greater understanding of these host-bacterial interactions 
should, in the future, lead to development of new treatment strategies [36]. 
 
1.1.4 Aetiology of bronchiectasis 
 
Mucociliary clearance is the first line defence against potentially pathogenic 
microorganisms (PPM). Kartageners syndrome, primary ciliary dyskinesia and 
Young’s syndrome result in defective mucociliary clearance. Ciliary immotility results 
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in pooled secretions that can act as a nidus for infection. Most patients will have a 
positive family history for a similar condition [37]. 
Childhood infection was a common cause for bronchiectasis. However with effective 
childhood vaccination strategies, measles and whooping cause are now less prevalent 
[38]. Yet up to 50% of patients may still have a post-infectious cause for their 
bronchiectasis [21]. Mycobacterial disease both typical and atypical is known to cause 
bronchiectasis. Mycobacterium avium complex in particular is known to have a 
subtype that affects older women usually in the right middle lobe and lingula. This is a 
very slow process [39]. Attributing bronchiectasis to a primary pulmonary infection is 
thought to be complicated as this relies on long term recall. Also patients with immune 
disorders are likely to suffer recurrent infections in childhood and this may cloud the 
history [40]. Fungal plugs and eosinophilic peribronchial inflammation seen in 
Allergic bronchopulmonary aspergillosis is also associated with bronchiectasis [40]. 
Hypogammaglobulinemia and HIV infection are also known to cause bronchiectasis 
[40]. Hypogammaglobulinemia can be classified into patients with low levels of 
Immunoglobulin G (Ig G) such as common variable immunodeficiency and Burton’s 
disease, and other forms such as Ig A deficiency and Ig G subclass deficiency [40]. 
Bronchiolitis oblitrans complicating lung transplant is also known to be associated 
with bronchiectasis [40]. 
Mechanical aspiration can cause repeated insults to the lung and result in bronchial and 
parenchymal damage. Patients with oesophagitis and oesophageal strictures are known 
to have a higher incidence of bronchiectasis [41]. A higher than expected rate of 
Helicobacter pylori sero-positivity is noted in these patients [42]. 
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Another group of patients with bronchiectasis is those with rheumatoid arthritis and 
inflammatory bowel disease. The bronchiectasis may precede the arthritis. It 
prevalence can vary between 3 – 30% in these patients [40, 43, 44]. Inherited disorders 
causing bronchiectasis may be genetic. An older age group at presentation makes 
genetic disorders less likely [5]. Consanguinity of parents is sometimes seen in up to 
37.2% of patients [45].  
Last but not least, a cause may never be found for the disease in many patients. This 
can be as high as 50% of a diseased population [45]. As treatment can be modified 
when a cause is found [18], these patients may miss the opportunity of optimal 
therapeutic benefit.  
 
 
1.1.5 Clinical features of bronchiectasis 
 
Virtually all patients with bronchiectasis have a cough [8]. In a large retrospective 
study from Texas, cough was reported by 90% of the cohort [5]. In a similar group of 
patients studied in stable state, 40% had a cough for more than 50% of days. The 
presence of this habitual coughing has been shown to exert a relative influence on 
Health related quality of life (HR-QoL) [46]. In the paediatric population reports of 
symptoms vary. Chronic cough has been reported as the commonest presenting 
symptom (83.3% of patients) in some studies [28, 45] while other workers have 
reported it as the second most common symptom after repeated chest infections [47]. 
Patients often suffer social embarrassment from their cough [40]. The aetiology of 
cough may be multi factorial. Neutrophilic inflammation within the airways in 
bronchiectasis is thought to cause an acidic environment. Endogenously reduced pH 
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causes potential discharge in Aδ and C fibres of airway afferent nerves in guinea pigs 
both of which mediate the cough reflex [48]. Also thick viscous sputum in larger 
airways induces cough [40].  
Sputum produced has variously been described as mucoid, mucopurulent, thick, 
tenacious, or viscid. Blood-streaked  sputum or copious haemoptysis may be seen as a 
result of erosive airway damage caused by infection [8]. Patients may produce mucoid 
sputum early in their disease, developing purulent sputum when they suffer an 
exacerbation [20]. Haemoptysis has been reported to be a frequent phenomenon 
(51.2%) with the episodes tending to recur and at least one episode when the 
haemoptysis exceeds a tablespoon of blood. Daily sputum producers are more frequent 
than patients who only produce sputum during an exacerbation [5]. Other groups have 
reported a lower frequency of only 20% of patients complaining of haemoptysis [46]. 
In the paediatric population this is less common. Young children rarely expectorate 
sputum [49]. The volume of sputum is thought to increase during an exacerbation. This 
may paradoxically reduce if the secretions are sticky and difficult to clear [50]. Sputum 
volume is correlated with the quality of life and decline in lung function [40, 46, 51]. 
Dyspnoea is another commonly reported symptom. A variety of expressions such as 
"out of breath," "can't breathe," or "chest tightness” can be used by patients when 
describing their symptoms. This suggests that each patient has a different rather than 
single sensory experience [52].  Aetiologically this may be related to mucous plugging 
or to increased inflammation within the airways. Up to 71% of patients may complain 
of dyspnoea in one form or another [5]. It is less common in the paediatric group and 
reported in much lower frequency [8.8%] [45]. Some subscales of the St Georges 
Respiratory Questionnaire  are significantly correlated to dyspnoea, daily sputum 
production and wheeze  [53]. A lower dyspnoea score is a predictor of mortality [21].  
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Chest pain may be pleuritic and present in 20-30% [5, 40]. These range from dull aches 
to sharp pains. Joint pains may also occur [50]. 
Fevers are reported as common by some [5] and rare by others [50]. Our experience is 
that it is an uncommon finding. 
Chronic rhino sinusitis may be present. Frequency has been reported from 20-30% [20] 
to 60-70% of patients and ranges in severity from a  mild postnasal drip to fulminant 
pan sinusitis [40]. 
Fatigue is a symptom that needs specific questioning but may be a dominant symptom 
for up to 70% of patients [40]. These symptoms are often out of proportion to the 
severity of disease and accepted by the patient as they are long term issues [50]. 
Recurrent lower respiratory tract infections are common [28] and patients often seek 
help. Children may show failure to thrive and reduced exercise tolerance [47].  
Bronchiectasis may be complicated by lung abscesses, pneumothorax and empyaema 
[40]. 
Regardless of the aetiology, symptoms include chronic cough, mucopurulent sputum 
production, haemoptysis, dyspnoea and tiredness. Although chronic suppuration is 
present, clinical manifestations of sepsis are infrequent. Pyrexia is not commonly 
reported in bronchiectasis. It is not complained of by patients and is rarely recorded 
during inpatient episodes. This may be due to a tolerance that is developed by patients 
to persistent sepsis.  
Digital clubbing was commonly described in the past. More recent reports suggest a 
prevalence of only 3% [5, 8]. Clubbing may be seen as part of an entity called 
hypertrophic osteoarthropathy which include periostitis, arthritis and sometimes 
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thickening and oedema of the skin around the affected joints. Pulmonary diseases such 
as bronchiectasis and cystic fibrosis are known to be associated with hypertrophic 
osteoarthropathy. Hypertrophic osteoarthropathy is due to the peripheral impaction of 
megakaryocytes and platelet clumps in the fingers and toes, to which this particulate 
matter has passed in an axial stream. The normal pulmonary vascular bed retains these 
large particles, which fragment before entering the systemic circulation. A right-to-left 
shunt allows them to bypass the pulmonary vascular bed. Platelets contain and release 
platelet-derived growth factor, whose known effects could explain all the pathological 
changes in clubbing. It may be associated with severe bronchiectasis and is less 
frequently reported in milder forms [54].  
Adventitious breath sounds on auscultation of the chest include crackles, wheezing and 
ronchi [8]. A clear chest does not exclude the diagnosis. 
Hemodynamic alterations due to bronchiectasis have been described [55, 56]. Left 
ventricular diastolic dysfunction has been described in patients with cystic fibrosis and 
bronchiectasis [57]. Right ventricular systolic dysfunction and pulmonary hypertension 
is more common than left ventricular systolic dysfunction in bronchiectatic patients 
[58]. Right ventricular systolic function may be impaired in both these groups which 
may be reflected in systemic blood pressure measurements 
Most patients with bronchiectasis will have visible abnormalities on CT scanning of 
their nose and sinuses ranging from mild mucosal thickening to pan sinusitis. Rhino 
sinusitis is common and can be present in up to 70% of patients [40]. Chronic fatigue 
is another symptom that most  patients complain of. It needs specific questioning and 
may be present in up to 70% of patients [40, 51]. 
 
12 
 
1.1.6 Diagnosis of bronchiectasis 
 
Ninety per cent of chest radiographs are abnormal in patients with chronic cough and 
phlegm who have bronchiectasis. These findings are nonspecific and may include focal 
pneumonitis, scattered irregular opacities, linear atelectasis or dilated thickened 
airways that appear as tram lines [5, 8]. However with the introduction of high 
resolution CT (HRCT) scanning, it has become much easier to diagnose 
bronchiectasis. The standard HRCT criteria are well established [40, 59]. The most 
specific criteria are internal diameter of bronchus wider than its adjacent artery and 
failure of the bronchi to taper. These criteria are based on comparisons between HRCT 
and subsequently resected lung samples [59].  
 
Spirometry shows a limitation of airflow in bronchiectasis [8]. Mucous plugging and 
bronchial inflammation results in this moderate airway obstruction [40].  A reduced 
forced vital capacity is often noted but is not diagnostic by any means.  Airway hyper-
responsiveness is also noted in up to 40% of patients  [60]. This may lead to a 
misdiagnosis of asthma in the early stages. This is thought to secondary to bronchial 
inflammation [59]. 
 
1.1.7 Therapeutics of bronchiectasis  
 
Identifying the underlying cause of bronchiectasis helps in directing treatment [18]. 
Once treatable causes of bronchiectasis have been excluded, principles of management 
include identification and treatment of acute exacerbations, suppression of microbial 
load, reduction of excessive inflammatory response, promotion of bronchial hygiene, 
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control of bronchial haemorrhage and surgical removal of damaged segments of lung 
when appropriate [8]. 
 
1.1.7.1 Prevention of microbial infection and suppression of microbial load 
 
In the majority of population, treatment is largely confined to rescue antibiotics during 
an exacerbation. This has a limited effect on chronic infections and disease 
progression. Antibiotic prophylaxis therefore is an appealing strategy [61].  
The most commonly isolated pathogens are Haemophilus influenzae, Pseudomonas 
aeruginosa and Streptococcus pneumoniae [8]. Pseudomonas aeruginosa is associated 
with increased sputum production and poorer quality of life [8, 62]. Reduction in the 
sputum volume may improve the quality of life [61].   
 
Resistance to β-lactams in subjects with Haemophilus influenzae, Streptococcus 
pneumoniae or Moraxella catarrhalis increases from 11% to 26% and resistance to 
gentamicin in subjects with Pseudomonas aeruginosa increases from 13% to 49% over 
a 5 year period when treated with these antibiotics [17] . Patients with resistant bacteria 
are significantly more likely to be hospitalised and have a greater number of 
exacerbations in a year [17]. The use of regular systemic prophylactic antibiotics 
therefore may be problematic due to side effects and development of antibiotic 
resistance [63]. It is important to encourage outpatient parental antibiotic use and use 
of multiple antibiotics simultaneously to try and reduce resistance [17]. 
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In an attempt to reduce the use of systemic antibiotics, inhaled or aerosolised 
antibiotics have been tried. Inhaled aerosol produces a high concentration of the drug 
locally and reduces systemic absorption. They have a better side effect profile and 
systemic complications are fewer. Side effects include unpalatable taste, expense and a 
hoarse voice. There is a small risk of bronchospasm with inhaled antibiotics. The most 
important drawback is that aerosolised antibiotics do not penetrate the deep lung. As a 
result there is a concentration gradient between the proximal and distal airways. This 
gradient encourages antibiotic resistance [64]. Coughing and haemoptysis are other 
limiting factors in the adoption of aerosolised antibiotics in bronchiectasis [64]. 
 
Aerosolised Tobramycin has also shown to increase significantly the time to 
exacerbation in patients with cystic fibrosis [65]. A statistically significant fall in 
bacterial density has been reported at 7 days after therapy with inhaled Tobramycin   
[3, 66, 67]. Nebulised aminoglycosides improve sputum Pseudomonas aeruginosa 
density  and myeloperoxidase levels in bronchiectasis [68]. The regular use of inhaled 
Tobramycin or Colistin can decrease exacerbations of lung disease, decrease bacterial 
counts, and improve pulmonary function in patients colonised with Pseudomonas 
aeruginosa [3]. Significantly fewer admissions were noted in a randomised control 
trial where the active group received aerosolised Ceftazidime and Tobramycin for 12 
months [69]. 
Various regimes including a single antibiotic on and off for alternate months and 
different antibiotics for alternate months have been used. The safety and effectiveness 
of these strategies are yet to be established [64]. 
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1.1.7.2 Anti-inflammatory therapy. 
 
Inflammatory mediators are implicated in the pathogenesis of bronchiectasis. It would 
therefore follow that suppression of this inflammation locally with inhaled 
corticosteroid therapy may be beneficial. Indeed in stable state bronchiectasis, inhaled 
corticosteroids improve 24hour sputum volume. The improvements in spirometric 
indices are small or none at all. Sputum purulence remains unchanged. 
Symptomatically cough is improved but exacerbation frequency is not altered [70, 71]. 
Daily sputum producers became unproductive when treated with long term 
Azithromycin. The mechanism of action of Azithromycin is not fully known but 
immune-modulatory effects seen in lung transplant patients along with antimicrobial 
effects are thought to be responsible [61]. The anti-pseudomonas effect of 
Azithromycin may represent an inhibitory effect on quorum sensing, biofilm 
formation, production of immune-stimulatory exoproducts and the inflammatory 
response to the organism [72, 73]. Low dose erythromycin is also known to down 
regulate glycoconjugate release and improves lung function and reduces sputum 
production. However the long term effects are unknown [74].  
 
1.1.7.3 Broncho-pulmonary hygiene and bronchiectasis 
 
Airway clearance is an integral component in the management of bronchiectasis. 
Physical therapy and mechanical aids in chest physiotherapy are used. The traditionally 
used method of postural drainage (PD) is now replaced by the active cycle of breathing 
technique (ACBT). ACBT comprises breathing control, thoracic expansion exercises 
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and forced expiratory technique and postural drainage. Some of these can be done 
independently while percussion and vibration need more than one person. The flutter 
valve is a simple mechanical device that produces oscillating pressure on exhalation, 
which helps loosen secretions and prevent airway closure. Acapella is a handheld 
device which combines positive expiratory pressure with high-frequency oscillation 
therapy. 
While efficacy is vital, tolerability of the procedure is an important consideration. PD 
is less tolerated when patients suffer with gastro-oesophageal reflux. Discomfort and 
lack of time also give mechanical aids an edge over physical therapy. Early 
acceptability and tolerability are likely to be influential in preference and ultimately 
adherence [22]. While ACBT-PD has been perceived as significantly more useful in 
clearing sputum, it also causes more discomfort and is time consuming. Patients prefer 
a flutter valve to ACBT-PD. Sputum volume is also more when patients use ACBT-PD 
[22].  
Airway clearance technique prescriptions are for life. Those that can be performed 
independently in the domiciliary setting are likely to influence adherence.  
 
 
1.1.7.4 Surgery and bronchiectasis 
 
The role of surgery is limited in the post antibiotic era. The goals of surgery include 
removing foreign bodies, obstructing tumours, elimination of segments that may be 
contributing to acute exacerbations and removal of lobes if suspected to cause 
haemorrhage [8]. 
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Lung transplant (LT) can be successfully performed on patients with advanced 
bronchiectatic lung disease with subsequent good post-transplant quality of life. 
Despite the presence of chronic lower respiratory tract infection with bacterial 
pathogens in these patients pre-transplant and post-transplant infections do not 
generally have significant impact on survival, although infection with antibiotic-
resistant bacteria may complicate post-transplant management [75]. 
 
 
1.1.8 Prognosis in non CF bronchiectasis 
 
Bronchiectasis is commonly disabling but not a fatal disease. The prognosis of patients 
with bronchiectasis remains unclear. While quality of life may be compromised fatality 
is uncommon. Survival rates are as high as 97%, 89%, 76% and 58% at 1, 2, 3 and 4 
years respectively. The mean survival time is estimated as 44±1.6 years [21]. 
Comorbidities increase the suffering in patients with bronchiectasis. It is often difficult 
to assess if these comorbidities are the cause or result of the bronchiectasis. Sinusitis is 
seen in up to 31% of patients while gastro-oesophageal reflux is reported in 17% of 
patients [22]. 
No significant radiological deterioration is seen to occur over periods almost as long as 
a decade. The annual fall in FEV1 may be small but some patients go on to develop 
respiratory failure [5]. The average age at death has increased in the last few decades 
and the cause of mortality is now mostly related to respiratory failure [76]. 
In cystic fibrosis it is recognised that patients with chronic infection with Pseudomonas 
aeruginosa have reduced survival and a more rapid decline in lung function than 
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patients with chronic infection with Staphylococcus aureus [77]. The evidence in non 
CF bronchiectasis is limited and conflicting. It is possible that Pseudomonas 
aeruginosa in non-CF bronchiectasis can cause accelerated decline in lung function but 
this can be modified by the use of nebulised antibiotic therapy [4]. 
Long term mortality is thought to be significantly associated with age, body mass 
index, MRC dyspnoea scale, vaccination, radiographic extent, hypoxemia, 
hypercapnia, and functional parameters [21]. 
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1.2 Acute infective exacerbations in bronchiectasis 
 
1.2.1 Defining an acute exacerbation in bronchiectasis 
 
A patient may identify an acute exacerbation in bronchiectasis. The clinician or 
researcher is usually guided by this to initiate treatment. No standard definition has 
been proposed or accepted as yet for an exacerbation in bronchiectasis. However in an 
attempt to understand, describe and measure an exacerbation various definitions have 
been used.  
 
A glance at practice in other respiratory diseases may be useful. In chronic obstructive 
pulmonary disease, increasing dyspnoea, sputum production and worsening sputum 
purulence is sometimes used whilst describing an exacerbation [78].  In Cystic fibrosis, 
a significant fall in lung function (measured as >200 mL reduction in the forced 
expiratory volume in 1st second (FEV1), together with three or more of: increased 
cough or shortness of breath; increased sputum volume; increased sputum purulence; 
haemoptysis; fever (>37.5°C); new or increased crackles heard in the chest; new 
shadowing on chest X-ray and weight loss is often used [79]. 
 
In a previous study testing the therapeutic effect of Deoxyribo nuclease, authors chose 
a variety of symptoms of which patients have only had to achieve 4 of 9 to achieve a 
protocol defined exacerbation. These included (i) change in sputum production 
(consistency, colour, volume or haemoptysis); (ii) increased dyspnoea (chest 
congestion or shortness of breath); (iii) increased cough; (iv) fever (38°C) (v) increased 
wheezing (vi) decreased exercise tolerance, malaise fatigue or lethargy; (vii) FEV1 or 
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FVC decreased by 10% from a previously recorded value; (viii) radiographic process 
indicative of a new pulmonary process; or (ix) changes in chest sounds [27]. 
 
Duration of symptoms can occasionally guide the definition. In a trial of inhaled 
corticosteroids, an exacerbation was defined as deterioration for more than 24 hours in 
at least three respiratory symptoms (including cough, dyspnoea, haemoptysis, 
increased sputum purulence or volume, and chest pain) with or without fever 
(≥37.5°C), radiographic deterioration, systemic disturbances or deterioration in chest 
signs [71]. 
 
Strict criteria can make patient recruitment to a project difficult. Simpler definitions are 
sometimes used in an attempt to include more patients. In a prospective adult cohort 
study assessing the effect of 2 weeks of intravenous therapy, increasing cough, sputum 
production and sputum purulence was adopted as a definition [80]. 
 
Choosing a symptom and sign along with an optimal duration of these parameters 
appears critical. An increase in the sputum volume usually over a 24 hour period 
remains invariable in most definitions [21, 46, 61]. Change in sputum colour, viscosity 
or purulence seems to be common and is frequently included [21, 46, 61]. 
Breathlessness, chest discomfort and haemoptysis are less often added. All these 
symptoms are experienced by patients and may be transient. Therefore the duration of 
symptoms is important. Most groups stress the need for symptoms to persist for more 
than 24hours [21, 46, 61]. 
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Our group has previously studied the therapeutic use of inhaled Tobramycin in the 
treatment of an exacerbation of bronchiectasis [3]. The criteria used to define an ‘acute 
exacerbation’ was the presence of at least two of the following symptoms: increased 
cough, increased volume of sputum produced, increased sputum purulence, increased 
dyspnoea or increased wheezing; and at least one of the following: fever ≥38°C, 
malaise. This definition has been adhered to for the purpose of this study. 
 
There is continuing difficulty in both research and clinical practice in distinguishing 
exacerbations from day-to-day symptom variation [81, 82]. Further research with 
symptom diaries would be required to validate definitions of acute exacerbations in 
bronchiectasis. This is beyond the scope of this study. 
 
1.2.2 Pathophysiology of an acute exacerbation in bronchiectasis 
 
Morbidity associated with bronchiectasis is related to recurrent exacerbations and HR-
QoL [80, 83]. While our understanding of the pathophysiology of stable state 
bronchiectasis has progressed, little is known about the changes that occur during an 
acute exacerbation [2].  These episodes are probably related to a complex relationship 
between host defence and airway microbiology that impacts on sputum production and 
airflow obstruction.  
 
Knowledge from the world of CF may provide us with clues. For instance it is possible 
that viral infections trigger these episodes when bacterial colonisation is already 
present [84, 85]. Perhaps, as in chronic obstructive airways disease, acquisition of new 
strains of a colonising organism alters the fine immune balance [86]. Bacterial 
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clearance at the end of antibiotic treatment is seen to be associated with reduced 
sputum volume [80].  
 
More work remains to be done to provide evidence to support these assumptions for 
patients with bronchiectasis [84]. Borrowing theories from CF has previously not 
worked.  While deoxyribonuclease 1 is an effective treatment in patients with CF, these 
benefits are not directly transferable to patients with bronchiectasis [27] Most studies 
of preventive and treatment strategies of respiratory exacerbations in bronchiectasis 
have been undertaken at a single centre and have included small patient numbers where 
power calculations have not been reported and where the definitions of exacerbations 
have been limited [84]. Table 1.1 lists the possible causes of an exacerbation in 
bronchiectasis. This is by no means an exhaustive list. 
 
 
Table 1.1: Some possible causes of an acute exacerbation in bronchiectasis 
       Possible cause 
 
1. New bacterial infection 
2. New strain of existing bacteria causing  infection 
3. Change in bacterial density i.e. sudden growth in numbers 
4. Viral infection 
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1.2.3 Therapeutics of exacerbations in bronchiectasis  
 
1.2.3.1 Antibiotic treatment of acute exacerbations of bronchiectasis. 
 
Antibiotic therapy is complex in bronchiectasis and includes short-term empirical 
treatment for acute exacerbation [87]. The choice of antibiotics is usually guided by 
previous isolates of potentially pathogenic microorganisms (PPM) in sputa.  The 
optimum period of treatment is also unknown but patients often require longer courses 
of antibiotics. While therapy has been administered for between 5 and 28 days, a 
period of 14 days is common practise [80].  
It is unknown if there is benefit from stopping prophylactic antibiotics at the time of an 
exacerbation. Most published studies have included patients if they were already on 
prophylactic antibiotics [80]. Two studies have shown clear benefit in 24 hour volume, 
microbial clearance and HR-QoL when patients are treated for a period of 14 days 
based on previous microbial sensitivities. We are therefore guided by these at the time 
of the study [80, 83]. Since then the British thoracic society have published guidelines 
that recommend 14 days of antibiotic treatment [88]. 
 
1.2.3.2 Active chest physiotherapy in exacerbations of bronchiectasis 
 
Limited information is available on exercise training in patients suffering an acute 
exacerbation of bronchiectasis Postural drainage and percussion represent the 
physiotherapist's mainstay in dealing with exacerbations of chronic obstructive disease. 
Similar manoeuvres may increase production of sputum and produce improvements in 
pulmonary function in bronchiectasis [89]. 
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 Effective physiotherapy could influence the frequency and outcome of an acute 
exacerbation. This has not been previously systematically studied. 
 
1.2.3.3 Other modalities of treatment of an exacerbation in bronchiectasis. 
 
Patients with bronchiectasis have a chronic low grade infection and inflammation, 
punctuated by exacerbations. These are characterised by increased inflammation 
locally often triggered by infection, exposure to aero-irritants, or gastric contents [64].  
It would therefore be reasonable to trial systemic or inhaled anti-inflammatory agents 
in the acute phase. However this study remains to be done and for the purpose of this 
thesis patients did not require adjunctive therapy in addition to antibiotics. 
 
 
1.3 Measuring outcome and setting end points for therapeutic trials in 
bronchiectasis 
 
“How will I know when my treatment has been clinically successful?” From an 
uninitiated observer the answer to this would be “when an increase in life expectancy 
and/or quality of life as measured by treatment burden, time in hospital, or similar has 
been reached” [90]. 
Markers of disease activity in bronchiectasis fall into the categories of inflammation, 
infection, imaging and lung physiology. With regard to stable state bronchiectasis a 
large cohort of patients would need to be studied for long periods of time to show 
significant benefits in treatment [90]. Currently a successful outcome relies 
predominantly on the subjective assessment of symptom resolution [80].  
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Spirometry - FEV1 (forces expiratory volume in the first second), FVC (forced vital 
capacity) has traditionally been used in lung disease to measure change. Longitudinal 
studies have been used to predict disease progression or the natural history of lung 
disease [91, 92]. It has historically also been used to study acute exacerbation in lung 
disease [91]. It is therefore not surprising that it has been frequently employed within 
studies of bronchiectasis to assess functional state and measure change. 
FEV1 and FVC reflect changes in the calibre of bronchi. In bronchiectasis the 
bronchial walls may be inflamed. Anti-inflammatory medication such as inhaled 
corticosteroid may reduce this inflammation. FEV1 and FVC were therefore useful end 
point to use in assessing response to inhaled fluticasone in a randomised controlled 
trial. However there was no significant change noted on treatment in these indices [71]. 
Secretions may accumulate in saccules of the wall within the bronchi. Also active 
bacterial invasion is thought to happen at the mucociliary surface. Trialling antibiotics 
by measuring change in spirometric indices would then be reasonable. Both 
aerosolised and long term oral antibiotics have been tested for efficacy in 
bronchiectasis. Spirometric indices failed to show an improvement but were used as 
end points in these studies [3, 61, 64]. It could be assumed that cleaving viscous 
sputum may decrease obstruction and improve compliance of lungs. In a study of the 
efficacy of DNase as a mucolytic in bronchiectasis, a fall of 1.7% in FEV1 was noted 
in the placebo arm including 176 patients. The therapeutic arm however noted an even 
greater fall in the FEV1 [27]. Although used frequently, spirometric indices need to be 
studied systematically in bronchiectasis. Their usefulness as end points is yet to be 
proven. 
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Frequency of exacerbations, counting episodes of hospitalisation, and time to 
exacerbation may be end points. Inhaled corticosteroids and additional antibiotic 
regimes have also failed to decrease the frequency and time to exacerbation [3, 93]. 
Indirect measurements such as requirement of intravenous antibiotics per month have 
also been used as end points [94]. 
 
Twenty four hour sputum volume is an attractive end point. Dyspnoea as measured on 
the Medical Research Council scale, forced spirometry functional variables, daily 
sputum volume, short-acting β2- agonist dosage, and HR-QoL are all significantly 
related to sputum volume [46]. Inhaled fluticasone and prophylactic oral Azithromycin 
reduce sputum volume significantly [61, 71]. Also in acute exacerbations of 
bronchiectasis 24 hour sputum volume is significantly reduced on treatment with 
antibiotics [80]. Twenty-hour sputum volume appears useful as an end point. 
 
Microbial presence in sputum is the hallmark of this disease. Microbiological culture 
of sputum is therefore critical to any study in bronchiectasis. Sputum appearance alone 
is useful and a purulence score has been successfully used as a marker of disease [71].  
Sputum bacterial density [64], sputum microbiology and microbial clearance [61, 80, 
83] have also been used as markers of disease to study outcome in therapeutic trials. 
Any study in bronchiectasis would be incomplete without a microbiological analysis of 
sputum. 
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Whilst symptoms may appear difficult to quantify, attempts have been made to 
measure them scientifically.  Dyspnoea has been measured on the Medical Research 
Council scale [46]. Indirectly HR-QoL questionnaires can assess patient’s symptoms 
and a specific cough questionnaire was designed in Leicester that has been validated in 
bronchiectasis [95]. The St George Respiratory questionnaire is validated in 
bronchiectasis [53].  
 
Improvements in inflammation may be associated with improvement in bronchiectasis 
symptoms. Biochemical measures of inflammation in sputum or serum can be 
measured to assess outcomes [80]. Functional outcomes are also important and 
although lung function parameters may not be helpful, a walk test such as the 
incremental shuttle walk is worth exploring [80]. Finally arterial blood gas changes 
may also prove useful [21]. 
 
Outcome-based measurements are important to guide health care delivery [96]. 
Respiratory tools therefore can play an important role in maximizing positive 
outcomes from therapy [97]. These outcome measures need to be validated, easily 
accessible and relevant [98]. In an attempt to understand which markers of lung disease 
are sensitive in predicting the outcome of treatment we have conducted a prospective 
longitudinal study that we hope will add more information to the current understanding 
of exacerbations in non CF bronchiectasis. 
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1.4 Quality of life in bronchiectasis 
 
1.4.1 Background 
 
In patients with chronic lung disease, the relationship between changes in symptomatic 
and functional state and conventional physiological indices is often weak [99, 100]. 
This is seen particularly in interventions such as respiratory rehabilitation programmes, 
in which patients are taught to cope with their physiological limitations [101]. Direct 
measurement of the impact on patient’s lives is therefore necessary to assess whether 
interventions are of benefit [100]. 
Health-related quality of life (HR-QOL) is therefore a relevant and quantifiable 
outcome of care. HR-QoL is impaired in stable state bronchiectasis and deteriorates 
during an acute exacerbation [83, 102]. HR-QoL is a potentially important marker for 
evaluating existing and new therapies in bronchiectasis. 
 
 
1.4.2 Determinants of quality of life in bronchiectasis 
 
Most aspects of bronchiectasis impact on the quality of life. Symptoms are experienced 
in mild disease, even in stable state. These deteriorate during an exacerbation and exert 
a greater impact. Appropriate management of symptoms on identifying the underlying 
aetiology has a positive impact on the quality of life in these patients. 
Demographically, age does not impair the quality of life, but women with 
bronchiectasis report poorer quality of life scores on physical functioning and social 
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functioning than males. A gender-related difference in response to chronic disease is 
important in tailoring an education and management plan to each individual patient. 
Evidence indicates that males and females perceive their health status differently, with 
females having a more accurate perception of objective clinical health status [102, 
103]. 
The amount of sputum produced by patients with bronchiectasis is a fundamental 
symptom that interferes decisively with HR-QoL. In stable state bronchiectasis, on 
analysis of variables influencing the different questionnaire subscales, daily sputum 
production explains a greater per centage of the variance of the symptoms subscale 
than dyspnoea alone. The amount of sputum produced accounts for over one fourth of 
the variance of the symptoms subscale (27%), while on adding dyspnoea to the 
analysis the explanation of variance increases by only 11%, while the cumulative effect 
accounts for 38% of the variance of the symptoms scale [53]. In the activity sphere, 
dyspnoea as measured on the Medical research council scale is an important variable 
that exerts an influence. A poorer activity score has been implicated as an independent 
variable among patients who have received repeated courses of steroid treatment [46, 
104]. 
Chronic productive cough is a common symptom in patients with bronchiectasis that is 
associated with a reduction in HR-QoL. Bronchopulmonary hygiene physical therapy 
(BHPT) is widely prescribed for patients with bronchiectasis, although the evidence for 
its efficacy is limited. As little as a 4 week outpatient-based BHPT regime can lead to a 
significant improvement in cough-related quality of life [105]. 
Upper airway symptoms are also frequent in patients with bronchiectasis. Associations 
between upper and lower airways diseases have been demonstrated in other respiratory 
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conditions including asthma (allergic rhinitis & nasal polyposis) and chronic 
obstructive lung disease (chronic rhinosinusitis). However while bronchiectasis itself 
has a considerable impact on the quality of life, upper airway symptoms have no 
additional impact on the quality of life of patients with bronchiectasis [102]. 
Patients with bronchiectasis often complain of abnormal tiredness, difficulty in 
concentrating or low spirits. Moderate-severe anxiety is more frequent than equivalent 
levels of depression. Anxiety and depression scores are associated with perceived 
health status. Up to 34% of patients have elevated scores for anxiety, depression or 
both. Therefore, treatment aimed at reducing symptoms and improving exercise 
capacity alone will not reduce levels of anxiety which requires alternative therapy 
[106]. 
The number of exacerbations in the previous year also seems to influence the quality of 
life. Some studies suggest that this is an important contributor while others have found 
hospital patient admissions due to exacerbation of the disease to be only weakly related 
to HR-QoL score as measured by the SGRQ [46, 53]. 
However after the onset of chronic respiratory failure, life expectancy and quality of 
life is poor in patients with bronchiectasis [107]. 
Bacterial colonisation of sputa has been shown to directly impact on the quality of life 
in patients with bronchiectasis. Patients in whom the sputa is colonised by 
Pseudomonas aeruginosa have a significantly worse quality of life than those who are 
colonised by other potentially pathogenic microorganisms or not at all [62, 108, 109].  
There is conflict in evidence as to whether other microorganisms affect the quality of 
life in bronchiectasis. In one study, identification of Haemophilus influenzae in the 
sputum meant a better quality of life than if no organism was isolated. However 
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isolation of Haemophilus influenzae did affect other parameters of disease activity, 
such as CT scan bronchiectasis scores and the frequency of exacerbations [62]. Others 
suggest that patients having microorganisms other than pseudomonas have a worse 
quality of life than those without microorganism [102, 108, 109]. 
Functional variables such as FEV1 do not affect the symptoms subscale of HR-QoL 
significantly. However, the FEV1 following bronchodilator therapy, is a relevant HR-
QoL conditioning variable. As in COPD, this should not be used as the sole severity 
marker of stable bronchiectasis [46, 104]. Inflammatory markers in exhaled breath 
have not been found to impact on the quality of life as measured by the SGRQ [110]. 
Appropriate treatment with antibiotics improves infection related inflammation and 
thus improves cough, wheeze and sputum volume. A significant improvement between 
onset of exacerbation and completion of treatment has been reported in dyspnoea 
scores, mastery and emotional domains of the Chronic Respiratory disease 
questionnaire [83]. Similarly the use of inhaled colistin in the treatment of 
bronchiectasis with recurrent Gram-negative infections is shown to improve quality of 
life and slow decline in forced expiratory volume in 1s and forced vital capacity [111]. 
Treatment with inhaled steroids in patients with non-CF steady-state bronchiectasis 
results in improvement in daily sputum production, dyspnoea, days without cough, and 
number of doses of short-acting β2 agonists required weekly. It is suggested that this 
improvement is seen as soon as within 1 month of commencement of treatment and 
persists for at least 6 months whilst on the treatment. A significant improvement is 
seen in the HR-QoL of these patients. Although the number of adverse events are 
greater, they are local and reversible [112]. Patients with chronic respiratory failure 
due to bronchiectasis, treated at home with nocturnal non-invasive for at least 12 
months have also reported an improvement in their quality of life [107]. 
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In the longer term, pulmonary rehabilitation programmes may be of some benefit. In a 
prospective study to determine the effects of a pulmonary rehabilitation programme 
some patients with bronchiectasis completed a 6-week outpatient pulmonary 
rehabilitation programme that included education, physical and respiratory care 
instruction and supervised exercise training. Outcome assessment was performed at 
baseline, on completion of the programme and 3 months after the programme. Disease-
specific quality of life was assessed using the Chronic Respiratory Disease 
Questionnaire (CRDQ). All domains of the CRDQ improved significantly and patients 
who completed a comprehensive pulmonary rehabilitation programmes showed an 
improvement in their health status [113]. 
If disease is localised, surgical treatment of bronchiectasis yields immediate resolution 
of symptoms, better quality of life and no mortality [114]. The amount of sputum 
produced, colonisation with Pseudomonas aeruginosa and appropriate medical or 
surgical management seem to be the most important determinants of the quality of 
health in bronchiectasis. 
 
1.4.3 HR-QoL and acute exacerbations in bronchiectasis. 
 
 A significant improvement has been noted in all individual domain scores of the 
SGRQ following completion of treatment with antibiotics during the course of an 
exacerbation [80]. In another prospective cohort study patients completed the 
questionnaire at the onset of an exacerbation, on completion of antibiotics at day 14 
and four weeks after the completion of antibiotics. A significant improvement was 
noted in three of the four domains (dyspnoea, emotional and mastery) of the CRDQ. 
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All the improvement was seen by Day 14 and there was no further change in 4 weeks 
[83]. No study has assessed quality of life in stable state and followed it through an 
exacerbation to date. 
 
 
1.5 Measuring lung function in bronchiectasis 
 
1.5.1 Background 
 
Spirometric indices have traditionally been used to stratify lung disease as mild 
moderate or severe. Variability in theses indices have been used as surrogate markers 
of inflammation. Assessing treatment effects and clinical outcomes therefore would 
seem a natural progression. 
Annual physiological decline in lung function is well known. The structural changes 
include chest wall and thoracic spine deformities which impairs the total respiratory 
system compliance leading to increased work of breathing. The lung parenchyma loses 
its supporting structure causing dilation of air spaces: "senile emphysema". Respiratory 
muscle strength decreases with age and can impair effective cough, which is important 
for airway clearance. The lung matures by age 20-25 years, and thereafter aging is 
associated with progressive decline in lung function. [115]. 
 
Lung function has been well studied in patients with Cystic Fibrosis. Measurement of 
lung function in these patients is known to reflect both acute and chronic changes [90]. 
The Forced expiratory volume in one second (FEV1) has been used as a surrogate 
marker in Cystic Fibrosis. An acute change in FEV1 caused by mucous plugging has 
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been clearly demonstrated and provides a short term endpoint [116]. The lung function 
declines no more than 1% per year in these patients [117]. This may be useful in 
longitudinal studies that occur over prolonged periods of time. 
 
1.5.2 Spirometry in non-CF bronchiectasis 
 
Most patients with bronchiectasis have a varying degree of airflow obstruction          
[28, 118]. There is also an increase in pulmonary flow resistance in a significant 
number of patients [119].  The mechanism of airway obstruction in bronchiectasis is 
thought to be multi factorial. Bronchial plugging by secretions, mucosal oedema, 
bronchospasm, distortion, kinking of bronchi or excessive dynamic collapse of airways 
on expiration may all contribute to this.  The decrease in dynamic pulmonary 
compliance could be attributed to a non-uniform distribution of airway resistance as 
well as increased stiffness of the lungs due to patchy fibrosis and atelectasis. The 
pulmonary transfer factor may be reduced or normal [120].  
 
1.5.3 Use of spirometry as a biomarker in bronchiectasis 
 
FEV1 has been used as an endpoint in studies to assess efficacy of treatment. Long 
term treatment with Azithromycin has shown no significant improvement in actual and 
% predicted FVC [61]. In another therapeutic trial of Azithromycin as a prophylactic 
antibiotic in bronchiectasis there was a trend of improvement in all lung function 
parameters but this was not statistically significant [94]. 
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1.5.4 Spirometry and prognosis in bronchiectasis 
 
Impaired pulmonary function is of prognostic importance in bronchiectasis. 
Physiological decline in lung function is said to be exacerbated in bronchiectasis. The 
majority of patients have impaired spirometry with airflow obstruction but normal 
carbon monoxide diffusing capacity. Multivariate analysis has shown that factors 
significantly associated with worse lung function are bronchial hyper responsiveness, 
concomitant asthma, higher serum globulin, higher peripheral leukocyte count, lower 
serum albumin, greater sputum volume, diffuse disease and older age [121]. 
Normal adults of may lose up to 30mls of their ventilatory capacity in a year. In 
bronchiectasis twenty per cent of patients show no decline or an improvement in the 
FEV1 [122].  But up to 60% of patients show a decline of some volume. This has been 
variously put at 39mls/year [123] , 49mls/year [5] , 50mls/year [122] and                             
54-55mls/year [5, 51]. The most important factor linked with an accelerated decline in 
FEV1 in stable patients with non-CF bronchiectasis is chronic colonization with 
Pseudomonas aeruginosa. This loss can be as much as 123 mls/year  [124]. Some 
reports place it at a smaller value with the overall decline in FEV1 in patients infected 
with Pseudomonas aeruginosa as 23mls. In those never infected with Pseudomonas 
aeruginosa it was recorded as 24mls [125]. The lung damage is thought to progress at 
the same rate in both sexes [18, 21].  In attempt to identify a relationship between 
inflammation and spirometry, a paediatric study was unable to find any correlation 
between Leukotriene B4 and FEV1 [126].  Patients with more advanced disease and 
moderate obstruction (FEV1 <65%) have more inflammation within the airway. Levels 
of TNF-α , IL-1B and IL-10 are higher in bronchial lavage fluid of these patients [127]. 
FEV1 and FVC have been found to be weak predictors of mortality [21]. 
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1.5.5 Impulse Oscillometry (Forced oscillation technique) and lung disease 
 
Conventional methods of lung function testing provide measurements obtained during 
specific respiratory actions of the subject. In contrast, the Impulse Oscillometry 
technique (IOS) determines breathing mechanics by superimposing small external 
pressure signals on the spontaneous breathing of the subject. IOS utilises the externally 
applied pressure signals and their resultant flows to determine lung mechanical 
parameters. These external forcing signals, may be mono- or multi-frequency, and are 
applied either continuously or in a time-discrete manner.  
These pressure–flow relationships are largely distinct from the natural pattern of 
individual respiratory flows, so that measured IOS results are, for the most part, 
independent of the underlying respiratory pattern. Therefore, Oscillometry minimises 
demands on the patient and requires only passive cooperation of the subject. Potential 
applications of Oscillometry include paediatric, adult and geriatric populations. 
Oscillometry is also useful in veterinary medicine and hence in animal studies. 
Diagnostic clinical testing, monitoring of therapeutic regimens, and epidemiological 
evaluations, are easily done using IOS and importantly are independent of the severity 
of lung disease [128].  
The most obvious relationship with other pulmonary function tests concerns the use of 
spirometry. Spirometry measures maximal forced respiratory efforts, while IOS 
measures quiet breathing. In bronchiectasis, IOS has not been compared to spirometric 
techniques as yet.  
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IOS has been used to monitor response to interventions in asthmatic children. IOS has 
been reported to show greater sensitivity to inhaled corticosteroid or to beta-agonist 
inhalation than spirometry. Both inhaled corticosteroids and beta-agonists improve 
small airways function, and IOS responses manifest prominent changes in indices of 
peripheral airway obstruction. In contrast, spirometric sensitivity to small airways 
function is less prominent. Accordingly, it is expected that IOS might provide useful 
indices of peripheral airway change in response to therapeutic interventions [129, 130]. 
In patients with chronic obstructive airways disease IOS is able to detect significant 
change after bronchodilator therapy and FEV1 is less sensitive [131]. 
In addition to its simplicity and non-invasiveness, IOS may be an useful clinical tool 
not only for detecting pulmonary functional impairment, but also to some extent in 
estimating the patient's quality of daily life and well-being [132].  
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1.6  Exhaled breath condensate and bronchiectasis 
 
1.6.1  Exhaled breath condensate 
 
Exhaled breath consists of a gaseous phase that contains volatile substances, such as 
nitric oxide, carbon monoxide and hydrocarbons, and a liquid phase termed exhaled 
breath condensate (EBC) [133]. It is assumed that the airway surface liquid is 
aerosolized during turbulent airflow such that the contents of the condensate reflect the 
composition of the airway surface liquid [134]. Exhaled breath condensate (EBC) was 
first reported as a human body fluid in 1980 in the context of studies of surface active 
properties/surfactant [135]. Naturally EBC contains mostly water vapour (>99.99%) 
The fraction of droplets are thought to contain analytes of interest [136]. These include 
a large number of mediators including adenosine, ammonia, hydrogen peroxide, 
isoprostanes, leukotrienes, nitrogen oxides, peptides and cytokines. Although EBC 
contains mainly metabolic products from the airways and the lung, it also contains 
products of other organs that reach the lung via the blood stream. As a consequence, 
the identification of products released from a particular site in the body may provide 
organ-specific information of oxidative stress [133].  Concentrations of these mediators 
are influenced by lung diseases and modulated by therapeutic interventions.  
 
1.6.2 Exhaled breath condensate and lung disease 
 
The lung exists in an oxygen rich environment which together with its large surface 
area and extensive blood supply, makes the organ susceptible to injury mediated by 
reactive oxygen species [ROS] [133]. Increased production of ROS has been directly 
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linked to lipid oxidation which may cause direct lung injury [137, 138]. Oxidative 
stress is associated with a range of inflammatory lung diseases, including asthma, adult 
respiratory distress syndrome, idiopathic pulmonary fibrosis, pneumonia, and chronic 
obstructive pulmonary disease [137]. It is thought that the various biomarkers 
identified in EBC may be indicative of different aspects of oxidative stress and that this 
non-invasive approach may be useful in categorising pulmonary disease. 
 
Hydrogen peroxide in exhaled breath is a direct measure of oxidant burden in air 
spaces, is soluble and equilibrates with air [139]. Increased concentrations of H2O2 in 
EBC has been demonstrated in asthma, ARDS, CF and lung cancer [134]. This is 
however complicated by confounding factors. EBC H2O2 is also elevated in smokers 
and during a common cold. Therefore more sensitive and specific assays will be 
required [133]. 
 
Nitric oxide [NO] is another marker of airway inflammation and indirectly a measure 
of oxidative stress. Stable NO derived products can be measured in the EBC.              
3-nitrotyrosine is one such product, concentrations of which are increased in 
association with worsening symptoms and deteriorating lung function in asthma     
[133, 140].  Total Nitrite and Nitrate concentrations are also elevated in cystic fibrosis 
patients and asthmatics compared to control subjects [137]. 
 
In addition pro and anti-inflammatory cytokines can be measured in exhaled breath. 
Interleukine-1β, Interleukine-6, Interleukine-8 have all been reported in EBC from 
human subjects [134]. Concentrations of IL-6 are raised in EBC of patients with cystic 
fibrosis [133, 141].  
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EBC can be exploited to assess a spectrum of potential biomarkers, thus generating a 
fingerprint characteristic of the disease. By assessing the nature of oxidative stress in 
this manner, the most appropriate therapy can be selected and the response to treatment 
monitored [133]. 
 
1.6.3 Monitoring lung disease by measuring pH of exhaled breath condensate. 
 
Airway pH homeostasis is maintained by a balance of different buffer systems and the 
production of acids and bases in the airways [142]. The assay used to determine EBC 
pH is easy and measurements are highly reproducible [133]. pH levels are also related 
to eosinophilic or neutrophilic inflammation of the airways [143]. The pH of EBC has 
been found to be low in stable asthma, COPD, bronchiectasis, cystic fibrosis, and acute 
respiratory distress syndrome [142]. The pH of EBC collected from patients with acute 
asthma is more than two log orders lower than normal but normalises with 
corticosteroid therapy [144]. Similar findings have been reported in COPD and 
bronchiectasis [145]. 
EBC can thus be exploited to assess a spectrum of potential biomarkers, generating a 
fingerprint characteristic of the disease both in stable state and during an acute 
exacerbation. By assessing the nature of oxidative stress in this manner, the most 
appropriate therapy can be selected and the response to treatment monitored [133]. 
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1.6.4 Exhaled breath condensate and bronchiectasis 
 
Most inflammatory markers identified in EBC have been described in CF with limited 
data in non-CF bronchiectasis. H2O2 is the only well described marker in 
bronchiectasis. In the respiratory system H2O2 is released both from inflammatory and 
structural cells. These include neutrophils, eosinophils, macrophages and epithelial 
cells. EBC H2O2 concentrations are elevated in bronchiectasis with a significant 
inverse correlation between lung function and EBC H2O2 levels [146]. No other marker 
has been clearly identified in EBC of patients with bronchiectasis alone. 
 
 
1.7 The microbiology of bronchiectasis 
 
1.7.1 Background 
 
The airways of patients in non-cystic fibrosis bronchiectasis become chronically 
infected with bacteria.  This leads to an intense inflammatory response within the 
bronchi not necessarily with a systemic inflammatory response. This reaction is 
exaggerated in patients colonised by microorganisms with potential pathogenicity 
(PPM), the most common being Haemophilus influenzae, Staphylococcus aureus, 
Streptococcus pneumoniae and Pseudomonas aeruginosa [4]. 
 
Bronchiectasis in the pre-antibiotic era predominantly affected young patients with a 
high mortality rate [40, 147]. The introduction of antibiotics and immunisation has led 
to a dramatic improvement in the outcome [8, 40]. However, bronchiectasis remains 
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prevalent and exacerbations continue to contribute to significant morbidity and poorer 
HR-QoL [83, 102]. 
The identification of a respiratory exacerbation in bronchiectasis is complex [8]. 
Sputum production is continuous and purulence may be common. Systemic symptoms 
are uncommon. Given that persistent bacterial infection of airways is responsible for 
progression of disease, it would be logical to identify markers of inflammation and 
endpoints for therapeutic trials from sputum. To this end either looking for a new 
pathogen or increase in the numbers of the existing predominant pathogen seems 
reasonable. 
 
1.7.2 Potentially pathogenic microorganisms in bronchiectasis (PPM) 
 
Effort has always been concentrated on isolating a PPM in sputum. The isolated 
pathogens include Haemophilus influenzae, Pseudomonas aeruginosa and 
Streptococcus pneumoniae [5, 18, 127]. 
Haemophilus influenzae is the most commonly isolated organism in stable cohorts 
[17]. The incidence can vary from 22% up to 47% in a group of patients [17, 46].  
Pseudomonas aeruginosa is the other commonly isolated pathogen in most series. It is 
considered a marker of more severe disease and is associated with compromised      
HR-QoL [62]. These patients also have poor lung function and extensive disease on 
HRCT [17]. The incidence varies between 12- 27% in some reports [17, 46, 71]. 
Moraxella catarrhalis, Streptococcus pneumoniae and Staphylococcus aureus are 
more infrequent. Commensals are noted most frequently.  Absence of pathogens is 
reported in lower numbers in some series [21%] and up to 60% by others [17, 71]. This 
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could indicate a fault in detection or perhaps early infection when host defence balance 
is adequate.  
Both Pseudomonas aeruginosa and Haemophilus influenzae are capable of forming 
biofilms [17]. The timing of acquisition of Pseudomonas aeruginosa is unknown 
[148]. As in CF early treatment may delay persistent infection. Infection with 
Staphylococcus aureus in patients with bronchiectasis is more frequently associated 
with ABPA and atypical variants of CF and is a useful marker of these conditions 
[149]. 
 
Anaerobic bacteria are not detected by routine aerobic culture methods. It is possible 
that these reside within the airway mucous. These may be present in healthy 
individuals however they are present in larger numbers in lungs of patients with cystic 
fibrosis. It is possible that they may be contributing to infection and inflammation in 
non-CF bronchiectasis [150]. Viral infection has yet to be formally studied in 
bronchiectasis. When neutrophils of patients with bronchiectasis are infected in vitro 
with Influenza A, there is a reduction in lysozyme release and bactericidal activity. 
This effect may contribute to increased bacterial load and to acute exacerbations [151].  
Microbial clearance, it would follow, may be crucial in therapeutic trials involving 
antibiotics for acute conditions. 
 
1.7.3 Chronic bacterial colonisation of the lower respiratory tract in bronchiectasis 
 
Microbial clearance may be achieved easily for acute infections. However airway 
colonisation and biofilms growth in a susceptible airway environment remains a 
problem and eradication is not always possible. 
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Identifying the colonising PPM is equally difficult. There has been no standard 
definition for chronic colonisation. It is unclear if frequency of isolation or duration of 
isolation should guide this definition. The time duration may vary from 3months to 2 
years. Patients are considered colonised if a bacterium is cultured for more than 2 years 
[34] , or have more than three positive cultures of the same organism at intervals of ≥6 
weeks [61] or have more than three isolates of a PPM  from separate samples over a 
period of 3 months [145].  
 
We have adhered to a previously used definition of more than three positive cultures 
within the previous year [3]. 
 
Evidence in Cystic fibrosis is more extensive. The first definition for chronic 
Pseudomonas aeruginosa infection was introduced in 1974 and was based on monthly 
microbiological examination of sputum. Chronic infection was defined as a continuous 
presence of Pseudomonas aeruginosa in the sputum for 6 months [152]. The European 
consensus definition for chronic Pseudomonas aeruginosa infection that is commonly 
used is at least three positive cultures over >6months with at least 1-month interval 
between samples [153]. The Leeds criteria in Cystic fibrosis defines chronic infection 
as >50% of sputum positive cultures with Pseudomonas aeruginosa over a 12 month 
period. While the study suggests that a sample be taken every 3 months, a minimum 
sample number is not specified [154]. This has been further validated along with anti-
Pseudomonas antibody levels in a combined paediatric and adult cystic fibrosis cohort. 
[155]. In cystic fibrosis, it is thought that chronic infection with Pseudomonas 
aeruginosa is preceded by intermittent infection and early detection and intensive 
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treatment can delay chronic infection [155-157]. Extrapolating data to the non–cystic 
fibrosis population would have to be done with caution. 
In bronchiectasis, once colonised, fifty per cent of patients will retain the same 
organism at 5 year follow up review. And this group of subjects will have a higher 
number of exacerbations [17]. 
 
 
1.7.4 Markers of infection in sputa. 
 
 
Quantitative bacterial load has been previously used as marker of therapeutic efficacy. 
In a study to assess efficacy of inhaled versus intravenous gentamycin, a 6-10 fold 
reduction in colony counts has been reported [158].  Longitudinal quantitative 
microbial data is absent in bronchiectasis. It is unknown if quantitative data correlates 
to other proven parameters such as HR-QoL markers and spirometric indices. It is time 
consuming and remains a research tool at the current time. 
 
More useful are markers that involve patients’ cooperation and can be measured in the 
home environment. Sputum volume and appearance are such tools. Sputum 
production, although common, remains variable in volume. While some patients are 
daily producers of copious amounts others less so and some only during an infection. It 
would be an easy tool for bedside testing. Doctor patient correlation has already been 
established [159]. 
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1.7.5 Non Tuberculous mycobacterial analysis in bronchiectasis 
 
Non-tuberculous mycobacterial (NTM) are ubiquitous environmental organisms that 
exist in pre-existing lung damage. NTM are inhaled as aerosol droplets and a single 
positive isolate could indicate recent exposure rather than active infection. However 
these patients warrant regular follow up. The age group of patients with multiple 
isolates is 7 years [mean age 62.2 years ѵ 55.1 years] more than those with single 
isolates [160]. It is possible that the time to active disease from first exposure is a few 
years. 
 
The prevalence of NTM is estimated to be about 2% in bronchiectasis [17]. A female 
predominance is noted. Single isolates are frequently Mycobacterium avium-
intracellulare (MAC). If patients have multiple isolates they are more likely to be 
smear positive on first sample. Pseudomonas aeruginosa and Staphylococcus aureus 
are frequently co-cultured [160]. 
 
Patients with bronchiectasis and non-tuberculous mycobacterial disease have a higher 
prevalence of coexisting Aspergillus-realed lung disease than patients with 
bronchiectasis and without non-tuberculous mycobacteria. Recurrent antibiotic use 
prior to diagnosis may drive culture findings to fungal isolates, or a common host 
defence abnormality may be implicated. It may be that lung disease with NTM is 
destructive and this provides a favourable environment for Aspergillus fumigatus 
[161]. 
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Distinguishing between lung colonisation and disease can be difficult [160]. 
Pulmonary mycobacterium avium (MAC) complex is recognised as presenting in two 
distinct ways. It can present as a fibro-cavitatory infection complicating pre-existing 
lung disease or as an infection in apparently immune-competent individuals with no 
pre-existing lung disease that then causes nodular bronchiectasis [4]. There is a debate 
as to whether MAC infection is a cause or simply a complication of bronchiectasis. 
Patients with bronchiectasis and NTM infection require long term follow up and 
regular assessment of sputum cultures in order to determine the optimum time to 
intervene as long term disease progression is likely [4]. 
 
It is important to screen all patients with bronchiectasis at referral for NTM infection 
and thereafter if there is an unexplained deterioration unresponsive to usual therapy 
[4]. 
 
  1.7.6 Anti-pseudomonal antibodies in bronchiectasis 
 
Specific serum antibodies could be helpful in defining the status of bacterial infection 
as well as the response to early treatment in patients. It may also confirm protection 
following vaccination. However antibodies induced by disease do not seem to offer 
protection in Cystic fibrosis [12]. The antibody response against Pseudomonas 
aeruginosa in CF is a marker of chronicity of infection and of inflammation and tissue 
damage. Some patients with non-cystic fibrosis bronchiectasis when infected with 
mucoid strains of Pseudomonas aeruginosa have high levels of anti-pseudomonal 
antibodies. It is not known if information from CF can be extrapolated to non-CF 
bronchiectasis [162]. 
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Immunoglobulin G (IgG) antibodies to Pseudomonas aeruginosa surface antigens in 
serum can be estimated by enzyme-linked immunosorbent assay (ELISA). Antibodies 
to Pseudomonas aeruginosa can be directed against alkaline protease (AP), elastase 
(ELA), exotoxin A (ExoA) or whole cell [153, 163] .The secretory IgA is the initial 
humoral response to infection in the lungs. While antibodies to IgG are commonly 
measured, it is possible that at the onset of infection an increase in specific serum IgA 
antibodies may occur before an increase in serum IgG antibodies [164]. High titres of 
serum IgG antibodies are associated with a poor clinical state, while low titres are 
associated with a better clinical state in both chronic and intermittently infected 
patients with CF [165]. Information on antipseudomonal antibody levels in patients 
with non-CF bronchiectasis remains limited. 
 
 
 
1.8 Cytokines and the lung in bronchiectasis  
 
1.8.1 Cytokines in bronchiectasis 
 
Three distinct pathogenic elements, namely infection, inflammation and enzymatic 
actions, interact with each other and have been implicated in the pathophysiology of 
bronchiectasis [166]. 
 
When exposed to bacterial endotoxin, bronchial epithelial cells release inflammatory 
mediators [166]. Some of these mediators are pro-inflammatory and others anti-
inflammatory. Among the pro-inflammatory mediators involved, IL-8, IL-1β, and 
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TNF-α play a role favouring the trafficking of activated neutrophils through the 
bronchial wall into the bronchial lumen. The anti-inflammatory mediators IL-6 and IL-
10 act as a counterpart of pro-inflammatory mediators by promoting the synthesis of 
natural antagonists  IL-1β and TNF-α  [127]. Intense neutrophil infiltration into the 
tracheo-bronchial tree occurs as a result, which further aggravates the release of 
inflammatory mediators [166]. 
 
Evidence now suggests that in bronchiectasis, airway inflammatory response triggered 
by bacterial stimulation is excessive in relation to the bacterial burden indicating a 
deregulated cytokine network. It continues to reverberate even after the infection is 
controlled. The altered homeostasis of airway inflammatory response to bacterial 
infection in the dynamic process of host–pathogen interaction dictates the clinical 
manifestations of the lung disease [166, 167]. 
 
Finally neutrophil toxic products impair the structure and functioning of the airway 
mucosa by digesting airway elastin, basement membrane collagen and proteoglycan, 
contributing in this way to the progression of the disease. 
 
1.8.2 Lower airway inflammation and bronchiectasis 
 
Sputum colour when graded visually relates to the activity of the underlying markers 
of bronchial inflammation confirming that increased purulence is a result of increased 
inflammation. Visual measurements of sputum colour strongly correlate with 
myeloperoxidase, interleukin 8, leukocyte elastase (both activity and total quantity), 
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and sputum volume [168].  In steady state bronchiectasis, sputum neutrophil elastase 
levels correlate with the per centage of neutrophils, pro-inflammatory cytokines (IL-8 
and TNF-α)  and 24-h sputum volume that is a marker of disease activity [166, 169]. 
The sputum elastase level correlates with sputum production, lung function, and 
airway cytokine expression in bronchiectasis [170]. 
 
There are several chemotactic factors present in secretions and the chemotactic activity 
of purulent secretions is higher than that of mucoid ones. This is largely related to an 
increase in IL-8 levels, whereas the contribution of LTB4 remains relatively stable. 
This observation has important implications in deciding future therapeutic strategies 
since continued neutrophil recruitment is thought to be important to the pathogenesis 
and progression of chronic bronchial disease. Removal or reduction of the chemotactic 
drive may present an attractive therapeutic strategy. However, neutrophil chemotaxis is 
clearly required during episodes of acute infective exacerbations of bronchial disease. 
Prevention of this normal response may therefore prove harmful. For this reason 
measures aimed at removing the IL-8 drive may prove counterproductive, whereas an 
approach in abrogating the LTB4 drive may be more successful [171]. 
 
Neutrophilic infiltration into bronchiectatic airways is also mediated by mediators such 
as host complement factor 5a (C5a), leukotriene B4 (LTB4), IL-8 and IL1, tumour 
necrosis factor –α and leukotriene (LT) B4 [6, 172]. These cause release of toxic 
products such as neutrophil elastase (NE), metalloproteases and reactive oxygen 
species. Because of the large number of neutrophils present, lung defences are 
overwhelmed [2, 172, 173]. Patients with more advanced disease have more 
inflammation within the airway. Levels of TNF-α , IL-1B and IL-10 are higher in 
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broncho-alveolar lavage fluid of these patients [127]. Activated neutrophils do not 
differentiate between bacteria and bystander lung tissue. This inflammatory shift is 
persistent post treatment. Modulation with therapy will need formal study [71]. 
 
While individual cytokines have different actions, there may well be an overlap in 
function. LTB4 promotes neutrophil migration and degranulation. IL-1β mediates 
airway inflammation and fibrosis; TNF-α interacts synergistically with IL-1 in 
prostaglandin induction; and IL-8 is one of the most potent chemo-attractants which 
also degranulates neutrophils in bronchiectatic airways [71].  TNF-α  and IL-1  have 
been shown to induce the breakdown of tight junctions in the blood/brain barrier in 
vivo [174]. A combination of anti-TNF and anti-IL-1 antibodies completely neutralized 
cell separation in the vascular endothelium that is induced by Streptococcus 
pneumoniae [175]. 
 
A non-clearing adaptive immune response to chronic infection of the lower respiratory 
tract in bronchiectasis subjects may contributes to the airway inflammatory process.  
Subjects with bronchiectasis and recurrent infections with non-typeable Haemophilus 
influenzae present a type 2 T-helper cell (Th2) predominant response with production 
of IL-4 and IL-10. Conversely, cytokine pattern in control subjects was consistent with 
a Th1 response. Non-typeable Haemophilus influenzae  also form adherent biofilms on 
the surface of airways epithelium. The epithelium in turn responds through increased 
secretion of several innate and adaptive immune factors that mediate airway 
inflammation H. influenzae stimulates respiratory epithelial production of macrophage 
inflammatory proteins, IL-8 and TNF-α both in vitro and in vivo [166, 176]. 
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Airway inflammation not related to colonization may be present in the early stages of 
the disease. However subjects with pathogenic organisms colonizing the airways have 
a more intense neutrophilic inflammatory reaction than non-colonized patients. Also 
markers of inflammation increase progressively with the increase in the bacterial load. 
Although it is speculated that the Pseudomonas spp. may cause a more intense 
bronchial inflammation, no differences in the inflammatory parameters according to 
the type of bacteria isolated has been noted [127]. 
Exacerbations are associated with further elevated inflammation in the form of 
augmented cytokine expression, cellular infiltrate, adhesion molecule expression, loss 
of lung function and symptomatic deterioration [177]. 
 
1.8.3 Systemic evaluation of airways inflammation 
 
Cytokine concentrations of IL-lα, TNF-α and IL-8 are normally below levels of 
detection in plasma [178]. The relatively low levels of plasma cytokines compared 
with broncho-alveolar lavage fluid and the poor correlations between them suggest that 
the inflammatory process in the airways is mostly compartmentalized. A complex 
interaction between cytokines and their natural antagonists in the local milieu or the 
relatively low intensity of the bronchial inflammatory process may explain this local 
effect. The systemic reflection of local inflammatory response is thought to be closely 
related to the severity of the disease, being more intense in cases of severe pneumonia 
and ARDS [127]. 
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In stable state chronic obstructive pulmonary disease (COPD) there is no evidence of 
correlation of inflammation in the systemic and lower airway compartments suggesting 
that the two compartments may be modulated separately [179]. However in 
exacerbations of (COPD), the systemic inflammatory response is proportional to that 
occurring in the lower airways and greater in the presence of a bacterial pathogen. In 
particular serum IL-6 is correlated significantly to sputum IL-8 [179]. 
 
Independent functioning of the two compartments is not fully explained. Perhaps the 
local inflammation does not spill over or perhaps counter-regulatory mechanisms are in 
action and need further study. 
 
1.8.4 Cytokines as a marker of inflammation in therapeutic trials 
 
There is no gold standard for measuring disease activity in bronchiectasis. The efficacy 
of inhaled corticosteroids has been studied using sputum output of leucocytes, IL-1β, 
IL-8 and LTB4 [93].  The first and only systematic evaluation of sputum pro-
inflammatory mediator profiles after fluticasone therapy showed a dramatic reduction 
in concentrations of IL-1, IL-8, and LTB4 activities in the bronchiectatic airways [71]. 
There are only a few longitudinal studies on sputum pro-inflammatory mediator 
profiles in bronchiectasis. Most studies have evaluated these mediators in stable state 
disease. Investigating these biomarkers has the potential to yield information about 
underlying mechanisms of disease and aid development of therapeutic strategies              
[71, 81]. 
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Chapter 2 
The COBEX study 
Characterisation of exacerbations in bronchiectasis 
 
2.1 Introduction 
 
 Acute exacerbations of bronchiectasis are recognised by a change in symptoms 
with patients complaining of an increase in cough, sputum volume and sputum colour 
with an associated increase in malaise.  In contrast to exacerbations of COPD, 
treatment of acute exacerbations of bronchiectasis has not been well studied and hard 
end points of treatment success have not been established.  In particular in contrast to 
asthma and COPD there is no convincing literature to suggest that change in FEV1 
provides a good marker of treatment success in acute exacerbations of bronchiectasis.  
It therefore remains unclear as to how we could measure treatment success when 
planning future interventional studies in acute exacerbations of bronchiectasis.  
Furthermore microbiological endpoints are not well validated in this disease. As 
infection is chronic, as in Cystic Fibrosis, then eradication of bacteria is a less likely 
endpoint and reduction of bacterial numbers is a more likely scenario.  However, there 
are no published studies of sufficient size which address this issue in acute 
exacerbations of bronchiectasis. Measurement of inflammatory markers provides a 
useful parameter of resolution of acute inflammation associated with an exacerbation 
but requires repeated blood sampling.  The introduction of analysis of breath 
condensates provides an alternative approach which could be as efficacious as blood 
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markers but has yet to be investigated in this context.  From a patient perspective a 
non-invasive marker of the need to start treatment for an exacerbation and time to 
complete treatment would be welcome.  Finally it is recognised that in the absence of 
change in lung function, antibiotic courses are stopped when the patient feels better.  
Whilst previous studies of the St George’s questionnaire in bronchiectasis have 
assessed stable disease there is a need to further evaluate quality of life measures in 
response to treatment of an acute exacerbation.  
 
2.2 Definition 
COBEX is an acronym for ‘Characterisation of bronchiectatic exacerbations’. We 
chose this for ease of use in day to day functioning of the study. While it does not do 
justice to the complete title, the purpose of convenience was served. 
 
2.3 Objectives 
We set out to study acute exacerbations in Non-CF Bronchiectasis with a view to 
defining clear end points towards which future interventions can be directed. To this 
end we intended to use all currently available clinical, biochemical, spirometric and 
microbiological parameters. Some parameters are easily available in most clinical 
settings while others are experimental. We have studied patients in stable state (not 
having had an infection in the preceding 4 weeks) and followed these patients through 
an exacerbation. 
The patient is at the centre of this study. Patients present with symptoms and 
measuring this would be paramount to any clinical study. Objectively assessing these 
symptoms will allow wide use with no economic burden. Any disease ultimately 
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compromises quality of life. Some symptoms however severe will be tolerated; others 
may be comparatively minor but less well tolerated as quality of life may be 
compromised. It follows that a measure of disease must include Health related quality 
of life (HR-QoL). We have employed two commonly used questionnaires to measure 
the HR-QoL –The St Georges’ respiratory questionnaire and the Euroqol. 
Copious and purulent sputum production has remained the primary complaint of this 
disease. Analysing sputa is thought to hold the secret to the persistent infection. 
Information sought from sputa is many fold. Microbiological load and quality is 
widely studied [5, 17, 80, 127]. More recently serum inflammatory markers including 
cytokines have yielded useful information in other lung diseases such as chronic 
obstructive pulmonary disease [180]. Correlation between microbiological load and 
inflammatory marker has been sought to explain the pathological process in detail. We 
have attempted to measure qualitative and quantitative microbiology. We have also 
analysed both serum and sputum for inflammatory mediators that are commonly 
described.  
Colonization with Pseudomonas aeruginosa is a poor prognostic factor in 
bronchiectasis [62]. Anti-pseudomonal antibodies are meant to be protective against 
infection. However a malfunction renders these ineffective and may in part be 
responsible for the persistence of infection. Raised levels are thought to precede 
colonisation. We have attempted to measure these levels in our study. 
Serum inflammatory markers range from regularly used indices such as ESR and CRP 
to more specific mediators of inflammation such as the cytokines. These have been 
reported to be raised in bronchiectasis. We have measured ESR, CRP and seven other 
inflammatory markers: Interferon γ (IFNγ), Tumour necrosis factor (TNF α),                         
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Interleukin 6 (IL-6), Interleukin 8 (IL-8), Interleukin 1β, Interleukin 10 (IL-10) and 
Interleukin 17 (IL-17) in this study. 
Forced expiratory volume in the first second (FEV1) remains a standard measure by 
which all lung disease is judged. It may not always provide useful information but will 
help assess patient’s functional level. Forced manoeuvres are difficult for patients with 
lung disease.  Newer methods such as Impulse Oscillometry (IOS) are less 
cumbersome and may provide the answer in the future. We have used both spirometry 
and IOS to identify useful markers in bronchiectasis. 
Finally, in an attempt to measure lower airway acidity we have used the exhaled breath 
condensate to predict the changes of an exacerbation. We have compared exhaled 
breath pH of healthy volunteers to patients with bronchiectasis to set a bench mark. 
 
2.4 Study Design 
The study is designed as a longitudinal prospective cohort study. We have followed 
patients for a period of two years and prospectively studied all reported exacerbations. 
  
2.5 Ethical approval 
The initial Ethical approval for this study was granted by the Cambridge 1 Research 
Ethics Committee on the 1st of August 2006. (MREC ref 06/Q0104/33). An 
amendment to the protocol was made on the 6th of February 2008 and ethical approval 
was sought again. A valid notice of approval of a substantial amendment was thereafter 
issued. Appendix i & ii.  
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2.6 Funding 
We are grateful to the Evelyn Trust (PO Box 27, Hitchin, Hertfordshire, SG4 7ZQ) for 
their generosity in funding the first year of this study. The second year was funded by 
the Department of Research and Development, Papworth Hospital, Cambridge 
CB23RE. 
 
2.7 Time frame 
The total study period of two years commenced on the 1st of September 2006 and 
ended on the 31st of August 2008. Ethical approval was granted in the same year. The 
first patient was recruited in February 2007. The last patient was recruited in June 
2008. The data was analysed thereafter. 
 
2.8 Subjects 
Subjects for this study were recruited from the Lung Defence Clinic at Papworth 
Hospital, Cambridge. The Papworth Lung Defence Clinic has defined a gold standard 
for characterisation of patients with Non CF bronchiectasis and already has a well-
defined cohort of patients [18]. The clinic currently follows over 500 patients with well 
characterised bronchiectasis. All patients had a diagnosis of bronchiectasis confirmed 
by previous HRCT and clinical features. All patients entered into this study are white 
Caucasian.   
 
Fifty-eight patients were recruited. Twenty-two of these patients suffered an 
exacerbation and were studied through this period. 
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2.9 Patient criteria  
The criteria set out for patient participation is listed below. This was strictly adhered to 
2.9.1 Inclusion criteria 
 
 Patients attending the Lung Defence Clinic with well characterised bronchiectasis 
[18]  
 Age 18 and upwards. 
 Patient able to cooperate for a period of 12 months. 
 Patients were daily sputum producers. 
 Fourteen healthy volunteers were recruited to study exhaled breath condensate. 
 
2.9.2 Exclusion criteria 
 
 Patients with Cystic Fibrosis. 
 Patients on immunoglobulin therapy 
 Patients on treatment for non-tuberculous mycobacterial lung disease. 
 
2.10 Protocol 
 
All subjects were studied in stable state not having suffered an exacerbation in the 
preceding 4 weeks (Baseline/visit 0). They were asked to contact the Research clinic in 
case they suffered an acute exacerbation. They attended the clinic again at the onset of 
an exacerbation prior to commencement of antibiotic treatment. Follow-up visits were 
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arranged for Day 7, Day 14 and day 42 thereafter.  Antibiotic treatment was prescribed 
based on previous microbiological status. All patients were treated for a period of 14 
days with either oral or a combination of oral, nebulised and intravenous antibiotics. 
Clinical, biochemical, microbiological, HR-QoL and lung function parameters was 
measured in all patients entered into the COBEX study and is listed in Table 2.1. All 
clinical, biochemical and microbiological parameters were measured at each visit.   
HR-QoL questionnaires are designed to be measures at an interval of either a minimum 
of 2 (Euroqol) or 4 weeks apart (SGRQ). Hence HR-QoL was measured at baseline, 
Day 1 and Day 42 for all patients. In addition patients were asked to complete a 
Euroqol questionnaire at Day 14.  
The Clinical research form used – Appendix iii 
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Table 2.1: Summary of the visit schedule for COBEX study.  
Clinical, biochemical, microbiological, HR-QoL and lung function parameters 
measured in all patients entered into the COBEX study. All clinical, biochemical and 
microbiological parameters were measured at each visit.  Patients completed the 
Euroqol at baseline, Day 14 and day 42. In addition patients were asked to complete a 
Euroqol questionnaire at Day 14. 
 
 
VISIT 
0 
baseline 
VISIT 1 
Day 1 of acute 
exacerbation 
VISIT 2 
Day 7 of acute 
exacerbation 
VISIT 3 
Day 14 after 
onset of acute 
exacerbation 
VISIT 4 
Day 42 after 
onset of acute 
exacerbation 
Clinicians  
assessment X X X X X 
Euroqol X X  X X 
St Georges  
questionnaire X X   X 
Sputum 24 hour 
volume X X X X X 
Qualitative 
Microbiology 
X X X X X 
Inflammatory 
Markers: 
Cytokines 
X X X X X 
Exhaled Breath 
Condensate 
(pH analysis) 
X X X X X 
WBC, CRP, 
ESR X X X X X 
Spirometry X X X X X 
Impulse 
Oscillometry X X X X X 
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Chapter 3 
Results 
Characteristics of patients in the COBEX study 
 
3.1 Study Subjects 
One hundred and sixty-five patients were approached with a view to recruiting them to 
the COBEX study. Information on the study was given to all patients. Sixty five 
patients consented to participating in the study. Six of these patients changed their 
minds prior to commencement of the study. One patient died during the trial of 
unrelated causes. Fifty-eight patients entered the study and were screened for the 
baseline visit.  
Twenty-seven patients suffered an exacerbation during the period of the study. Five of 
these patients were unable to attend for a visit at the start of an exacerbation. Three 
patients felt their symptoms worsen at the beginning of a weekend and commenced 
their antibiotics as advised. Two patients were unable to attend for other reasons. 
Twenty-two patients were screened during an exacerbation of bronchiectasis. Twenty 
patients finished all visits. Two patients deteriorated before the final visit. Data from 
these patients is included in all initial visits. 
A total of 144 patient visits were recorded between February of 2007 and August of 
2008. Only three patients needed to be admitted to hospital for inpatient care. While 
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two patients had prolonged hospital visits, one patient was admitted for 14 days and 
attended for the last visit as an out-patient. 
The mean age (SD) of our cohort was 64years (11.4). Most patients were female 
(34/58, 58%). 
The use of antibiotics was variable among the patients studied. The mean number of 
courses of antibiotics used was 3 (range 0 – 12). Intravenous antibiotics were less 
commonly used as an out-patient and were needed by only one patient. 
Eighteen patients (31%) were been admitted to hospital in the preceding one year for 
treatment of bronchiectasis. Three patients had been admitted more than once. Only 
one patient needed care on the Intensive therapy unit. 
 
3.2 BMI 
The mean (SD) Body Mass Index (BMI) for this group of patients was 25(4). The 
mean (SD) weight for the men was 80(11) kilograms and for the women 68(22) 
kilograms. 
 
3.3 Smoking History 
Thirty patients had never previously smoked tobacco. Twenty-six patients had 
previously smoked. Only 2 patients were current smokers. These patients were not 
studied during an exacerbation as they met the exclusion criteria for exhaled breath 
condensate collection. The mean use of tobacco for all patients was 21 pack years 
(Range 5-180). Subject characteristics are summarised in Table 3.1 
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Table 3.1: Characteristics of patients and healthy volunteers entered into the COBEX    
               study.  
 
 
 Full cohort  
n=58  
Exacerbators  
n=22  
Healthy 
volunteers  
n=14  
Mean age 
 (+/-SD)          
64years (11.4) 63years (8.5) 65years (5.9) 
Sex (M: F)                  24:34 5:17 7:7 
Smoking history        
   
Ex-smokers  26 11 9 
Non-smokers                   31 11 4 
Current smoker  1 
 
1 
Mean  
FEV1 (±SD)         
1.9L (0.71) 1.9L (0.61) 2.3L (0.82) 
Mean FEV1 % 
predicted (±SD)  75 %( 25) 81 %( 28.2) 100 %( 27.1) 
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3.4  Past medical history 
In addition to bronchiectasis, twenty four patients (41%) had asthma, 23(40%) suffered 
with Gastro-oesophageal reflux disease, 6(10%) had Chronic obstructive pulmonary 
disease and 8(14%) had Ischaemic heart disease. 
 
3.5  Diagnosis of bronchiectasis 
The median age at diagnosis in our cohort was 42 years (range 1-79 years n=55,        
no data on 3 patients). The duration of disease as identified by patients was (median, 
IQR) 39 (12.5 - 59) years. The time of potential primary insult was before 35 years of 
age in 40 % of patients. 
 
3.6 Aetiology of bronchiectasis 
This cohort of patients has well defined bronchiectasis as previously described [18]. 
Aetiology for the bronchiectasis was known in over 70% of patients (41/58). 
Bronchiectasis as a consequence of childhood infection was the commonest in the 
group of patients studied. All known causes are listed in Table 3.2. 
Aetiology of bronchiectasis in the cohort that was followed through an exacerbation of 
bronchiectasis is listed below Table 3.3. 
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Table 3.2: Aetiology of bronchiectasis in all subjects recruited to the COBEX study. 
 
Aetiology n=58 
Post pneumonic 3 (5.2%) 
Aspiration 2(3.4%) 
Ciliary dysfunction 1(1.7%) 
Rheumatoid arthritis 3(5.2%) 
ABPA 2(3.4%) 
Antibody deficiency with normal 
immunoglobulins 
7(12%) 
Childhood Infections 23(39.6%) 
Idiopathic 22(37.4%) 
 
 
 
Table 3.3: Aetiology of bronchiectasis in the cohort that was followed through an acute 
              exacerbation. 
 
Aetiology n=22 
Post pneumonic 2(9%) 
Aspiration 1(4.5%) 
Rheumatoid arthritis 1(4.5%) 
Antibody deficiency with normal 
immunoglobulins 
4(18%) 
Childhood Infections 7(31%) 
Idiopathic 7(31%) 
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3.7 Antibiotic therapy in bronchiectasis 
 
3.7.1 Prophylactic oral antibiotics 
 
The Lung Defence clinic at Papworth practises a policy of prescribing oral antibiotics 
as prophylaxis to patients who have previously required frequent courses of treatment. 
This is thought to reduce the requirement of antibiotic use annually and also reduce the 
bacterial load. Most patients do so with little or no side effects and are compliant. 
Thirty seven (64%) of the patients recruited to the COBEX study were taking oral 
antibiotics regularly in the absence of an exacerbation. Six (10%) Amoxicillin; 
11(19%) Doxycycline; 14(24%) Azithromycin; 1(2%) Erythromycin; 5 (8%) 
Trimethoprim.  
In the group of patients followed through an exacerbation, 2(9%) were taking 
Amoxicillin, 4(18%) Doxycycline; 6(27%) Azithromycin and 2 (9%) were on 
Trimethoprim prophylactically. 
 
3.7.2 Prophylactic nebulised antibiotics 
 
Fourteen patients were using nebulised antibiotics prophylactically. Nine (15%) 
Colomycin; 3(5%) Gentamycin; 1(2%) Tobramycin; and   1(2%) Meropenem. 
In the group of patients followed through an exacerbation, 3(5%) patients were 
Colomycin nebuliser and one patient (2%) on Gentamycin nebuliser prophylactically. 
Eight patients were on more than one antibiotic prophylactically. One patient who had 
end stage bronchiectasis was on four antibiotics at the same time. 
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3.8 Domiciliary oxygen 
Only two patients had domiciliary oxygen. One was on Long term oxygen therapy and 
another patient was on short burst oxygen therapy. 
No patient in this cohort was on domiciliary ventilatory support                              
(Non-invasive ventilation). 
 
3.9 Mucolytic agents  
Eleven patients (19%) were prescribed a mucolytic agent. 
 
3.10 Vaccination history 
This patient group was well immunized. Fifty four (93%) patients had been immunised 
with the annual Influenza vaccine and 46(79%) had been immunised with the 
Pneumococcal vaccination. 
 
3.11 Chest Physiotherapy 
Patients in this cohort were well educated in the importance of regular chest 
physiotherapy techniques. Forty four (76%) followed some form of physiotherapy on a 
regular basis, 42 (72%) patients did so several times a month. Nineteen patients (33%) 
used more than one form of physiotherapy. The methods of physiotherapy used are 
listed in Table 3.4. Frequency of physiotherapy employed by our patients is listed in 
Table 3.5. 
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There was no significant difference in the number of exacerbation suffered between the 
group that did physiotherapy several times a month and those that did so less 
frequently (p=0.55).Mechanical aids were not frequently used in our cohort of patients. 
 
Table 3.4: Various methods of physiotherapy employed by subjects within the COBEX 
      study. 
Method of Physiotherapy used  Number of patients 
Active cycle of Breathing Technique (ACBT) 30 
Postural Drainage 26 
Flutter Valve 3 
Acapella 2 
Autogenic Drainage 0 
General Exercise 2 
Percussion & Vibration 5 
 
Table 3.5:  Frequency of various techniques in physiotherapy employed by subjects 
      within the COBEX study. 
Frequency of use of physiotherapy Number of patients 
Never 14 
Once every other month 1 
Once a month 1 
Several times a month 2 
Once a week 8 
Several times a week 5 
Daily 27 
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3.12 Use of Inhaled corticosteroid therapy 
Forty eight (83%) patients were prescribed and were using inhaled corticosteroids at 
the time of the study. The average dose of inhaled corticosteroid was the equivalent of 
800mcgs beclamethasone. This was not correlated to the number of exacerbations                  
(r = - 0.10) or the 24hour sputum volume (r = 0.02). 
  
3.13  Discussion 
Our cohort of patients is comparable to other series in age and sex match. Mean age in 
other series has been reported as 57.2 [5], 63 [61], 57 [127] and 56 years [109]. 
Younger patients are rare. In one series only 6% of patients were younger than 30 
years [5]. Although some studies have reported a wider age range [19-92 years] [109]. 
Female predominance is reported in most studies. Our group is therefore 
representative. Female population within other studies have been reported as 64% 
[109], or up to 68% [5, 61] . 
The Mean (SD) Body Mass Index (BMI) for this group of patients was 25 kg/m2, 
indicating a healthy cohort. This also points to a bias in the study as patients who were 
able to attend the out patients when unwell were more likely to consent to the study. 
However this is comparable to other groups [21, 22]. Underweight subjects (lower 
BMI) have a higher mortality rate. Mortality is thought to be higher when the BMI is 
less than 20 kg/m2 [21]. Women are also known to have a higher BMI [21]. 
A formal diagnosis of bronchiectasis can often be delayed. However patients often 
recall the duration of disease based on symptoms such as chronic production of 
sputum. Most patients are able to identify the time of onset of symptoms. Patients also 
identify a definite time at which potential pulmonary insult or injury has occurred. This 
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varies between 14 years to 20 years of age [5, 127]. There is sometimes a lag between 
insult and the onset of symptoms and has been reported as 13.6 years in one series [5]. 
The mean duration of suffering with the disease was 37 years (range 4-85 years). This 
is well comparable to other reports. 
A majority of patients with bronchiectasis are non-smokers. Even those who have 
previously smoked tend to discontinue due to chest discomfort. In a Texan series 55% 
of patients were lifetime non-smokers [5], whilst in an Australian cohort 82% of 
patients were non-smokers [17]. Mean pack years has been reported to be between 8.9-
29.8 [5, 21]. Our patients are comparable to other published series with 53% being 
non-smokers. 
Aetiologically, between 30-80% of patients are reported to have idiopathic 
bronchiectasis [5, 71]. The proportion of patients with idiopathic bronchiectasis is 
much smaller in our cohort compared to other groups. Our cohort of patients is well 
characterised and have been studied in some detail [18]. Proportion of patients with 
other causative factors of bronchiectasis is comparable to our group. In a large series 
from Texas, 35% had post pneumonic, 20% post childhood infections, 10% post 
granulomatous disease, 4% genetic disease  causing bronchiectasis (α1-antitrypsin 
disease, immotile cilia syndrome and cystic fibrosis) [5]. 
The average number of exacerbations in a year seems to vary. While some suggest that 
patients may suffer an exacerbation only every eight months[27], others think it more 
frequent, between 2-4 times a year [71, 181]. Our group identifies with the latter two 
studies and our patients suffered a mean of three exacerbations the preceding year. 
Patients with antibiotic resistance seem to suffer significantly more number of 
exacerbations in a year than those with sensitive organisms [17]. Use of antibiotic 
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prophylaxis may alter the number of exacerbations that patients suffer in a year. In one 
study the average number of exacerbation per year significantly reduced from 10 to 5 
per year when these patients were treated with long term Azithromycin (mean duration 
of 9.1 months) [61]. Admissions to Hospital are rare, as most patients are treated with 
oral antibiotics. Patients needing intravenous antibiotics may be admitted to hospital at 
some centres. At the Lung Defence Clinic at Papworth, patients are trained to self-
administer intravenous antibiotics. This reduces the rate of hospital admissions. Two of 
our patients were admitted to hospital. Both had other comorbidities such as chronic 
obstructive airways disease and needed advanced nursing and medical care. Rates of 
hospitalisation have been variously reported as 0.6-1.6 per year [181]. 
 
Inhaled corticosteroids have been shown to have a clear benefit in asthma. However in 
bronchiectasis evidence for use remains limited. When fluticasone is administered at a 
dose of 500mcgs twice daily, 24 hour sputum volume is improved but it has no 
influence on the number of exacerbations. This may suggest that exacerbations are 
infective while improvement from ICS is inflammatory [71]. We were unable to 
correlate the dose of inhaled corticosteroids in our study with either the frequency of 
exacerbations or the 24 hour sputum volume. 
 
The benefit of mucolytic therapy in bronchiectasis is doubtful [8]. Recombinant 
deoxyribonuclease I administered in conjunction with standard therapies is effective in  
treatment of patients with cystic fibrosis. However this effect is not observed in non 
CF bronchiectasis [27]. A 15 day trial of erdosteine (a mucoactive thiol derivative) 
along with chest physiotherapy has been shown to improve the FEV1 by 200mls in a 
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randomised controlled trial. However this was in a small group of 30 patients [182]. 
Inhaled mannitol increases mucus clearance in patients with bronchiectasis by an 
unclear mechanism. The effect of mannitol on lung function, health status and sputum 
properties was investigated. Mannitol significantly improved the health status over 12 
days and this improvement was maintained for 6-10 days after cessation of treatment. 
In addition, mannitol reduced the tenacity, increased the hydration of mucus acutely 
and improved cough clearability in patients with bronchiectasis [183]. A trial of 
mucolytic is often offered to our patients to see if it helps ameliorate symptoms. 
Nebulised hypertonic saline can be used safely and effectively as an adjunct to 
physiotherapy in selected patients. A long-term prospective trial is now indicated to 
determine its effectiveness on long-term infection rate, quality of life and lung function 
[184]. 
We think there may be a bias in recruitment of subjects to the study. Patients who lived 
within a convenient travel distance to the Hospital tended to consent to the study.  
Patients living further away were less keen and admitted to being unable to travel all 
the way when ill. The use of prophylactic antibiotics compared to other cohorts may 
also introduce a bias within this study. Otherwise our cohort is fairy representative and 
comparable to groups in other reports in terms of a demographic match.  
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Chapter 4 
 
Analysis of clinical features in bronchiectasis 
Symptoms and signs of disease in stable state and in acute exacerbations from 
the COBEX study 
 
4.1  Introduction 
 
The Clinical features of bronchiectasis have been described in Chapter 1. It was our 
aim to establish using the COBEX study cohort whether we could track symptom 
scores and show differences at an exacerbation with improvement on treatment without 
the use of diary cards. We employed Visual Analogue scores and the Modified Borg’s 
breathlessness score. We also wished to characterise changes in clinical signs i.e. body 
temperature, respiratory rate, oxygen saturations and chest auscultatory findings during 
the course of an exacerbation. 
 
4.1.1 Visual analogue Score 
 
Pain, as a symptom, is often scored on a scale of 1 to 10. Medication is often 
ordered and administered on the basis of the patient's subjective pain response. 
A similar self-rating scale could be used for patients with varying levels of 
symptoms in patients with bronchiectasis.  
 
A Visual Analogue Scale is a measurement instrument that tries to define a 
characteristic or attitude that is believed to range across a continuum of values that 
cannot easily be directly measured [142]. From the patient's perspective this spectrum 
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appears continuous and their symptoms do not take discrete jumps, as a categorization 
of none, mild, moderate and severe would suggest. The VAS captures this idea of an 
underlying continuum. Operationally a VAS is usually a horizontal line, 100 mm in 
length, anchored by word descriptors at each end, as illustrated in Appendix iii. The 
patient marks on the line the point that they feel represents their perception of their 
current state. The VAS score is determined by measuring in millimetres/centimetres 
from the left hand end of the line to the point that the patient marks.  
 
As such an assessment is highly subjective, these scales are of most value when 
looking at change within individuals, and are of less value for comparing across a 
group of individuals at one time point. Therefore the VAS is useful in trying to 
produce interval data out of subjective values that are at best ordinal [185]. 
 
Visual analogue scores have been used to assess dyspnoea in bronchiectasis. In a study 
to looking at the beneficial effects of acupressure in bronchiectasis, the authors used a 
modified VAS score to measure improvement in dyspnoea [186]. A change in 
modified VAS has also been used to measure change in "chest unpleasantness due to 
secretions" after airway clearance techniques [187].  
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4.1.2  Borg’s Breathlessness score 
 
The sensation of breathlessness is a sensory experience that is perceived, interpreted, 
and rated by the individual [188]. An objective assessment of breathlessness includes 
clinical examination: evidence of cyanosis, respiratory rate, ability to speak in full 
sentences. Simple bedside tests used in respiratory diseases include measuring a peak 
flow, trans-cutaneous oxygen saturation measurement (SaO2) and blood gas analysis. 
 
The Modified Borg breathlessness (MBS) score is a simple questionnaire that is a valid 
and reliable assessment tool. Patients were asked to rate their breathlessness by 
indicating a score between 0 (no breathlessness at all) and 10 (maximal 
breathlessness). Patients with a Borg score of zero were considered to be free of 
breathlessness. Subjects with any other Borg score were taken to have breathlessness 
[189, 190]. Table 4.1 is the modified Borg’s breathlessness score used in the COBEX 
study. 
 
Objective measurement of dyspnoea using the MBS has been described in other 
respiratory conditions. In a group of patients with asthma the MBS was related to 
changes in airflow obstruction [191]. In COPD, a strong relationship between MBS 
and respiratory effort with exercise has been described [192] and an association with a 
6 minute treadmill walk test has been reported [193]. In a study using normal 
volunteers with induced dyspnoea, it was found that subjects could distinguish between 
different sensations of breathlessness and that the term breathlessness encompassed 
multiple sensations. It was found that subjects could distinguish between levels of 
breathlessness using the MBS [52]. 
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Table 4.1: The modified Borg’s breathlessness Score (MBS).Using the following score 
of 0-10, breathlessness is assessed. Zero is nothing at all and 10 is maximal 
breathlessness. 
 
SCALE SEVERITY 
0 No breathlessness at all 
0.5 Very very slight (Just Noticeable) 
1 Very slight 
2 Slight 
breathlessness 
3 Moderate 
4 Somewhat severe 
5 Severe 
breathlessness 
6 
 
7 Very severe breathlessness 
8 
 
9 Very very severe (almost maximum) 
10 Maximum 
 
Note: The word "breathlessness" was added in our version of the scale for clarification 
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4.2 Aims 
 
Symptoms in bronchiectasis are known to deteriorate during an exacerbation. This has 
not been quantified previously. We have attempted to quantify symptoms at baseline 
(in stable state) and during an exacerbation. We wished to measure change in 
symptoms with a view to defining clear end points towards which future interventions 
can be directed. 
A clinician’s assessment was also carried out. The aim was to measure clinical 
parameters during the course of an exacerbation of bronchiectasis. 
The clinician’s assessment included out-patient objective measurements of  
 
• Blood pressure – Systolic and diastolic 
• Respiratory rate 
• Oxygen saturations as measured by standard digital pulse oximetry 
• Body temperature measured in degrees centigrade 
• Examination of the hand for finger clubbing 
• Auscultation of the chest 
 
4.3  Methods 
 
As described in Chapter 2, section 2.11 patients were recruited from the Lung Defence 
Clinic at Papworth Hospital, Cambridge. All patients had well characterised Non CF 
Bronchiectasis1. All patients were screened at Baseline (No exacerbation in the 
preceding 4 weeks), Day 1 of an exacerbation (not having commenced antibiotics), 
Day 7 during treatment with antibiotics, Day 14 completion of treatment with 
antibiotics and Day 42 on recovery from exacerbation. 
79 
 
4.3.1 Study Protocol 
 
4.3.1.1 Visual analogue scale     
 
Patients attended the Research Clinic and a ten point visual analogue scale was 
completed at each visit by all subjects. The following symptoms were assessed using a 
ten point visual analogue scale: 
 Cough 
 Breathlessness, 
 Chest pain  
 Chest discomfort 
 Volume of sputum 
 Colour of sputum  
 Fatigue 
The VAS is included in the Clinical Record form in Appendix iii. 
 
4.3.1.2 Modified Borg’s breathlessness score. 
 
All patients completed a Modified Borg’s breathlessness score (MBS) at each 
visit. 
 
The MBS is included in the Clinical record form in Appendix iii. 
 
4.3.1.3 Clinical examination 
Blood pressure was measured using an electronic device. Oxygen saturations were 
recorded using digital pulse-oximetry. Body temperature was measured using a 
sublingual probe. The clinician then conducted a full respiratory physical examination. 
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4.4  Statistics 
 
VAS scores are described in absolute values with inter quartile ranges.  
MBS scores are described as absolute values with standard deviation.  
All correlations are made with linear regression using the Pearson correlation 
coefficient (r). A global test for repeated measures (ANNOVA) was used to measure 
change over time. Change was considered significant if p≤0.05 
 
4.5 Results  
 
4.5.1 Visual analogue scale 
4.5.1.1   Stable state bronchiectasis 
Fifty-five patients completed the Visual analogue scale questionnaires at baseline. 
Patients scored fatigue maximally over cough and sputum production. Values from the 
VAS questionnaires completed in stable state are listed in Table 4.2. 
 
4.5.1.2 Acute exacerbation of bronchiectasis. 
Twenty two patients were followed through an exacerbation having been studied at 
baseline. Nineteen of these patients completed all four visits. There was an increase in 
the perception of all measured symptoms at Day 1 of exacerbation. This trend was 
reversed by Day 14 and there was no difference between Baseline and Day 42 recovery 
from exacerbation. Values from VAS questionnaires completed during visits made at 
the time of an exacerbation are listed in Table 4.3. Graphical representation of each of 
the symptoms recorded on the visual analogue score at different times during the 
exacerbation are shown in figures 4.2 – 4.8 
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Table 4.2: Median and inter quartile range visual analogue scale scores in centimetres 
for patients in steady state bronchiectasis (not having had an exacerbation in the 
preceding four weeks). 
 
 
 Baseline Inter quartile range 
Breathlessness 
 
2.70 1.2-4.1 
Chest pain 
 
0.97 0.15-0.95 
Chest tightness 
 
1.66 0.4-2.4 
Colour of sputum 
 
2.43 1-3.4 
Volume of sputum 
 
2.67 0.95-4.65 
Cough 
 
2.95 1.1-4.75 
Fatigue 
 
3.86 1.45-5.4 
 
 
 
 
 
 
 
 
Table 4.3: Median and inter quartile range visual analogue scale scores in centimetres 
for patients during an acute exacerbation of bronchiectasis. 
 
 Baseline Day 1 Day 14 Day 42  p value 
Breathlessness 
 
2.20 
(1.2-3.1) 
5.55 
(3.5-7.4)        
1.95 
(1.5-4.65)       
1.6 
(0.45-3.2) 
p<0.001 
Chest pain 
 
0.25  
(0.1-0.8)        
1.75 
(0.2-2.9)        
0.9  
(0.2-1.4)       
0.6  
(0.2-1.2)      
p=0.012 
Chest tightness 
 
2.1 
(1.3-4.7) 
 
4.8  
(2.2-6.9) 
1.35 
(0.9-2.95) 
0.9  
(0.2-2.55)      
p<0.001    
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Colour of 
sputum  
1.9 
(0.7-2.5) 
5.9 
(3.1-7.8) 
2.0 
(0.7-3.4)    
1.7 
(0.3-4.3) 
p<0.001  
Volume of 
sputum 
1.5 
(0.3-2.9) 
4.0 
(2.4-6.6) 
1.8 
(0.8-4.8) 
1.1 
(0.5-2.8) 
p<0.001   
Cough 
 
2.1 
(1.3-4.7) 
6.3 
(5.0-7.8) 
4.2 
(2.0-5.2)    
1.4 
(0.8-4.4) 
p<0.001             
Fatigue 
 
3.5 
(1.2-5.9) 
7.1 
(5.7-8.2) 
3.1 
(1.3-5.7)    
1.7 
(0.6-3.0) 
p<0.001         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Box plot showing the median and inter quartile range in centimetres for 
breathlessness as scored on the visual analogue score. The x-axis depicts the time of 
visit - baseline (steady state with no exacerbation in the preceding 4 weeks), Day 1 
onset of exacerbation, Day 7 on treatment for exacerbation, day 14 completion of 
antibiotic treatment and Day 42 recovery from exacerbation. The y-axis depicts visual 
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analogue score in centimetres. All extreme observations are marked with an *. The 
change was significant over the course of the exacerbation. p<0.001  
 
 
 
 
Figure 4.2: Box plot showing the median and inter quartile range in centimetres for 
chest pain as scored on the visual analogue score. The x-axis depicts the time of visit - 
baseline (steady state with no exacerbation in the preceding 4 weeks), Day 1 onset of 
exacerbation, Day 7 on treatment for exacerbation, day 14 completion of antibiotic 
treatment and Day 42 recovery from exacerbation. The y-axis depicts visual analogue 
score in centimetres. All extreme observations are marked with an *. The change was 
significant over the course of the exacerbation. p=0.012  
 
 
Figure 4.3: Box plot showing the median and inter quartile range in centimetres for 
chest tightness as scored on the visual analogue score. The x-axis depicts the time of 
visit - baseline (steady state with no exacerbation in the preceding 4 weeks), Day 1 
onset of exacerbation, Day 7 on treatment for exacerbation, day 14 completion of 
antibiotic treatment and Day 42 recovery from exacerbation. The y-axis depicts visual 
analogue score in centimetres. All extreme observations are marked with an *. The 
change was significant over the course of the exacerbation. p<0.001  
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Figure 4.4: Box plot showing the median and inter quartile range in centimetres for 
colour of sputum as scored on the visual analogue score. The x-axis depicts the time of 
visit - baseline (steady state with no exacerbation in the preceding 4 weeks), Day 1 
onset of exacerbation, Day 7 on treatment for exacerbation, day 14 completion of 
antibiotic treatment and Day 42 recovery from exacerbation. The y-axis depicts visual 
analogue score in centimetres. All extreme observations are marked with an *.  The 
change was significant over the course of the exacerbation. p<0.001  
 
 
 
 
Figure 4.5: Box plot showing the median and inter quartile range in centimetres for 
volume of sputum as scored on the visual analogue score. The x-axis depicts the time 
of visit - baseline (steady state with no exacerbation in the preceding 4 weeks), Day 1 
onset of exacerbation, Day 7 on treatment for exacerbation, day 14 completion of 
antibiotic treatment and Day 42 recovery from exacerbation. The y-axis depicts visual 
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analogue score in centimetres. All extreme observations are marked with an *.  The 
change was significant over the course of the exacerbation. p<0.001 
 
 
 
 
 
Figure 4.6: Box plot showing the median and inter quartile range in centimetres for 
cough as scored on the visual analogue score. The x-axis depicts the time of visit - 
baseline (steady state with no exacerbation in the preceding 4 weeks), Day 1 onset of 
exacerbation, Day 7 on treatment for exacerbation, day 14 completion of antibiotic 
treatment and Day 42 recovery from exacerbation. The y-axis depicts visual analogue 
score in centimetres. All extreme observations are marked with an *. The change was 
significant over the course of the exacerbation. p<0.001 
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Figure 4.7: Box plot showing the median and inter quartile range in centimetres for 
fatigue as scored on the visual analogue score. The x-axis depicts the time of visit - 
baseline (steady state with no exacerbation in the preceding 4 weeks), Day 1 onset of 
exacerbation, Day 7 on treatment for exacerbation, day 14 completion of antibiotic 
treatment and Day 42 recovery from exacerbation. The y-axis depicts visual analogue 
score in centimetres. All extreme observations are marked with an *. The change was 
significant over the course of the exacerbation. p<0.001   
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4.5.2    Modified Borg’s Breathlessness score 
 
4.5.2.1       Stable state bronchiectasis 
 
Fifty eight patients were studied in stable state (not having had an 
exacerbation in the preceding 4 weeks).  
The mean (SD) MBS score 3.32(1.6). 
The MBS significantly correlated with the trans-cutaneous oxygen 
saturations (SaO2). (r=0.160, p=0.000) 
 The MBS did not significantly correlate with the partial pressure of 
oxygen while inspiring room air -PaO2 (r=-0.118, p=0.44, n=45).  
The MBS was significantly correlated with FEV1%predicted (r= -
0.334, p=0.012, n=56).  
The MBS was significantly correlated with the breathlessness score 
on the Visual analogue scale (r=0.669, p=0.000, n=55).  
 
4.5.2.2      Acute exacerbation of bronchiectasis 
 
The MBS significantly increased from baseline to day 1(p=0.000). 
The increase persisted despite 7 days of treatment with antibiotics 
(p=0.012). This trend was reversed only by day 14 on completion of 
treatment (p=0.425). There was no difference in the MBS between 
baseline and day 42 (p=0.209) 
Overall there was a significant variation in the MBS over the course 
of the exacerbation (p=0.000). Figure 4.9 
The mean (SD) values of the MBS during the course of an 
exacerbation are listed in Table 4.4. 
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Table 4.4: Mean (SD) values of Modified Borg’s score at different time points during 
the exacerbation 
 
Day 
Modified Borg’s 
breathlessness score 
Mean value 
Standard Deviation Number of patients 
Baseline 3.30 1.4 22 
Day 1 5.95 2.3 22 
Day 7 4.85 2.4 22 
Day 14 3.55 1.3 22 
Day 42 3.60 1.5 20 
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Figure 4.8: Interval plot showing the mean and 95% confidence interval Modified 
Borg’s breathlessness score. The x-axis depicts the time of visit - baseline (steady state 
with no exacerbation in the preceding 4 weeks), Day 1 onset of exacerbation, Day 7 on 
treatment for exacerbation, Day 14 completion of antibiotic treatment and Day 42 
recovery from exacerbation. The y-axis depicts score as listed on the modified Borg’s 
questionnaire. The change was significant over the course of the exacerbation. p=0.000 
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4.5.3 Clinical examination 
 
4.5.3.1 Blood pressure 
 
The mean (SD) systolic blood pressure was 137(19) mm Hg and mean diastolic blood 
pressure was 77(13) mm Hg. This was within the normal range for age and sex of this 
cohort. (n=57). 
The systolic blood pressure demonstrated a fall of 4mmHg between stable state and 
Day 1. However this was not statistically significant, p=0.120. There was no 
significant change in the systolic blood pressure during the course of the exacerbation, 
p=0.849. Figure 4.10 demonstrates the mean and 95% confidence interval change in 
systolic blood pressure at various visits during the acute exacerbation. 
The diastolic blood pressure demonstrated a fall of 4mmHg between stable state and 
Day 1. However this was not statistically significant, p=0.234. There was no 
significant change in the diastolic blood pressure during the course of the exacerbation, 
p=0.785. Figure 4.11 demonstrates the mean and confidence interval change in 
diastolic blood pressure at various visits during the acute exacerbation. 
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Figure 4.9: Interval plot showing the mean and 95% confidence interval systolic blood 
pressure. The x-axis depicts the time of visit - baseline (steady state with no 
exacerbation in the preceding 4 weeks), Day 1 onset of exacerbation, Day 7 on 
treatment for exacerbation, day 14 completion of antibiotic treatment and Day 42 
recovery from exacerbation. The y-axis depicts the blood pressure in mm Hg. The 
change was not statistically significant over the course of the exacerbation. p=0.849 
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Figure 4.10: Interval plot showing the mean and 95% confidence interval diastolic 
blood pressure. The x-axis depicts the time of visit - baseline (steady state with no 
exacerbation in the preceding 4 weeks), Day 1 onset of exacerbation, Day 7 on 
treatment for exacerbation, day 14 completion of antibiotic treatment and Day 42 
recovery from exacerbation. The x-axis depicts the blood pressure in mm Hg. The 
change was not statistically significant over the course of the exacerbation. p=0.785 
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4.5.3.2  Oxygen saturations as measured by digital pulse oximetry 
 
The mean (SD) oxygen saturations were 96 (2.2) % on room air (Range 90 – 100%). 
The mean oxygen saturations as measured by pulse oximetry fell by 1.2% between 
stable state and Day 1[(p=0.483).There was no significant change in the oxygen 
saturations measured at room air during the course of the exacerbation of 
bronchiectasis. (p=0.559). Figure 4.12 demonstrates mean and 95% confidence interval 
oxygen saturations during the course of an exacerbation. 
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Figure 4.11: Interval plot showing the mean and 95% confidence interval oxygen 
saturations at room air. The x-axis depicts the time of visit - baseline (steady state with 
no exacerbation in the preceding 4 weeks), Day 1 onset of exacerbation, Day 7 on 
treatment for exacerbation, day 14 completion of antibiotic treatment and Day 42 
recovery from exacerbation. The y-axis depicts the per centage saturation. The change 
was not statistically significant over the course of the exacerbation. p=0.559 
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4.5.3.3  Body temperature as measured by the sublingual probe. 
 
The temperature was less than 38 degrees centigrade in all our patients at baseline 
(n=58).Only one patient demonstrated a temperature of greater than 38 degrees 
centigrade at Day 1 of the exacerbation. 
 
4.5.3.4  General clinical examination and auscultatory findings 
 
Only 10% of patients had finger clubbing (6/55). On auscultation of the chest, in 
steady state, seventeen patients were found to have normal breath sounds. Eleven 
patients had unilateral crackles, 28 had bilateral crackles and 2 patients had high 
pitched inspiratory squeaks. There was no significant change in the auscultatory 
findings during the course of the exacerbations. Table 4.5 lists the auscultatory 
findings in steady state bronchiectasis. 
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Table 4.5: Auscultatory findings in patients of the COBEX study in steady state 
bronchiectasis. 
 
Number of 
patients Wheeze 
Unilateral 
crackles 
Bilateral 
crackles 
High pitched 
inspiratory 
squeaks 
Baseline 0 4 7 1 
Day 1 2 5 7 1 
Day 7 3 4 5 1 
Day 14 0 6 0 3 
Day 42 0 0 4 0 
 
 
95 
 
4.6  Discussion 
 
We have attempted to quantify subjective symptoms in bronchiectasis with a 
view to measure change. Most symptoms in bronchiectasis vary at the time of 
an exacerbation. The Visual analogue scores have demonstrated the validity of 
our definition of an exacerbation. 
 
Our patients gave fatigue a very high score both in steady state and during an 
exacerbation on the visual analogue scale. This would clearly affect quality of 
life and is essential that it be addressed when treating an exacerbation. Fatigue 
can be a presenting feature in bronchiectasis [194] and can be out of proportion 
to the severity of disease [50]. We have demonstrated a clear measurable 
change in this symptom on a simple VAS questionnaire. 
 
Breathlessness was the second most severe symptom recorded by our patients. 
The mean score for breathlessness at baseline as recorded on the VAS- 2.7 cm 
is comparable to other reports. Mean (SD) score for perception of 
breathlessness, measured on a visual analogue scale, to assess the usefulness of 
gravity-assisted drainage positions with a head-down tilt in clearing sputum was 
2.3 (1.6) and this improved to 3.3 (2.0) cm [195]. 
 
We found a significant deterioration in breathlessness at the onset of an 
exacerbation as measured on the VAS. This trend was reversed on treatment 
with antibiotics by day 14 and back to baseline at this time and on recovery 
from the exacerbation. 
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Breathlessness as measured on the MBS also increased from baseline to onset of 
exacerbation. This improved on treatment with antibiotics by Day 14. Other workers 
have used a change in Borg’s score in bronchiectasis to demonstrate improvement in 
breathlessness in relation to airway clearance techniques and histamine challenges. 
However they report a change in score rather than absolute values [196, 197] 
 
In our study the visual analogue score strongly correlates to the MBS. This has 
previously been shown in healthy young volunteers with dyspnoea during exercise 
[198]. The MBS was also significantly correlated to trans-cutaneous saturations (SaO2), 
FEV1 per centage predicted, and the partial pressure of oxygen on room air as 
measured with a capillary blood gas analyser with samples taken from an ear lobe 
(PaO2).  
Surprisingly, cough featured third in severity in stable state and second at the onset of 
an exacerbation in our patients. Other reports have placed it as the primary and most 
important symptom. A recent study has identified different phenotypes of patients with 
bronchiectasis in relation to the onset of a productive cough and this may explain some 
of the differences in cohorts [199]. We demonstrated a significant increase in cough as 
measured by the VAS that improved and reverted to baseline on treatment and on 
recovery from the exacerbation respectively. The score on VAS for cough in our study 
in stable state (2.95) is comparable to other published reports. In a study looking at the 
improvement in symptoms after bronchopulmonary hygiene physical therapy in stable 
state patients, there were significant improvements in cough symptoms (mean cough 
VAS before 43.3 vs. after 27.5mm) [105]. 
The volume and colour of sputum increased significantly at the onset of the 
exacerbation and reverted to baseline after treatment by Day 14. Chest discomfort and 
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pain were less important to our patients. However we recorded a significant increase in 
these symptoms too.  
We found no significant abnormalities when patients were clinically examined. Pulse 
rate, body temperature, systolic and diastolic blood pressure remained unchanged 
during the course of the exacerbation.  
We acknowledge that the small number of patients included in our study is a 
drawback. Also the patient cohort was clinically less ‘sick’ and possibly had 
milder disease.  
 
The visual analogue score for various symptoms as described and the Modified Borg’s 
score are both very effective tools in measuring change and assessing outcomes in the 
management of bronchiectasis. They could certainly be used as endpoints when future 
therapeutic interventions are studied. Measurement of blood pressure, body 
temperature and oxygen saturations are unlikely to be of any benefit in future studies 
directed at measuring efficacy of any intervention in non cystic fibrosis bronchiectasis. 
 
An exacerbation can be detected on patient history of cough, increased volume of 
sputum, change in colour of sputum, chest pain and discomfort, breathlessness and 
fatigue. For future longitudinal studies patients could complete visual analogue scores 
online without attending the out-patient clinic. 
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Chapter 5 
 
Quality of Life in stable bronchiectasis and during an acute exacerbation from the 
COBEX study 
 
 
5.1 Background 
 
Direct measurement of the impact of disease on patients’ lives is necessary to assess 
whether interventions are of benefit [100]. Health-related quality of life (HR-QoL) is 
impaired in stable state bronchiectasis and deteriorates during an acute exacerbation 
[83, 102]. Frequent exacerbations cause a vicious cycle of bronchial wall destruction 
and further bacterial colonisation [6]. HR-QOL is a relevant and quantifiable outcome 
of care and is an important marker for evaluating existing and new therapies in 
bronchiectasis. 
 
Most aspects of bronchiectasis impact on the quality of life. Appropriate management 
of symptoms on identifying the underlying aetiology has a positive impact on the 
quality of life in these patients. Daily sputum production, chronic cough, upper airway 
symptoms and abnormal tiredness are all associated with a reduction in health-related 
quality of life (HR-QoL) in bronchiectasis [46, 62, 102, 104, 105].  Some studies 
suggest that the number of exacerbations in the preceding year is an important 
contributor to HR-QoL [46, 53]. Appropriate treatment with antibiotics improves 
inflammation and thus cough, wheeze and sputum volume. A significant improvement 
in HR-QoL between onset of exacerbation and completion of treatment has been 
previously reported [83].  
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5.2 Measuring Health-related quality of life in bronchiectasis  
 
Instruments used for the assessment of HR-QoL in bronchiectasis. 
 
Various instruments have been used in assessment of the quality of life in 
bronchiectasis. The St. George Respiratory Questionnaire (SGRQ) has been used in 
more than eight studies of stable state bronchiectasis [102, 183, 200-205]. Other 
instruments include the SF-36 [102], The Chronic respiratory disease questionnaire 
[83] and nonspecific patient reported quality of life measures [206]. 
 
5.2.1 St George’s Respiratory Questionnaire 
 
The original St. George Respiratory Questionnaire (SGRQ) was developed in 1990 by 
Jones et al to quantify the impact of disease on the health and well-being of patients 
with COPD [207]. Since then, the SGRQ has been translated into many languages and 
has been validated for use in different ethnic groups. To date, several adaptation and 
validation studies have been published in English and non-English populations. These 
studies have performed on Swedish, Spanish, Japanese, and American-English and 
Chinese speaking populations, who have independently validated the reliability and 
sensitivity of the translated versions. While other quality-of-life instruments are 
available, the SGRQ is the only validated instrument in the assessment of patients with 
bronchiectasis [207-210] 
The SGRQ is a self-administrated health-related QoL measure containing 50 items and 
76 weighted responses divided into three components: symptoms, activity, and 
impacts. The subscales include symptoms (8 items), activity (16 items) and impacts 
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(26 items).The symptoms subscale refers to the frequency and severity of cough, 
wheezing, expectoration, or exacerbation. The activity subscale in turn refers to the 
limitations in patient activity due to dyspnoea, and involves 16 dichotomous response 
items. The impact subscale summarizes the alterations in the psychological, 
occupational, and social spheres, based on the way in which the patient perceives his or 
her disease. It consists of 26 items addressed by eight questions. The total 
questionnaire score and score corresponding to each of the three subscales are 
calculated as a function of the item scores, based on a range from 0 to 100 points. A 
higher SGRQ score, either the total score or individual component score, represents a 
poorer quality of life [207-209]. A 4 unit difference in the total SGRQ score has been 
established as a clinically significant score [208]. The questionnaire has been designed 
for self-administration in 10 min. The recall period of the SGRQ symptoms component 
needs to be shortened to make more appropriate for the use during an acute 
exacerbation [211]. 
 
5.2.2 Euroqol 
 
The Euroqol 5 dimension (EQ-5D) is a generic instrument for the measurement of      
HR-QoL. The EQ-5D includes single item measures of: mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression. Each item is coded using 3-levels     
(1 = no problems; 2 = some problems; 3 = severe problems). The instrument includes a 
global rating of current health using a visual analogue scale [142] ranging from 0 
(worst imaginable) to   100 (best imaginable). 
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EQ-5D is designed for self-completion by subjects within a study. It is cognitively 
simple, taking only a few minutes to complete. Instructions to subjects are included in 
the questionnaire. 
 
5.2.3 Assessment of HR-QoL during acute exacerbations in bronchiectasis. 
 
Only two studies have so far assessed the quality of life during an acute exacerbation 
of bronchiectasis [80, 83]. Murray et al used the SGRQ, which is validated in 
bronchiectasis. The questionnaire was adapted for the end of exacerbation assessment 
to ask about symptoms in the preceding week. In this prospective cohort study patients 
were asked to complete the SGRQ at the start of an exacerbation and one week 
following antibiotic treatment completion. There was a significant improvement in all 
individual domain scores of the SGRQ following completion of antibiotics. Eighty-
nine per cent of patients showed an improvement of more than 4 units in all domains 
[80]. 
Courtney et al have used the chronic respiratory disease questionnaire (CRDQ) in their 
study of acute bronchiectatic exacerbations. In this prospective cohort study patients 
completed the questionnaire at the onset of an exacerbation, on completion of 
antibiotics at day 14 and four weeks after the completion of antibiotics. A significant 
improvement was noted in three of the four domains (dyspnoea, emotional and 
mastery) of the CRDQ. All the improvement was seen by Day 14 and there was no 
further change in 4 weeks [83]. 
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5.3 Aims 
 
 
The aim of this study was to define the change in HR-QOL during the course of an 
acute exacerbation of bronchiectasis. Describing a significant change will help in using 
HR-QOL as an endpoint to study therapeutic interventions. 
 
5.4 Methods 
 
 
In this study two questionnaires have been to assess HR-QoL - The SGRQ and the 
Euroqol. 
 
The SGRQ was completed by all patients at Day 0 (baseline, in stable state), at                
Day 1(onset of acute exacerbation and prior to commencement of antibiotics) and   
Day 42 (on recovery from acute exacerbation).  
The Euroqol was completed by all patients at Day 0 (baseline, in stable state), Day 
1(onset of acute exacerbation and prior to commencement of antibiotics), Day 14 (on 
completion of antibiotics) and Day 42 (on recovery from acute exacerbation).  
The schedule of questionnaires employed in the study is listed in table 5.1. The 
questionnaires themselves are appended for information. St Georges respiratory 
questionnaire employed in this study can be found in the Appendix 2 and the EuroQol 
questionnaire employed in this study can be found in the Appendix 3. 
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Table 5.1:  Schedule of the two HR-QoL questionnaires employed in the COBEX 
study. The columns (Day 0, Day 1, Day 14 and Day 42) indicate the visit in stable state 
and during an exacerbation of bronchiectasis. 
 
 Day 0 Day 1 Day 14 Day 42 
 
Euroqol 
 
√ 
 
√ 
 
√ 
 
√ 
 
St George 
Respiratory 
Questionnaire 
 
 
√ 
 
√ 
 
  
√ 
 
 
 
 
5.5 Statistics 
 
Data analysis was performed using statistical software (SPSS version 14). Analysis of 
variance was used to compare the questionnaire scores between the four groups and the 
Fisher test for pair wise comparisons. A 4 point change in the SGRQ was considered a 
clinically significant improvement. Values are expressed as Mean±SD. Differences 
were considered significant at p-values less than 0.05. 
 
 
 
5.6 Results  
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5.6.1 St Georges Respiratory Questionnaire 
 
 
Stable state bronchiectasis 
 
Quality of life scores in the 3 domains and total score at baseline (in stable state) are 
listed in Table 5.2. The mean score was higher in the symptoms domain and was 
65.04. The activities score was less affected in stable state (49.66) than symptoms 
followed by the impacts score (30.19).  
 
Table 5.2: Mean, minimum and maximum score in the different domains of the                   
St Georges Respiratory Questionnaire during stable bronchiectasis in the study cohort 
 
 Minimum Maximum Mean Std. Deviation 
Symptoms score 31.47 95.49 65.04 16.40 
Activities score 41.00 93.86 49.66 25.10 
Impact score 23.93 57.13 30.19 14.80 
Total score 12.90 72.01 42.62 16.34 
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Acute exacerbation of bronchiectasis 
Thirteen patients completed a questionnaire at baseline, Day 1 and Day 42. In the 
symptom domain, there was no significant change during the course of the 
exacerbation, p= 0.269. There was no significant deterioration between stable state and 
onset of the exacerbation, p= 0.160. Table 5.3 lists the mean [SD] values of symptom 
sub-scores at baseline (Day 0), onset of exacerbation - Day 1 and completion of 
exacerbation - Day 42.  Figure 5.1 is a box plot depicting median values of symptom 
scores at baseline, Day 1 or onset of exacerbation and Day 42 on completion of the 
exacerbation. 
 
Table 5.3: Mean (SD) symptom sub-scores on the St Georges respiratory questionnaire 
     during an acute exacerbation of bronchiectasis 
 Mean score Standard deviation N 
Day 0 
Baseline, Stable state 66.57 13.30 13 
Day 1 
Onset of exacerbation 
Prior to 
commencement of 
antibiotics 
59.38 21.80 13 
Day 42 
On recovery from 
acute exacerbation 
60.70 18.50 13 
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Figure 5.1: Median and SEM values of the symptom sub-score on the St George’s 
Respiratory Questionnaire at baseline (stable state), onset of (Day 1) and 4 weeks later 
(Day 42), in patients with an acute exacerbation of bronchiectasis. The x-axis lists the 
time point during the exacerbation and the y-axis is the symptom score on the SGRQ. 
No significant difference was detected between stable state and onset of exacerbation 
p=0.160, or over the course of the exacerbation p = 0.269. 
 
Baseline Day 1 Day 42 
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In the Activities domain, although there was an increase in the score between baseline 
and onset of exacerbation suggesting deterioration, however this was not statistically 
significant, p=0.122. The change during the course of the exacerbation was not 
statistically significant either, p=0.296. Table 5.4 lists the mean [SD] values of 
activities score at baseline (Day 0), onset of exacerbation - Day 1 and completion of 
exacerbation - Day 42.  Figure 5.2 is a box plot depicting median values of activities 
sub-score at baseline, Day 1 or onset of exacerbation and Day 42 on completion of the 
exacerbation. 
 
Table 5.4: Mean activity sub-scores on the St George’s respiratory questionnaire 
                 during an acute exacerbation of bronchiectasis 
 
 Mean Std. Deviation N 
Day 0 
Baseline, Stable 
state 
57.17 17.35 8 
Day 1 
Onset of 
exacerbation 
Prior to 
commencement of 
antibiotics 
59.15 25.79 8 
Day 42 
On recovery from 
acute exacerbation 
50.84 21.61 8 
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 Figure 5.2: Box plot depicting median and SEM values of the activities sub-score on 
the St George’s Respiratory Questionnaire at baseline (stable state), onset of 
exacerbation-Day 1, and 4 weeks later -Day 42, in patients with an acute exacerbation 
of bronchiectasis. The x-axis lists the time point during the exacerbation and the y-axis 
is the activities score on the SGRQ. No significant difference was detected between 
stable state and onset of exacerbation p = 0.122, or over the course of the exacerbation, 
p=0.296. 
 
 
 
Baseline Day 1 Day 42 
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In the Impacts domain, again deterioration in scores was noted at the onset of an 
exacerbation. However this was not statistically significant p=0.983. There was no 
significant change during the course of the exacerbation either, p=0.160. However 
there was a significant improvement in scores between onset of exacerbation ie Day 1 
and recovery from exacerbation – Day 42, p=0.044. Table 5.5 lists the mean [SD] 
values of the impact scores at baseline (Day 0), onset of exacerbation - Day 1 and 
completion of exacerbation - Day 42.  Figure 5.3 is a box plot depicting median values 
of the impact sub-scores at baseline, Day 1 or onset of exacerbation and Day 42 on 
completion of the exacerbation. 
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Table 5.5: Mean (SD) impacts score on the St George’s respiratory questionnaire 
    during an acute exacerbation of bronchiectasis. 
 
 Mean Std. Deviation N 
Day 0 
Baseline, Stable 
state 
23.23 15.67 6 
Day 1 
Onset of 
exacerbation 
Prior to 
commencement of 
antibiotics 
36.86 17.22 6 
Day 42 
On recovery from 
acute exacerbation 
23.12 17.39 6 
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Figure 5.3: Box plot depicting the median and SEM values of the impacts sub-score on 
the St George’s Respiratory Questionnaire at baseline (stable state), onset of (Day 1) 
and 4 weeks later (Day 42), in patients with an acute exacerbation of bronchiectasis. 
The x-axis lists the time point during the exacerbation and the y-axis is the impacts 
score on the SGRQ. No significant difference was detected between stable state and 
onset of exacerbation  p = 0.983, or over the course of the exacerbation, p=0.160. 
 
 
Baseline Day 1 Day 42 
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Only three patients completed the questionnaires at all periods appropriately to be able 
to analyse data for total scores. There was no significant change in the total scores 
during the course of the exacerbation. p=0.769. Table 5.6 lists the mean [SD] values of 
the total scores at baseline (Day 0), onset of exacerbation - Day 1 and completion of 
exacerbation - Day 42.  Figure 5.4 is a box plot depicting median [95%CI] values of 
the total scores at baseline, Day 1 or onset of exacerbation and Day 42 on completion 
of the exacerbation. 
Table 5.6: Mean (SD) total scores on the St George’s respiratory questionnaire during  
     an acute exacerbation of bronchiectasis 
 
 
 
 Mean Std. Deviation 
Day 0 
Baseline, Stable state 
35.89 8.2 
Day 1 
Onset of exacerbation 
Prior to commencement 
of antibiotics 
35.72 16.8 
Day 42 
On recovery from acute 
exacerbation 
31.80 12.9 
113 
 
T
o
ta
l 
sc
o
re
 o
n
 t
h
e
 S
G
R
Q
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
Figure 5.4: Box plot depicting median and SEM values of the total scores on the St 
George’s Respiratory Questionnaire at baseline (stable state), onset of (Day 1) and 4 
weeks later (Day 42), in patients with an acute exacerbation of bronchiectasis. The x-
axis lists the time point during the exacerbation and the y-axis is the total score on the 
SGRQ. No significant difference was detected over the course of the exacerbation,       
p = 0.769. 
Day 42 Baseline Day 1 
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5.6.2 Euroqol 
 
There was a significant change in the quality of life as measured by the Euroqol 
questionnaire over the course of an exacerbation, (p=0.000). There was a significant 
decrease in the quality of life as measured by the Euroqol questionnaire between 
baseline (stable state) and the onset of an exacerbation, Day 1- p=0.003. However this 
change was reversed by Day 14 at the end of treatment with antibiotics. p=0.800. 
There was no difference in the quality of life between Day 0 (baseline) and Day 42 
(recovery from exacerbation), p=0.797. Table 5.7 lists the mean (SD) Euroqol scores at 
baseline (Day 0), Day 1-onset of exacerbation, Day 14- completion of treatment and 
Day 42-recovery from exacerbation. Figure 5.5 is a box plot depicting median and IQR 
for Euroqol scores at baseline, Day 1, Day 14 and Day 42. 
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Table 5.7: Euroqol score in stable state and during an acute exacerbation of  
    non-CF bronchiectasis 
 
 
 Mean score Standard deviation p value 
Day 0 
Baseline, Stable state 0.84 0.16 
 
p= 0.000 
Day 1 
Onset of 
exacerbation 
Prior to 
commencement of 
antibiotics 
0.67 0.27 
Day 14 
On completion of 
antibiotics 
0.86 0.18 
Day 42 
On recovery from 
acute exacerbation 
0.80 0.21 
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Figure 5.5: Median and SEM values of the total score on the Euroqol at baseline 
(stable state), onset of exacerbation (Day 1), at the end of treatment (Day 14), and 4 
weeks after the onset of an acute exacerbation (Day 42), in patients with 
bronchiectasis. The x-axis lists the time point during the exacerbation and the y-axis is 
the median score on the Euroqol questionnaire. Extreme outliers are depicted by an 
asterix. The numbers accompanying these are patient identification numbers from the 
study. There was a significant change in quality of life as assessed by the Euroqol 
questionnaire over the course of an exacerbation, p=0.000. 
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Quality of life at baseline as measured by Euroqol at baseline (stable state) was 
significantly correlated to the number of exacerbations the patients has suffered in the 
preceding 1 year, (r= -0.27, p= 0.04). Figure 5.6 is a scatter plot showing the 
significant relationship between Euroqol scores at baseline and the number of 
exacerbations suffered by the patient in the preceding year. 
 
 
Figure 5.6: Scatter plot of relationship between Euroqol score at baseline and number 
of exacerbations suffered by a patient in the preceding year. The variables on the x-axis 
are the number of exacerbations suffered by the patient while the variables on the y-
axis are the EuroQol score for the same patients. Extreme outliers are depicted by an 
asterix. The numbers accompanying these are patient identification numbers from the 
study.  This was a statistically significant relationship. (r= -0.27, p= 0.04) 
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In stable state bronchiectasis, the quality of life as measured by the Euroqol was not 
significantly related to the total dose of inhaled corticosteroids being used by the 
patients(r= -0.025, p=0.85) Figure 5.7 is a scatter plot showing the relationship 
between Euroqol scores at baseline and the total daily dose of inhaled corticosteroid for 
patients with bronchiectasis in stable state. 
 
 
 
 
Figure 5.7: Scatter plot of relationship between Euroqol score at baseline and the total 
daily dose of inhaled corticosteroid used by a patient. The variable on the x-axis is the 
total daily dose of inhaled corticosteroid used by the patient while the variables on the 
y-axis are the EuroQol score for the same patients. Extreme outliers are depicted by an 
asterix. The numbers accompanying these are patient identification numbers from the 
study. This was not a statistically significant relationship, (r= -0.025, p=0.85). 
 
E
u
ro
Q
o
l 
sc
o
re
 a
t 
b
a
se
li
n
e
 
Total daily dose of inhaled corticosteroid 
119 
 
5.7 Discussion 
 
 
The aim of this study was to assess HR – QoL in patients experiencing an exacerbation 
of bronchiectasis with a view to defining end points for future therapeutic 
interventions. We employed two frequently used questionnaires that have been 
validated in bronchiectasis- St Georges Respiratory questionnaire and the EuroqoL 
questionnaire. Patients were studied in stable state prior to the onset of an exacerbation 
so as establish a baseline to later compare parameters with. 
 
Quality of life scores was assessed in 3 domains (Symptoms, Activity and Impact) by 
the SGRQ. In 2 of these 3 domains (symptoms and activity) we failed to show a 
significant change based on the SGRQ scores alone. This was not in keeping with 
findings in another arm of our study. In particular symptoms as assessed by the Visual 
analogue scale suggested an initial deterioration at the onset of exacerbation followed 
by very significant improvement. There was a significant improvement in the impact 
scores on treatment with antibiotics. 
 
The mean scores on the SGRQ were in our study were (n=22): symptoms score 66±13, 
activity score 57 ± 17; impact score 23 ± 15 and total score 35 ± 8. These are 
comparable to other groups of patients who have been studied in stable where the mean 
scores on the SGRQ were: symptoms score 45.4 ± 18.8, activity score 53.5 ± 23.5, 
impact score 39.7 ± 19.9 and lower than other reports total score 45.5 ± 17.6 and 
Symptoms:47±17, Activity:41±17, Impact:55±19 [46, 110, 205].  
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Local and systemic inflammation improves on treatment with antibiotics but this may 
not be reflected in HR-QoL parameters as measured by the chronic respiratory disease 
questionnaire (CRDQ) [83]. Local inflammation may be modified by inhaled 
corticosteroid. In a randomised study looking at the benefit of inhaled corticosteroid, 
there were no differences among three treatment groups as regards the total SGRQ 
score or scores of the three scales. When patients were administered 100mcg of inhaled 
corticosteroid, a clinically significant improvement (4 points) in total SGRQ score 
from baseline was noted. 3 months of treatment. This improvement persisted at 6 
months [112]. However we were unable to demonstrate any correlation between QoL 
and the dose of inhaled corticosteroid. Comparing the quality life score in groups of 
patients according to colonization, patients colonized by Pseudomonas have a poorer 
quality of life on all scores of the SGRQ. Patient groups colonized by other 
microorganisms also have poor quality of life when compared to those not colonized 
[109]. 
 
The SGRQ in our hands did not prove to be an useful tool to measure change during an 
exacerbation of bronchiectasis. The small number of patients and the even smaller 
number of valid SGRQ questionnaires may contribute to this. This is in contrast to 
other similar studies who have demonstrated a 89% significant improvement in the 
domains of SGRQ during an exacerbation of bronchiectasis. The nature of our study 
was such that it involved repeated out-patients clinic visits. We found a bias in our 
cohort as patients who volunteered, felt they would be able to attend these visits and 
may have had milder disease. 
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The Euroqol on the other hand was found to be very useful. We demonstrated a 
significant change during the course of an exacerbation. The mean score on the 
Euroqol as measured in our study at baseline was 0.84. Other studies report a slightly 
lower value of 0.70 in stable state bronchiectasis [212]. This difference may be 
explained by a difference in the cohort. However the number of patients in both studies 
is small (less than 20) and results should be viewed with caution [183]. 
 
Dyspnoea, FEV1 and daily sputum production are the main variable that best explain 
HR-QoL [210]. As other workers before us, we found that the number of exacerbations 
in the preceding year was significantly correlated to the HR-QoL and propose that it is 
a further determinant. Interventions aimed at reducing these exacerbations will almost 
certainly improve HR-QoL [213]. 
 
Health-related quality of life is a potentially important marker for evaluating existing 
and new therapies in bronchiectasis. We were able to demonstrate a significant change 
in the quality of life as measured by the Euroqol questionnaire during the course of an 
acute exacerbation of bronchiectasis. Quality of life as measured by the SGRQ has 
proven useful in studies measuring chronic symptoms but this questionnaire did not 
pick up change from baseline in our hands.  
The Euroqol is a valid end point that could be used in the assessment of therapeutic 
interventions for acute changes in bronchiectasis in the future. 
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Chapter 6 
 
Lung Function Tests  
Spirometry and Impulse Oscillometry in bronchiectasis in the COBEX 
study. 
 
 
6.1 Introduction 
 
Spirometry has been considered the mainstay of assessment in bronchiectasis. It is 
assumed that because an exacerbation represents a flare of airways disease, that 
spirometry will change at that stage. 
 
Lung function has been well studied in patients with Cystic Fibrosis. Measurement of 
lung function in these patients is known to reflect both acute and chronic changes [90]. 
The Forced expiratory volume in one second (FEV1) has been used as a surrogate 
marker for mortality in Cystic Fibrosis. An acute change in FEV1 caused by mucous 
plugging has been clearly demonstrated in exacerbations of CF and provides a short 
term endpoint [116]. The lung function declines no more than 1% per year in these 
patients [117]. Chronic colonization with Pseudomonas aeruginosa is thought to be an 
independent factor associated with an accelerated decline of lung function [115]. After 
antibiotic treatment for an exacerbation, patients infected with Pseudomonas do not 
show any improvement in FEV1 or FVC, while patients infected with other 
microorganisms show a significant improvement in both indices [80]. In cystic fibrosis 
it is recognised that patients with chronic infection with Pseudomonas aeruginosa have 
reduced survival and a more rapid decline in lung function than patients with chronic 
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infection with Staphylococcus aureus [77]. The evidence in non CF bronchiectasis is 
limited and conflicting. It is possible that Pseudomonas aeruginosa in non-CF 
bronchiectasis can cause accelerated decline in lung function but this can be modified 
by the use of nebulised antibiotic therapy [4]. Frequent severe exacerbations and 
systemic inflammation are also thought to be independent factors associated with an 
accelerated decline of lung function [115]. 
Our clinical experience suggested that FEV1 and FVC did not change despite changes 
in symptoms. We hypothesised that simple spirometry would not change during the 
course of an exacerbation. We also sought to investigate IOS – as a tool for 
longitudinal follow up of bronchiectasis patients. 
 
6.2 Impulse Oscillometry (Forced oscillation technique) 
 
Conventional methods of lung function testing provide measurements obtained during 
specific respiratory actions of the subject. In contrast, the Impulse Oscillometry 
technique (IOS) determines breathing mechanics by superimposing small external 
pressure signals on the spontaneous breathing of the subject. IOS utilises the externally 
applied pressure signals and their resultant flows to determine lung mechanical 
parameters. These external forcing signals, may be mono- or multi-frequency, and are 
applied either continuously or in a time-discrete manner [214] .  
 
These pressure–flow relationships are different to the natural pattern of individual 
respiratory flows, so that measured IOS results are independent of the underlying 
respiratory pattern. Therefore, Oscillometry minimises demands on the patient and 
requires only passive cooperation of the subject.  
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The impulse oscillation technique allows measurement of up to 10 impedance spectra 
per second. This allows a useful analysis of intra-breath variation in impedance, 
comparable to that obtained with mono-frequency applications. However, a 
disadvantage of such high impulse rates is the inability to record longer respiratory 
time constants that may be more informative in respiratory abnormalities. Therefore 
the common application of impulse oscillation utilises recordings of 5 impedance 
spectra (5 impulses) per second [214]. 
 
The resistive component of respiratory impedance, Rrs, includes proximal and distal 
airways (central and peripheral), lung tissue and chest wall resistance. Normally, 
central resistance dominates, depending on airway calibre and the surface of the airway 
walls, while lung tissue and chest wall resistance are usually negligible. Rrs may be 
considered within normal limits if Rrs at 5 Hz (Rrs5) is within 1.64 standard deviation 
of the predicted value. Rrs 5 values between 1.64 and 2 SD above predicted may be 
considered minor, 2+ SD moderate and 4+ SD above predicted severe obstruction 
[215]. 
 
The reactive component of respiratory impedance, Xrs incorporates the mass inertive 
forces of the moving air column in the conducting airways, expressed in the term 
inertance (I) and the elastic properties of lung periphery, expressed in the term 
capacitance (Ca). Respiratory Ca is not identical to compliance. The component of Xrs 
associated with Ca is defined to be negative in sign. It is most prominent at low 
frequencies. In contrast, the component of Xrs associated with inertance is always 
positive in sign and dominates at higher frequencies. Thus, interpretation of Xrs is 
primarily influenced by the oscillation frequency range under consideration. 
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Low frequency capacitive Xrs essentially expresses the ability of the respiratory tract 
to store capacitive energy, mostly in the lung periphery. Xrs5 characterises the lung 
periphery, but is nonspecific as to the type of limitation. Additional information is 
needed to differentiate peripheral obstruction from peripheral restriction [214]. 
 
The most obvious relationship with other pulmonary function tests concerns the use of 
spirometry. Spirometry measures maximal forced respiratory efforts, while IOS 
measures quiet breathing. In bronchiectasis, IOS has not been compared to spirometric 
techniques as yet. 
 
IOS has been used to monitor response to interventions. IOS has been reported to show 
greater sensitivity to inhaled corticosteroid or to beta-agonist inhalation in asthma than 
spirometry. Both inhaled corticosteroids and beta-agonists improve small airways 
function, and IOS responses manifest prominent changes in indices of peripheral 
airway obstruction. In contrast, spirometric sensitivity to small airways function is less 
prominent. Accordingly, it is expected that IOS might provide useful indices of 
peripheral airway change in response to therapeutic interventions [129, 130]. 
 
In patients with chronic obstructive airways disease IOS is able to detect significant 
change after bronchodilator therapy and FEV1 is less sensitive [131] . Also IOS 
measurements, especially indices of peripheral airway function, are significantly 
correlated with health status and dyspnoea in patients with COPD. IOS indices R5-R20 
and X5 are also significantly correlated with the St Georges respiratory questionnaire 
and the MRC scale. Therefore, in addition to its simplicity and non-invasiveness, IOS 
may be a useful clinical tool not only for detecting pulmonary functional impairment, 
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but also to some extent at least estimating the patient's quality of daily life and well-
being [132]. Similarly in cystic fibrosis airway resistances can be adequately estimated 
by forced impulse Oscillometry [216]. 
IOS remains under investigated in non CF bronchiectasis. 
 
 
6.3 Aims   
 
1. To measure variability in spirometric indices during the course of an acute 
exacerbation of bronchiectasis.  
The Functional indices measured are as follows  
• Forced expiratory volume in the first second- actual(FEV1) 
• Forced expiratory volume in the first second per centage predicted (FEV1% 
predicted) 
• Forced Vital Capacity-actual (FVC) 
• Forced Vital Capacity %predicted (FVC % predicted) 
 
2. To determine the sensitivity of Impulse Oscillometry (R5, X5) in patients with 
stable bronchiectasis by comparing it to standard spirometric manoeuvres.  
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6.4 Methods 
 
6.4.1 Spirometry 
 
Dynamic lung volumes were assessed at all visits. Static lung volumes were performed 
at Baseline visit only. Total lung capacity and residual volume were measured by 
helium dilution technique. All manoeuvres were performed after the exhaled breath 
condensate was collected. All measurements were performed to ARTP/BTS guidelines.  
FEV1 and FVC were expressed as absolute values and as per cent predicted values for 
the patient’s age, sex, and height using European Community of Steel and Coal 
references values. A maximum of three manoeuvres were performed to obtain a 
coefficient of variation of < 5% in FEV1 relative to the best manoeuvre. 
6.4.2 IOS 
 
Impulse Oscillometry was performed at Baseline visit only.  
IOS measures airway resistance by sending a pulse-shaped sound wave produced by a 
loudspeaker to the patient’s lungs and listening for the reflection of that wave. The 
overall impedance of the pulse is due to the resistive and viscoelastic forces of the 
respiratory system. This is reported as R5, R20 (respiratory resistance at 5 and 20Hz, 
respectively) and X5 (reactance at 5 Hz). The point at which reactance is zero is known 
as the resonant frequency (RF) and is measured in Hertz. 
Subjects were connected to the IOS machine via a mouthpiece with tongue depressor 
and instructed to breathe quietly at FRC. All measurements were performed using a 
nose peg with the patient sitting in an upright position and head in a neutral position. 
Three to five tests were performed each 60 seconds in length. Data with glottis closure, 
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swallowing or irregular breathing was discarded and the remaining clean data 
analysed. 
 
IOS indices 
 
Resistance was measured at an impulse frequency of 5Hz (R5). R5 reflects total 
respiratory resistance i.e. resistance attributable to both central and peripheral airways. 
Reactance was measured at an impulse frequency of 5Hz(X5). Since inertance is 
negligible at lower frequencies X5 is used to measure the elastic properties of the 
peripheral respiratory system. Reactance comprises reactive elastance and inertance. 
 
 
6.4.3 Equipment used 
 
The Jaeger Masterscreen PFT and body have been used to measure FEV1, FVC, and 
Residual volume and total lung capacity (RV/TLC). 
The Jaeger Impulse Oscillometry System (IOS) have been used to measure R5 and X5.  
 
 
6.4.4 Statistical Analysis 
All data were tabulated as the mean and SD for quantitative variables, and as absolute 
values and per centages for qualitative variables. The normality of all variables was 
verified. In the absence of a normal distribution, nonparametric tests were used. Global 
test ANNOVA has been used to measure change over time and paired t-test to make 
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within group comparisons. Any comparison with a p value < 0.05 was considered to be 
statistically significant. 
 
6.5  Results  
 
6.5.1    FEV 1 (Forced expiratory volume in first second) 
 
Patients, who had an infective exacerbations, had FEV
 1 actual measured at each visit 
during the study. The mean (± SD) values for FEV1 at these time points are listed in 
Table 6.1. 
Table 6.1: Mean (SD) FEV1 at different time points during an exacerbation of 
bronchiectasis. 
 
FEV1 Number of patients Mean (L) Standard Deviation 
Baseline 22 1.91 0.62 
Day1 20 1.95 0.62 
Day7 22 1.93 0.83 
Day14 22 1.97 0.73 
Day42 18 2.00 0.67 
 
 
There was no significant change in FEV
 1 measured over the time course of an 
exacerbation, n=17, p=0.996. Figure 6.1 is an interval plot demonstrating change in the 
mean FEV1 during the course of an exacerbation. 
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Twenty patients had FEV
 
1 measured at baseline and Day 1 {mean (± SD) 1.91(0.61) ѵ 
1.95(0.61)}.There was no change in FEV
 1 between stable state and onset of an 
exacerbation (baseline ѵ Day 1) p= 0.917. There was no difference between FEV
 1 in 
stable state and on recovery from the exacerbation, (n=18, baseline ѵ Day 42) p=0.466. 
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Figure 6.1: Interval Plot of Mean (95% confidence interval) FEV1 at baseline (stable 
state), onset of exacerbation (Day 1) and 4 weeks later (Day 42), in patients with an 
acute exacerbation of bronchiectasis. The x-axis lists the time points during the course 
of an exacerbation. The y axis is the FEV1 value in litres. No significant difference was 
detected between stable state and onset of exacerbation, or at different time points 
during an exacerbation of bronchiectasis. p=0.996 
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6.5.2   FEV1 % predicted. 
 
Patients, who had infective exacerbations, had FEV
 1 % predicted measured at each 
visit. The mean (± SD) values for FEV1 % predicted at these time points are listed in 
Table 6.2.  
Table 6.2: Mean (SD) FEV1% predicted at different time points during an exacerbation 
of bronchiectasis. 
 
FEV1 
%predicted 
Number of patients 
Mean Standard Deviation 
Baseline 22 80.32 28.3 
Day1 20 84.00 26.7 
Day7 21 80.14 31.3 
Day14 21 82.14 30.6 
Day42 18 83.89 27.6 
 
There was no significant change in FEV
 
1% predicted measured over the time course 
of an exacerbation, n=15, p=0.988. Figure 6.2 is an interval plot demonstrating change 
in the mean FEV1 % predicted during the course of an exacerbation. 
Twenty patients had FEV
 
1 % predicted measured at baseline and Day 1 [mean (± SD) 
83.4(27.3) ѵ 84(26.7)].There was no change in FEV
 1 % predicted between stable state 
and onset of an exacerbation (baseline ѵ Day 1) p= 0.853. There was no difference 
between FEV
 1% predicted between stable state and after the completion of an 
exacerbation (n=18, baseline ѵ Day 42) p=0.293. 
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Figure 6.2: Interval Plot of Mean (95% confidence interval) FEV 1% predicted at 
baseline (stable state), onset of exacerbation (Day 1) and 4 weeks later (Day 42), in 
patients with an acute exacerbation of bronchiectasis. The x-axis lists the time points 
during the course of an exacerbation. The y axis is the FEV1 % predicted value. No 
significant difference was detected between stable state and onset of exacerbation or at 
different time points during an exacerbation of bronchiectasis. p=0.988. 
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6.5.3   FVC Actual 
 
Patients, who had infective exacerbations, had FVC measured at each visit. The mean 
(± SD) values for FVC at these time points are listed in Table 6.3. 
Table 6.3: Mean (SD) FVC at different time points during an exacerbation of 
bronchiectasis. 
 
FVC actual 
 
Number of 
patients 
Mean (L) Standard Deviation 
Baseline 22 3.07 0.69 
Day1 19 2.86 0.77 
Day7 22 2.81 0.77 
Day14 21 2.96 0.70 
Day42 17 3.05 0.76 
 
 
There was no significant change in FVC actual measured over the time course of an 
exacerbation, n=14, p=0.749. Figure 6.3 is an interval plot demonstrating change in the 
mean actual FVC values during the course of an exacerbation. 
Nineteen patients had FVC measured at baseline and Day 1 [217].There was a 
significant fall in the measured FVC actual (L) between stable state and onset of an 
exacerbation (baseline ѵ Day 1) p= 0.032. This fall in FVC recovered to baseline 
values only on completion of treatment with antibiotics (Day 14) n=19, p=0.200. There 
was no difference in the FVC actual measured in stable state and on recovery from an 
exacerbation (Baseline ѵ Day 42) n=17, p=0.116. 
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Figure 6.3: Interval Plot of Mean (95% confidence interval) FVC actual at baseline 
(stable state), onset of exacerbation (Day 1) and 4 weeks later (Day 42), in patients 
with an acute exacerbation of bronchiectasis. The x-axis lists the time points during the 
course of an exacerbation. The y axis is the FVC actual value in litres. No significant 
difference was detected between stable state and onset of exacerbation or at different 
time points during an exacerbation of bronchiectasis, p=0.749. 
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6.5.4        FVC % predicted   
 
In sixty three patients, at baseline, the FVC % predicted was measured as Mean (± SD) 
98% (22). 
Patients, who had infective exacerbations, had FVC % predicted measured at each 
visit. The mean (± SD) values for FVC% predicted at these time points are listed in 
Table 6.4. 
Table 6.4: Mean (SD) FVC% predicted at different time points during an exacerbation 
of bronchiectasis. 
 
FVC 
% predicted 
Number of patients Mean Standard Deviation 
Baseline 22 105.3 23.9 
Day1 19 103.1 25.1 
Day7 21 99.1 29.0 
Day14 20 100.9 22.9 
Day42 17 104.6 25.9 
 
There was no significant change in FVC % predicted measured
 
over the time course of 
an exacerbation, n=17, p=0.933. Figure 6.4 is an interval plot demonstrating change in 
the mean FVC % predicted values during the course of an exacerbation. Nineteen 
patients had FVC% predicted measured at baseline and Day 1 - Mean (± SD) 
[110(21.8) ѵ 103(25.1)].There was no change in FVC % predicted between stable state 
and onset of an exacerbation (baseline ѵ Day 1) p= 0.077. There was no difference 
between FVC % predicted in stable state and on recovery from an exacerbation (n=17, 
baseline ѵ Day 42) p=0.199. 
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Figure 6.4: Interval Plot of Mean (95% confidence interval) FVC % predicted at 
baseline (stable state), onset of exacerbation (Day 1) and 4 weeks later (Day 42), in 
patients with an acute exacerbation of bronchiectasis. The x-axis lists the time points 
during the course of an exacerbation. The y axis is the FVC % predicted value. No 
significant difference was detected between stable state and onset of exacerbation or at 
different time points during an exacerbation of bronchiectasis, p=0.933. 
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6.5.5 Spirometric indices and chronic colonisation with bacteria. 
 
Chronic bacterial colonisation with Pseudomonas aeruginosa was seen in 17 patients. 
Only three patients were colonised with other organisms [Haemophilus influenzae and 
Streptococcus pneumoniae]. There was no difference in the absolute or % predicted 
values of spirometric indices between groups. Table 6.5 lists the mean (SD) values for 
all measured spirometric indices. 
 
Table 6.5: Mean (SD) values of spirometric indices in patients chronically colonised    
    with bacteria. 
 
 
Number of 
patients 
FEV1 
Absolute 
Mean (SD) 
FEV1 
%predicted 
Mean (SD) 
FVC 
Absolute 
Mean (SD) 
FVC 
%predicted 
Mean (SD) 
Colonised 
With  
Pseudomonas 
aeruginosa 
 
17 1.67 (0.63) 66 (22) 3.05 (0.24) 96 (21) 
Colonised 
With  
Other PPM 
3 1.86 (0.30) 82 (35) 3.43 (0.45) 116 (24) 
p values  0.446 0.532 0.508 0.315 
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6.6        IOS 
 
IOS indices were significantly correlated to spirometric indices. In stable state 
bronchiectasis, fifty seven patients completed spirometry and 52 patients had complete 
data for IOS indices. Although the study planned to measure IOS indices only in stable 
state bronchiectasis, some measures of IOS indices were taken during an exacerbation 
in 42 patients –number of patients- Day 1-n=12, Day 7-n=10, Day 14-n=11 and Day 
42-9. 
 
Resistance 
Resistance increases as FEV1 decreases (Figure 21). At lower FEV1 values, R5 shows 
greater increase per unit decrease in FEV1. Resistance increases as FEV1% predicted 
decreases (Figure 22). R5 is influenced both by the size of the lungs and the degree of 
airways obstruction. Resistance is significantly correlated (negatively) to FEV1 in both 
stable state and during an exacerbation of bronchiectasis (Table 6.5 & 6.6). 
 
Reactance 
Reactance increases in magnitude as FEV1 decreases (Figure 23). At lower FEV1 
values, X5 shows greater increase in magnitude per unit decrease in FEV1. Reactance 
increases in magnitude as FEV1 % predicted decreases (Figure 24), suggesting airways 
obstruction has a negative impact on lung elastance. X5 is influenced both by the size 
of the lungs and the degree of airways obstruction. Reactance is significantly correlated 
(negatively) to FEV1 in both stable state and during an exacerbation of bronchiectasis 
(Table 6.6 & 6.7). 
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Table 6.6: Pearson’s correlation between spirometric and IOS indices in stable state 
bronchiectasis. **Correlation is significant at the 0.01 level. *Correlation is significant 
at the 0.05 level.  
 
IOS parameters FEV1 
 
 
FEV1 
%predicted 
RV/TLC 
R5 -0.550** -0.283*              0.333** 
X5 -0.686** -0.542** 0.601**              
 
 
 
 
Table 6.7: Pearson’s correlation between spirometric and IOS indices during an 
exacerbation of bronchiectasis. **Correlation is significant at the 0.01 level. 
*Correlation is significant at the 0.05 level.  
 
IOS parameters FEV1 
 
FEV1 
%predicted 
R5 -0.309 * -0.069 
X5 -0.629 ** -0.495* 
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Figure 6.5 and 6.6 are scatter plots depicting the significant relationship between 
Resistance at 5Hz (R5) and FEV1 actual [p=<0.001] and FEV1 % predicted [p=<0.05] 
in stable-state bronchiectasis.  
Figure 6.7 and 6.8 are scatter plot depicting the significant relationship between 
Reactance at 5Hz (X5) and FEV1 actual [p=<0.001] and FEV1 % predicted [p=<0.001] 
in stable-state bronchiectasis.  
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Figure 6.5: Scatter plot depicting significant relationship between Resistance at 5Hz 
(R5) and FEV1 actual in stable-state bronchiectasis. The variables on the x-axis are 
FEV1 actual values in litres and variables on the y-axis are R5 actual values in kPA/sec. 
There was a significant correlation between FEV1 actual and Resistance at 5Hz, 
p=<0.001. 
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Figure 6.6: Scatter plot depicting significant relationship between Resistance at 5Hz 
(R5) and FEV1 %predicted in stable-state bronchiectasis. The variables on the x-axis 
are FEV1 %predicted values and variables on the y-axis are R5 actual values in 
kPA/sec. There was a significant correlation between FEV1 % predicted and Resistance 
at 5Hz, (p=<0.05).
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Figure 6.7: Scatter plot depicting significant relationship between Reactance at 5Hz 
(X5) and FEV1 actual in stable-state bronchiectasis. The variables on the x-axis are 
FEV1 actual values in litres and variables on the y-axis are X5 actual values in 
kPA/sec. There was a significant correlation between FEV1 actual values and 
Reactance at 5Hz, p=<0.001. 
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Figure 6.8: Scatter plot depicting significant relationship between Reactance at 5Hz 
(X5) and FEV1 %predicted in stable-state bronchiectasis. The variables on the x-axis 
are FEV1 %predicted values and variables on the y-axis are X5 actual values in 
kPA/sec. There was a significant correlation between FEV1 % predicted and Resistance 
at 5Hz, Scatter plot depicting significant relationship between Reactance at 5Hz (R5) 
and FEV1 %predicted, p=<0.001. 
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Correlation of gas trapping 
A linear relationship exists between R5 and RV/TLC. Total respiratory resistance 
increases as the degree of gas trapping increases r=0.356, p=0.007. Figure 6.9 
demonstrates this linear relationship between R5 and RV/TLC. 
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Figure 6.9: Scatter plot depicting the significant linear relationship between Resistance 
at 5Hz (R5) and gas trapping measured as RV/TLC in stable state bronchiectasis. The 
x-axis variables are the actual values of RV/TLC, while the y-axis variables are the 
measures R5 values, r=0.356, p=0.007. 
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6.7   Discussion 
 
Our aim was to measure change in spirometric indices during exacerbation in 
bronchiectasis with a view to identifying markers that may help in future therapeutic 
trials. 
In stable state bronchiectasis, the mean FEV1 in our cohort was 1.9 L [95% predicted]. 
This indicates a relatively healthier cohort. At the onset of an exacerbation, our cohort 
had a mean FEV1 of 1.9 L. Other groups have reported FEV1 actual values between 
1.5 and 1.6 L for a similar cohort of patients at the onset of an exacerbation [80, 83].  
Similarly the FVC values at the onset of an exacerbation were higher than other studies 
at 2.86 L. Other reports put this value at 2.35 – 2.45L [80, 83]. We have identified a 
selection bias in our study. It was felt that subjects only volunteered when they felt 
they were able to make the many visits that the schedule involved. This may have 
resulted in a group of patients with milder disease. 
Our aim was however to check for change in these measured spirometric values. We 
were unable to demonstrate any clear change or improvement in the FEV1, FVC. 
There is no evidence in bronchiectasis to suggest that treatment of acute exacerbations 
modifies spirometric measures. Pre and post antibiotic spirometry has been 
convincingly investigated in two studies of adult patients with bronchiectasis. Both 
studies had a similar cohort of patients to us. Both studies failed to show a statistically 
significant change in these parameters [80, 83]. It may be assumed that the bronchi in 
children are possibly more elastic. But a similar paediatric study failed to demonstrate 
any improvement in spirometry on treatment with antibiotics [218]. These results must 
however be viewed with caution. As in our study the number of patients in all these 
other reports were limited to 18 [83], 32 [80] and 30 [218]. 
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Reversibility of FEV1 has been demonstrated in bronchiectasis. Up to 37% of patients 
have been noted to a have significant (>20%) bronchodilator induced reversibility in 
FEV1 and up to 60% patients can have an improvement in the FEF 25-75 [217]. Peak 
flow readings at the bedside can increase by 26% after an inhaled bronchodilator. 
These patients who respond to bronchodilators cannot be identified by clinical or 
immunological features [219]. An obstructive defect is common in bronchiectasis. A 
reduced FEV1/FVC ratio of less than 70% documenting airway obstruction was found 
in most (54%) patients in a cohort from Texas [5]. The mean FEV1/FVC ratio in our 
study was 59%. Other workers report this to vary between 50% [220] and 60% [80].  
Forced respiratory manoeuvres remain uncomfortable for our patients. Our aim was to 
establish a relationship between spirometry and IOS so that we could offer our patients 
a less distressing procedure that would still help us investigate airways. To this end we 
were successful. In our cohort, IOS indices significantly correlated to spirometric 
indices (FEV1 and FVC). FEV1 in particular shows a striking relationship. While we 
primarily studied stable disease, we included some measures from patients with 
exacerbation. The relationship remained significant. IOS is a useful measurement in 
patients with stable bronchiectasis. Further study will need to be done to validate its 
use in acute exacerbations of bronchiectasis. 
Bacterial colonisation is thought to affect the FEV1. Patients colonized by 
Pseudomonas have lower values of  FEV1  and FVC  than patients not colonized., 
Comparing patients colonized by Pseudomonas against a heterogeneous group of 
patients colonized by other microorganisms also finds the group colonized with 
Pseudomonas has worse pulmonary function values [109]. The FEV1 and FVC values 
were lower in the group colonised with Pseudomonas aeruginosa, however this 
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difference did not reach statistical significance. The number patients in our study were 
too small for us to interpret this difference accurately. 
Patients get breathless during an exacerbation of bronchiectasis; however these clinical 
symptoms cannot be quantified with spirometric indices. Spirometry is unlikely to be a 
useful measure as end point in future therapeutic trials. IOS is strongly correlated to 
spirometry but needs further investigation. 
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Chapter 7 
 
Exhaled breath condensate in bronchiectasis in the COBEX study. 
 
 
7.1 Introduction 
7.1.1 Exhaled breath condensate 
 
“A stuck tuning slide is one of the hazards of old flutes. The nasty organic compounds 
in your breath condensate continue working on the metals your slide is made from and 
effective weld them together”.       Unknown 
 
Flautists have known for a long time that there are “nasty” compounds in our breath 
that work on metals. Exhaled breath in the gaseous phase contains volatile substances 
that we wished to investigate.  
 
7.1.2  pH of exhaled breath condensate 
 
Airway pH homeostasis is maintained by a balance of different buffer systems and the 
production and release of acids and bases in the airways [142]. This airway pH 
homeostatic process is not completely understood. EBC pH is determined by volatile 
and non-volatile components [221-226]. In health, exhaled breath condensate pH is 
slightly alkaline [225]. The pH of the airway has been reported to be in the range of   
7–8 [225, 227, 228]. 
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Altering the pH of the airway environment is known to affect airway function. 
Nebulised citric or acetic acids are used to trigger bronchoconstriction and cough for 
testing anti-tussive agents. Chlorine gas is thought to cause wheezing and coughing in 
substantial part because of the rapid formation of hydrochloric and hypochlorous acids 
upon contact with the airway lining fluid [225, 226].  
Neutrophils are an important part of the natural defences against acute bacterial 
infections. In healthy state there is rapid clearing of airway neutrophils. In 
bronchiectasis this inflammation persists and causes release of tissue damaging 
neutrophil products such as neutrophil elastase and myeloperoxidase.  Reduced pH 
values in EBC have been associated with neutrophilic inflammation [229]. Carbon 
dioxide (CO2) is the major volatile component of EBC. In the aqueous environment 
CO2 forms H+ and HCO3- and profoundly affects the pH of dilute solutions. An acidic 
pH has been shown to have detrimental effect on the airway defences. Reduction in 
ciliary beat, enhancement of bacterial binding to mucous, and reduction of bactericidal 
effect of antibiotics  are some of these effects [230]. Mild acidification (below pH 6.5) 
increases mucous viscosity, converting it from sol to gel and may cause mucous 
plugging [231, 232] An acidic environment has also shown to increase the adherence 
of Streptococcus pneumoniae [233]. Exposure to acidic solutions causes action 
potential discharge in Aδ fibres and C fibres of airway afferent nerves in guinea pigs 
both of which mediate the cough reflex [48].  
It has also been suggested that mild airway acidification may be a subtle and innate 
host defence mechanism, one which takes advantage of the weak endogenous acids to 
defend the airway against airborne pathogens. Airway acidosis may have antimicrobial 
effects mediated through protonation reactions involving reactive nitrogen and oxygen 
species. Nitrite acidification has been proposed as a mammalian host defence 
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mechanism [234]. The abundant NO2 of the airway is present as bacteriotoxic HNO2 in 
relevant quantities only when the pH is low. Mycobacterium tuberculosis produces a 
gene product specifically protecting against the cidal effects of HNO2 [235]. Some of 
the toxicity of HNO2 occurs because of its reactive decomposition to NO, which is 
known to inhibit mycobacterial growth [236] for females and males [225]. 
It is this diversity of EBC itself that has prevented it from achieving clinical 
applicability yet [142]. None of the biomarkers in EBC has been validated sufficiently 
for clinical use. Measurement of pH of EBC has been reported in respiratory diseases 
including asthma, chronic obstructive airway disease, bronchiectasis and cystic 
fibrosis. There are no markers of dilution either yet. 
Age of subject does not seem to affect exhaled breath condensate pH [225]. There is 
conflicting evidence with regards to smoking and pH of EBC. Some authors claim an 
effect and others deny it [133, 225].  Collection of EBC can be affected by diurnal 
variation [133]. Evaluation of the reproducibility of EBC pH measurements from seven 
consecutive mornings has revealed a mean coefficient of variation of 4.5% (full intra 
subject range 0.9 to 20%). The mean intraday coefficient of variation in the same 
cohort has been reported as 3.5% (range 0.6 to 23%) [142]. 
 
7.1.3 Collection of exhaled breath condensate 
 
Most lung diseases involve chronic inflammatory changes and oxidative stress. 
Peripheral blood markers are unlikely to be adequate as the important mediator and 
cellular responses occur locally in the airways. Means to measure this inflammation in 
the past has always been invasive and not easily repeatable. Methods to assess this 
airway inflammation has included the use of bronchoscopy and induced sputum for 
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analysis. The use of induced sputum may be less invasive but involves inhalation of 
hypertonic saline that may induce coughing and bronchoconstriction. The technique 
itself cannot be repeated for 24 hours. A non-invasive technique that is easily repeated, 
useful in children and possible in patients with severe disease who may be intubated 
has led to the increase use of EBC to study inflammation in the airways [224]. While it 
is currently used as a research tool, further studies could make it more useful as a home 
device to study response to treatment and to monitor improvement. 
In healthy subjects, the pH of EBC immediately tested tends to be unstable. To enhance 
the stability of the readings, de-aeration (gas standardisation) with a CO2 free gas (such 
as argon, nitrogen oxygen or another CO2-free gas) can be performed. During de-
aeration, the pH gradually rises to a point when stable reading can be obtained. In 
healthy subjects, EBC pH after de-aeration has a mean pH of 7.7, with a range of 
normal considered by the investigators to be 7.4–8.8. These values are obtained from 
orally collected EBC samples. From intubated subjects without lung disease, the mean 
pH of de-aerated samples is likewise 7.7 with no difference from matched oral 
collections [142].  
The collection time in our study was 10 minutes. This time period is recommended so 
that a typical yield of 1–2 mL is obtained. Subjects usually tolerate this period of 
sampling without fatigue. Direct comparison for pH levels, shows no effect of changes 
in collection time between 3–20 min on EBC pH in healthy subjects [142, 237]. 
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7.1.4 Markers of inflammation in exhaled breath condensate and bronchiectasis 
 
Condensate measurement reflects different markers and molecules derived from the 
mouth (oral cavity and oropharynx), tracheobronchial system and alveoli. It is assumed 
that the airway surface liquid becomes aerosolised during turbulent airflow, so that the 
contents of the condensate reflects the composition of the airways surface liquid, 
although large molecules may not aerosolize as well as small soluble molecules [238]. 
A strong correlation exists between levels of CO2 and O2 in exhaled fluid and exhaled 
breath suggesting that aerosol particles exhaled in human breath reflect the 
composition of bronchoalveolar extracellular lining fluid [239]. 
There are also many potential chemo attractants including Interleukin (IL)-8 and 
leukotriene (LT) B4 in EBC. The final common pathway is oxidative stress which 
results in airway damage. This can be quantified using reactive oxygen species 
(Hydrogen peroxide) or Isoprostanes (IPs) [240]. Most inflammatory markers 
identified in EBC have been described in CF with limited data in non-CF 
bronchiectasis. In the respiratory system H2O2 may be released both from 
inflammatory and structural cells. These include neutrophils, eosinophils, macrophages 
and epithelial cells. EBC H2O2 concentrations are elevated in bronchiectasis with a 
significant inverse correlation between lung function and EBC H2O2 levels [146]. 
We hypothesised that the inflammatory burden increases during an exacerbation and 
this would lead to a fall in pH of EBC. This could be used to assess the onset of an 
exacerbation and also outcome of treatment. As the technique of EBC collection is 
simple it could be modified for monitoring and use in the home environment in 
patients with bronchiectasis. 
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7.2 Aims 
 
We hypothesised that  
a)  Airways in non CF Bronchiectasis would be acidified 
b)  This may be worsened during an infective exacerbation and 
c)  This could be used to confirm onset of an exacerbation and outcome on 
treatment with antibiotic therapy.  
 
We wished to investigate exhaled breath condensate (EBC) pH as a biomarker of 
infection and or inflammation in these patients 
 
7.3 Methods 
 
7.3.1 Subjects 
 
Fifty eight adult patients with well characterised non CF bronchiectasis [18] (34 
women) of mean (SD) age 64(11.4) attending the Lung Defence centre at Papworth 
Hospital Cambridge were recruited. An exacerbation was defined as a patient having at 
least two of the following symptoms: increased cough, increased volume of sputum, 
increased dyspnoea or wheezing and at least one of the following: fever>/= 38oC or 
malaise. Fourteen healthy volunteers (seven men) of mean (SD) age 63(5.9) acted as 
controls.  
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7.3.2 Study protocol 
 
All patients were initially seen when in stable state (no infective exacerbation in the 
preceding 4 weeks). Twenty two of these patients were followed through an 
exacerbation as described in Chapter 2.  EBC was always obtained prior to spirometry. 
Exhaled breath condensate collection was performed using the RTubeTM EBC 
collection system (Respiratory Research, Inc, Charlottesville, Virginia, USA). As per 
the American Thoracic society/European Respiratory Society task force 
recommendations [142], subjects were asked to breath at tidal volumes for a period of 
ten minutes, wearing a nose clip. A typical yield of 1-2mls of condensate was obtained.   
pH was measured immediately using a portable pH meter (pH boy, Camlab pocket pH 
meter, UK). The aluminium sleeves were stored in a freezer (– 4 to -17oC). The 
aluminium plunger never comes into contact with the EBC sample. The collected 
condensate has been stored at -80 oc. The plunger was cleaned between patients. 
Sputum appearance was recorded as described in Chapter 8. Spirometry was recorded 
as described in Chapter 6  
 
 
7.3.3   Statistical analysis 
Data are expressed as mean ± Standard deviation (SD). Change over time was 
measured using the global test ANNOVA. Comparison between groups was made 
using the unpaired t test. Correlation between groups was determined by nonparametric 
Spearman correlation analysis. Significance was defined as a value of   p < 0.05. 
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7.4  Results 
 
7.4.1 Patient characteristics 
 
Patient characteristics for our cohort, subjects followed through an exacerbation and 
the healthy volunteers are listed in Tables 7.1. This has previously been described in 
Chapter 3. It is included here for the ease of reference. 
 
Table 7.1: Patient characteristics for the exhaled breath condensate analysis arm of 
COBEX study. 
 
 Full cohort 
n=58 
Exacerbators 
n=22 
Healthy volunteers 
n=14 
Mean age (+/-SD)   64years (11.4)  63years (8.5)  65years (5.9) 
Sex (M:F)  24:34 5:17 7:7 
Smoking history    
Ex-smokers  26 11 9 
Non-smokers 31 11 4 
Current smoker 1  1 
Mean FEV1(±SD)        
 
1.9L(0.71) 
 
1.9L(0.61) 
 
2.3L(0.82) 
 
Mean FEV1 % 
predicted (±SD) 
75%(25) 81%(28.2) 100%(27.1) 
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7.4.2 Stable state bronchiectasis 
 
The pH of EBC was significantly lower in our patient cohort than the healthy control 
group [Mean (SD) n=58, 6.26(0.41) ѵ n=14, 6.75(0.17); p= 0.000]. Figure 7.1 is an 
interval plot demonstrating the difference in the mean pH of EBC between patients 
with bronchiectasis in stable state and healthy volunteers. 
When pH of EBC fluid was compared to sputum appearance alone there was a trend 
with the purulent sputum being more acidic than the mucopurulent and mucoid sputum 
{n=56, 6.06(0.40), 6.28(0.43), 6.45(0.28)} this was not significant p= 0.180. Figure 7.2 
is a box plot demonstrating the differences between pH of EBC at different time points 
during the course of an exacerbation. 
There was no correlation between EBC pH and lung function (% predicted FEV1)    
{r= 0.108, p=0.430}, CRP (r=0.11, p=0.434, n=53) or ESR (r=0.052, p= 0.721, n=49).  
There was a significant correlation between EBC pH and the total bacterial load         
(r= -0.471, p=0.03, n=21). Figure 7.3 is a scatter plot demonstrating the significant 
relationship between pH of EBC and the total bacterial count in sputum. 
There was no difference in the EBC pH between patients, in whom Pseudomonas 
aeruginosa was cultured in stable state as compared to those without (13:43), 
{6.19(0.39) ѵ 6.29(0.43), p=0.421}. There was also no difference in EBC pH between 
patients in whose sputa a PPM was isolated as compared to those in whom it wasn’t 
isolated {n=27:29 6.29(0.43)  ѵ  6.29(0.39), p=0.684} 
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Figure 7.1: Interval plot of Mean (95% confidence interval) EBC pH in stable state 
bronchiectasis ѵ healthy volunteers. The x-axis lists the group of patients i.e. with 
Bronchiectasis or healthy volunteers and the y-axis is pH values of exhaled breath 
condensate. There was a statistical significant difference in the two groups, p= 0.000. 
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Sputum appearance 
 
Figure 7.2: Interval plot of EBC pH when compared according to sputum appearance. 
Sputum was classified on appearance as purulent, mucopurulent, and mucoid.          
The x-axis lists the time point at which the pH of EBC was measured i.e. baseline or 
stable state, Day 1, Day 7, Day 14 of the exacerbation, or Day 42 after recovery from 
exacerbation. Outliers are marked with an o and extreme outliers are marked with an 
asterisk. Numbers accompanying these are patient identification numbers for the study. 
There was no significant difference in pH of EBC when compared to appearance alone, 
p=0.180. 
Purulent 
Mucopurulent 
Mucoid 
158 
 
7.4.3 Acute exacerbation of bronchiectasis 
 
The pH of EBC did not significantly change between baseline and Day 1(onset of 
exacerbation, prior to antibiotic treatment), {n=22, mean (SD) 6.21(0.45) ѵ 6.28(0.35), 
p=0.595}. The pH of EBC did not alter significantly when followed longitudinally 
through an exacerbation {Day 14, at the end of treatment, 6.1(0.29)] or Day 42, after 
recovery from the exacerbation 6.15(0.56)} p=0.525.  There was no significant change 
between EBC pH at baseline and Day 42 (n= 20, p=0.079). Figure 7.4 is an interval 
plot demonstrating change in mean pH of EBC from baseline, during the course of an 
exacerbation and on recovery from an exacerbation. 
At Day 1, there was no correlation between CRP (r=-0.205, p=0.387, n=20) or ESR 
(r=0.066, p= 0.802, n=17).There was no significant correlation between EBC pH and 
lung function (% predicted FEV1) {r= 0.44, p=0.059, n=19}. At day 7, there was no 
correlation between EBC pH and lung function (% predicted FEV1) {r= 0.098, 
p=0.673, n=21}, CRP (r=0.156, p=0.511, n=20) or ESR (r=-0.242, p= 0.318, n=19).  
At Day 14, there was no correlation between EBC pH and lung function                      
(% predicted FEV1) {r= 0.374, p=0.104, n=20}, CRP (r= -0.168, p=0.479, n=20) 
Figure 16 or ESR (r=0.066, p= 0.807, n=16). At day 42, there was no correlation 
between EBC pH and lung function (% predicted FEV1) {r= 0.280, p=0.261, n=18}, 
CRP (r=-0.084, p=0.749, n=17) or ESR (r=0.026, p= 0.931, n=14). Table 7.2 lists the 
Pearson’s correlation coefficient between EBC pH, ESR, CRP and % predicted FEV1. 
There was no significant correlation between EBC pH and the total bacterial load 
during and after the exacerbation. {Day 1(r= 0.231, p=0.30, n=21), Day 14(r= 0.160, 
p=0.318, n=21). Day 42(r= -0.336, p=0.18, n=17)}.  
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Table 7.2: Correlation between EBC pH and markers of inflammation- ESR and CRP 
and % predicted FEV1. Pearson’s correlation coefficient ‘r’ and p values for measured 
parameters and pH of EBC at baseline and during the course of an exacerbation. 
 
 Baseline Day 1 Day 7 Day 14 Day 42 
EBC pH    and 
% predicted 
FEV1 
r= 0.108  
p=0.430 
n=49 
r= 0.44 
p=0.059 
n=19 
r= 0.098 
p=0.673 
n=21 
r= 0.374 
p=0.104 
n=20 
r= 0.280 
p=0.261  
n=18 
EBC pH and 
ESR 
r=0.052    
p= 0.721 
n=49 
 
r=0.066  p= 
0.802 n=17 
r=-0.242 
p= 0.318 
n=19 
r=0.066 
p= 0.807 
n=16 
r=0.026, 
p= 0.931 
n=14 
EBC pH and 
CRP 
r=0.11 
p=0.434 
n=53 
r=-0.205 
p=0.387 
n=20 
r=0.156 
p=0.511 
n=20 
r= -0.168 
p=0.479 
n=20 
r=-0.084 
p=0.749 
n=17 
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Figure 7.3: Interval plot depicting Mean (95% CI) EBC pH at baseline and during the 
course of an exacerbation. Variables on the x-axis are the time points during the study 
when EBC pH was measured i.e. baseline, day 1, day 7, day 14 and day 42. Variables 
on the y-axis are the EBC pH values. Global test ANNOVA has been used to calculate 
change over time. There was no significant change in the EBC pH during the course of 
an exacerbation in the COBEX study, p = 0.525  
 
 
 
 
161 
 
7.5 Discussion 
 
Exhaled breath condensate pH is considered to reflect the acid-base balance within the 
airways [224]. The contributors to this pH balance are yet to be explained. The pH is 
currently considered the most robust variable of EBC [225]. 
Our study was designed to evaluate EBC pH in stable state bronchiectasis, to compare 
it to healthy volunteers and study its variation during the course of an exacerbation of 
Bronchiectasis. 
The EBC pH in our cohort was significantly lower than in the healthy volunteer group. 
This confirms our hypothesis that the pH of EBC in patients with bronchiectasis is 
more acidic than normal subjects. In bronchiectasis caused by cystic fibrosis [12], the 
pH is significantly lower (5.67) [241] than if CF is excluded 7.19 (0.08) [145]. The 
values of pH of EBC in our study lie between published values and may be explained 
by difference in the methodology. The lower pH values that are observed in 
bronchiectasis are attributed to the neutrophilic inflammation. This in turn is due to the 
activity of the enzyme neutrophil myeloperoxidase that catalyzes the reaction between 
hydrogen peroxide and a chloride to form hypochlorous acid. This acid is highly 
volatile and might be responsible for the acidification of exhaled breath condensate 
[145]. 
The mean (SD) EBC pH {6.75(0.17)} for healthy volunteers in our cohort was lower 
than some reports and comparable to others. The mean pH in healthy subjects has been 
reported variously as 8.26 [242], 7.65 [144], 7.57 [145] and 6.15 [241]. This may be 
explained by the different methodology employed to collect and measure the pH. 
While the former two workers [144, 242] used frozen and defrosted EBC samples and 
the latter [145] used neat samples, all three groups performed argon de aeration prior to 
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measurement of pH. Tate et al measured pH from neat EBC and that may explain a 
comparable value [241]. We acknowledge that our method of pH measurement does 
not confirm to the task force recommendations [142]. 
 We expected to find a fall in pH with the onset of an exacerbation however found no 
significant change. The pH of EBC is almost a log order lower in exacerbations of 
Cystic Fibrosis [241]. The small size of our cohort may have been inadequate to 
measure a significant change but a significant change has been detected with as few as 
eleven patients with CF [241]. Other components that contribute to this pH balance 
require further study. 
Exhaled breath analysis has proven useful in monitoring therapy with corticosteroids in 
asthma. The breath condensate in acute asthma is acidified and this normalises to 
control values on treatment [144]. The pH in our cohort however did not rise on 
treatment with antibiotics and there was no significant difference between baseline and 
recovery from exacerbation. The eosinophilic inflammation in asthma is treated easily 
with corticosteroids but the neutrophilic inflammation implicated in bronchiectasis 
may be multifactorial and not affected by antibiotics alone.  
Patients with bronchiectasis that are chronically colonized by P. aeruginosa have a 
significantly lower pH (6.96, 95% CI, 6.88–7.05 ) [145]. This was not our finding 
despite having a large number of patients with steady state bronchiectasis. It has also 
been shown in vivo that leukocyte metabolism in the presence of live bacteria could 
produce a fall in pleural fluid pH. This may contribute to the low pH observed in 
patients with bronchiectasis chronically colonized by bacteria [145].    However there 
was no difference in the EBC pH between patients whose sputa isolated Streptococcus 
pneumoniae and those that did not {6.27(0.71) ± 6.26(0.37), p=0.98}. We do not think 
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that the colonising pathogen contributes significantly to the EBC pH. We found no 
correlation between EBC pH and % predicted FEV1. Other workers have found a 
significant relationship between the FEV1 % predicted and pH of EBC but in a smaller 
cohort of patients [145].  
We acknowledge that the number of patients in this study is small. We have not 
adhered to the task force recommendation on pH measurement methodology either. 
The pH in our study was measured immediately following collection of EBC. Our aim 
was to be enable patients to use this equipment at home to confirm the onset of an 
exacerbation. However as our samples are preserved we hope to reanalyse with 
deaeration and should be able to then compare results.  We also did not measure intra 
subject variability which has previously been reported as 4.5% [225]. 
pH of exhaled breath condensate is more acidic in patients with stable bronchiectasis 
than in healthy subjects. pH of EBC in our limited cohort failed to confirm the onset of 
an exacerbation or recovery in a significant way. There may be other markers of 
inflammation or oxidative stress that may be more significant in bronchiectasis and 
will need to be investigated. New and more sensitive assays will allow detection of 
these other markers and help produce a specific finger print for bronchiectasis. 
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Chapter 8 
 
The microbiology of stable state and exacerbations in  
bronchiectasis –the COBEX study 
 
8.1 Introduction 
 
Microorganisms with potential pathogenicity (PPM) - Haemophilus influenzae, 
Staphylococcus aureus, Streptococcus pneumoniae, Moraxella catarrhalis and 
Pseudomonas aeruginosa - lead to an intense inflammatory response within the 
bronchi in patients with bronchiectasis [4, 17]. Exacerbations are common and 
continue to contribute to significant morbidity and poorer HR-QoL [83, 102]. As there 
is persistent bacterial infection of airways, it would be logical to identify markers of 
inflammation and endpoints for therapeutic trials from sputa. 
 
8.1.1 Use of qualitative analysis of sputum as an end point in therapeutic trials in 
bronchiectasis. 
 
Pathogens isolated in sputa include Haemophilus influenzae, Pseudomonas aeruginosa 
Staphylococcus aureus, Moraxella catarrhalis and Streptococcus pneumoniae             
[5, 18, 127]. Pseudomonas aeruginosa is considered a marker of severity and is 
associated with compromised HR-QoL [62]. Its presence is associated with poor lung 
function and extensive disease on HRCT [17]. As HR-QoL is compromised to begin 
with, deterioration may not be easily measured. Microbial clearance in sputa may or 
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may not always be achieved. Both Pseudomonas aeruginosa and Haemophilus 
influenzae are capable of forming biofilms [17].  Eradication therefore can be difficult. 
However microbial clearance can be achieved in a majority of patients [80]. 
 
8.1.2 Quantitative total bacterial counts as markers of infection. 
  
Quantitative bacterial load has been previously used as marker of therapeutic efficacy. 
In a study to assess efficacy of inhaled versus intravenous gentamicin, a 6-10 fold 
reduction in colony counts has been reported [158]. Longitudinal quantitative 
microbial data is absent in bronchiectasis. It is unknown if quantitative data correlates 
to other proven parameters such as HR-QoL markers and spirometric indices. It is time 
consuming and remains a research tool at the current time. 
More useful are markers that involve patients’ cooperation and can be measured in the 
home environment. Sputum volume and appearance are such tools.  
 
8.1.3 Twenty-four hour sputum volume as a marker of infection 
 
Twenty four hour sputum has been used in studies to assess the outcome of treatment 
in exacerbations of bronchiectasis. An improvement in sputum volume on treatment 
with antibiotics, during an exacerbation has been demonstrated. This alone would 
validate it for future use in therapeutic interventions. However a baseline reference 
volume from stable state was not  included [80]. A standardised approach to sputum 
volume collection for future studies would also be useful. Most workers have used 
single day collections. A mean volume from a three day sputum collection may give a 
more accurate measurement [46, 71].  Presence of a PPM is known to affect this 
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volume. Patients with Pseudomonas aeruginosa produce more sputum than those with 
other or no pathogens in their sputa. [17]. A potential limitation of 24 hour sputum 
volume as an outcome measure is the reliance on patient compliance for collection 
[243].  The volume of sputum produced remains variable. While some patients are 
daily producers of copious amounts others less so and some only do so during an 
infection. 
 
8.1.4 Sputum appearance as a marker of infection 
 
Sputum appearance and colour can predict bacterial colonisation accurately [159]. A 
standardised approach to sputum description would be useful. Currently sputum 
description can be scored between 0 and 10 as follows: 1-absence of, 2-completely 
transparent, 3-almost transparent, 4-translucent but colourless, 5-opaque and 6-milky 
white, 7-grey, 8-pale green, 9-moderately green and 10-dark green sputum or is 
dependent on the investigator [71].  We have simply classified sputum as mucoid, 
purulent and mucopurulent. 
Sputum appearance would be an easy tool for bedside testing. A significant correlation 
has already been established between the doctor’s and the patient’s interpretation of 
sputum appearance [159]. 
 
8.1.5 Non-tuberculous mycobacterial infection in bronchiectasis 
 
It is important to screen all patients with bronchiectasis at referral for NTM infection 
and thereafter if there is an unexplained deterioration unresponsive to usual therapy 
[4]. It is also known that patients with bronchiectasis and non-tuberculous 
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mycobacterial disease have a higher prevalence of coexisting Aspergillus-related lung 
disease. Outcome in such cases is poor and therefore it is important to investigate 
frequent exacerbators for both not tuberculous mycobacterial disease and Aspergillus 
related lung disease [161].  
 
8.1.6 Obtaining sputum samples for analysis  
 
Finally obtaining the sample of sputum for analysis is crucial. Spontaneously 
expectorated samples are easy to obtain and cause the patient least trouble. Induced 
sputum and bronchoscopic lavage may be alternatives in adults who do not 
expectorate. Oropharyngeal swabs have a high predictive value in the paediatric 
population with cystic fibrosis [148]. For this study only spontaneously expectorated 
samples were used. 
   
It has been hypothesised that the inflammation within the bronchi is increased during 
an exacerbation [31]. We have sought to measure this increase with a view to using it 
as clinical endpoint in future therapeutic trials. 
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8.2 Aims 
 
Our aim was to study the bacterial profile of our patients with bronchiectasis in stable 
state and during the course of an exacerbation. 
We wished to investigate the following: 
In stable state 
• The prevalence of bacterial colonisation in our patients. 
• The correlation between serum inflammatory markers and total bacterial count 
in sputa. 
• The relationship between antibiotic prophylaxis and prevalence of PPM in the 
study cohort. 
During an acute exacerbation 
• Change in sputum appearance [alone] 
• Change in 24 hour sputum weight 
• Change in bacterial profile of sputa. 
• Change in total bacterial count of sputa 
 
We hoped to identify markers of infection that respond to treatment and could be used 
as valid end points in future therapeutic trials. 
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8.3 Materials and methods 
 
We prospectively studied 58 patients with bronchiectasis in a stable clinical state. Fifty 
five of these patients were able to provide samples of sputa. All patients had well 
characterised non CF Bronchiectasis.[18] We followed 22 of these patients through an 
exacerbation. The patients were studied at 
   Baseline  - No exacerbation in the preceding 4 weeks 
   Day 1 - of an exacerbation (not having commenced antibiotics) 
   Day 7 - during treatment with antibiotics 
   Day 14 - on completion of treatment with antibiotics 
   Day 42 - recovery from exacerbation 
 
8.3.1 Specimens 
 
Fresh sputum samples were collected for analysis at each visit. We aimed to process 
the sputum within two hours of expectoration. In addition patients were advised to 
collect all sputum expectorated over a 24 hours period.  At Day 1 of their exacerbation 
they were asked to collect the 24 hour sputum following the study visit. This sample 
was weighed and the result recorded. The 24 hour sputum sample provided at the 
screening visit was also used to check for presence of non tuberculous mycobacterium 
(NTM). For the purpose of this study it has been assumed that sputum weight is equal 
to volume i.e. 1g=1ml. All samples were collected in sterile containers. Samples at 
Day 1 were collected prior to antibiotic use.  
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8.3.2 Sputum analysis 
 
Sputum was classified as purulent, mucopurulent and mucoid based on appearance 
alone. The specimen was then divided into three parts – Two samples were a hundred 
microlitre aliquot each (Samples A&B) and the third was a three hundred microlitre 
aliquot (Sample C).  Analysis of sample is described in Appendix iv (Sample B). 
 
8.3.3 Antibiotic treatment advice 
 
 
Antibiotics chosen to treat an exacerbation were usually based on previous sputum 
microbiology history. All patients received 14 days of antibiotic treatment. When 
given intravenously, two agents were used.  Oral antibiotics used included 
Ciprofloxacin, Clarithromycin, Oofloxacin, Trimethoprim, Doxycycline, 
Moxifloxacin, Flucloxacillin and Septrin. Intravenous antibiotics used were 
Tobramycin, Meropenem, Ceftazidime and Aztreonam. One patient received nebulised 
antibiotic used was Tobramycin. If patients were on long term oral Azithromycin or on 
nebulised Colomycin, they were advised to remain on these antibiotics during the 
exacerbation 
 
8.3.4 Statistical analysis 
 
Data is expressed as Mean and standard error of mean or Mean and Standard deviation 
as appropriate. Change over time has been calculated using a global test [Repeated 
measures ANOVA] .  Paired t-test has been used to assess difference between values 
when required. Chi squared test has been used to analyse differences in tabulated data. 
All bacterial counts are expressed log10 unless otherwise specified. Results were 
considered significant when p value was less than 0.05. 
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8.4 Results 
 
Fifty seven patients were studied in stable state. Twenty two of these patients were 
followed through an acute exacerbation. Number of samples of sputa analysed varies 
between different sections described below. The reasons for this is - i) specimens 
obtained were not always adequate in quantity; ii) patients did not expectorate sputum 
within two hours of the clinic visit; iii) patients did not attend a visit. 
 
8.4.1 Sputum appearance 
 
In stable state bronchiectasis 
 
Appearance is described in 56 sputum specimens. Most patients had mucopurulent 
sputum when in stable state 40/56, [72%]. Eight patients [14%] produced mucoid sputa 
and eight [14%] produced purulent sputa at baseline.  
 
Acute exacerbation of bronchiectasis 
 
In the group of patients followed through an exacerbation, sputum appearance was 
most commonly mucopurulent at baseline {n =14/21 (1=no sputum)}. There were 
more patients with purulent sputum at the onset of an exacerbation. (Baseline 3/21, 
Day 1 10/22) and this change was statistically significant, p=0.046. By Day 7 fewer 
patients had purulent sputum n=5/22. By day 14 and Day 42, only one patient had 
purulent sputum. There was significant change in appearance over the course of an 
exacerbation, p=0.018. Figure 8.1 is a bar chart demonstrating change in frequency of 
sputum appearance from baseline and during the course of an exacerbation in the study 
cohort. 
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Figure 8.1: Bar chart showing frequency of change in appearance of sputa at each 
during the study. Variables on the x-axis are the time points in the study when sputum 
appearance was described i.e. Day 0-baseline, Day 1,7,14 during the course of an 
exacerbation and Day 42 on recovery from the exacerbation, p=0.018.                     
Baseline ѵ Day 1-p=0.046, Day 1 ѵ Day 7-p=0.270, Day 1 ѵ Day14-p=0.004,   
Baseline ѵ Day 42-p=0.632. The black bars denote purulent sputum, the grey bars 
denote mucopurulent sputum and the white bars denote mucoid sputum. There was a 
significant change in sputum appearance during the course of the exacerbation.  
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8.4.2 24 hour sputum collection 
 
In stable state bronchiectasis  
The mean (SD) of 24 hour sputum weight (g) was 9.89(8.72). 
There was no significant difference in sputum weight between patients who isolated 
Pseudomonas aeruginosa in sputa when compared to those that isolated Haemophilus 
influenzae or in whom no pathogen was isolated. {Pseudomonas aeruginosa n=10, 
12.39(9.86) ѵ Haemophilus influenzae n=3, 11.20(9.95) ѵ no pathogen n=21, 
9.23(8.61)} p=0.658.   
 
Acute exacerbation of bronchiectasis 
 
The 24 hour sputum weight was measured at baseline and Day 1. There was no 
significant change, n=12, baseline-9.0 (7.2) ѵ Day 1-11.6 (12.2), p = 0.444. 
There was no significant change in 24 hour sputum weight between Day 1 and Day 7 
of the exacerbation,, n=14, Day 1-11.5 (11.3) ѵ Day 7-7.8 (6.2) p=0.184.   
There was no difference in the 24 hour sputum weight between Day 1 (onset of 
exacerbation) and Day 14 (completion of treatment), n=16, 10.2 (8.7) ѵ 8.7 (6.4),               
p = 0.549.  
There was no significant change in 24 hour sputum weight during the course of an 
exacerbation, n=7, p=0.273. Table 8.1 lists the mean (SD) 24 hour sputum weight at 
baseline and during the course of an exacerbation in the study cohort.                            
Figure 8.2 is an interval plot demonstrating change in the mean 24 hour sputum weight 
during the course of an exacerbation. 
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Table 8.1: The mean (SD) 24 hour sputum weight in grams at baseline and during the 
course of an exacerbation in the study cohort followed through an exacerbation of 
bronchiectasis. 
Visit Number of patients 
24 hour sputum weight  
Mean ± SD (g) 
Baseline 17 9.89 ± 8.72 
Day 1 14 11.5 ± 11.38 
Day 7 20 8.36 ± 7.25 
Day 14 20 7.87 ± 6.27 
Day 42 14 7.76 ± 6.13 
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Figure 8.2: Interval plot demonstrating change in 24 hour sputum weight during the 
course of an exacerbation in the study cohort. The variables on the x-axis are the time 
points at which 24 hour sputum weight was measured during the exacerbation i.e. 
baseline, Day 1, Day 7, Day 14 and Day 42. The variable on the y-axis is the mean 24 
hour sputum weight in grams. 
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8.4.3 Qualitative analysis of sputum 
 
In stable state Bronchiectasis 
Forty seven per cent (26/55) of patients had PPM above the established threshold            
(≥103 cfu/ml) in their sputa.  
The PPM isolated in sputa were: 13 Pseudomonas aeruginosa, 7 Streptococcus 
pneumoniae, 4 Haemophilus influenzae, 2 Staphylococcus aureus, 1 
Stenotrophomonas maltophilia and 1 Achromobacter xylosoxidans. 
More than one PPM was isolated in two patients. No pathogen was isolated in twenty 
nine patients (53%) at baseline. 
 
Acute exacerbation of bronchiectasis 
 
At baseline, in the group of patients followed through an exacerbation, many patients 
isolated only mixed upper respiratory tract flora (10/21-48%) in their sputa. Nine 
patients had a single PPM in their sputum. More than one PPM was isolated in sputum 
of only one patient.  
The PPM isolated were: 5 Pseudomonas aeruginosa, 2 Streptococcus pneumoniae, 2 
Haemophilus influenzae, 1 Staphylococcus aureus. Achromobacter xylosoxidans was 
isolated along with Pseudomonas aeruginosa in one patient. 
At Day 1, the onset of an exacerbation, twelve of the 22 patients (55%) isolated a PPM 
in their sputa. These were: 5 Pseudomonas aeruginosa; 4 Haemophilus influenzae; 2 
Streptococcus pneumoniae; 3 Staphylococcus aureus; 1 Moraxella catarrhalis;             
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1 Achromobacter xylosoxidans. Four patients (33%) isolated more than one organism 
in the sputa. 
At the onset of an exacerbation, Day 1, similar organisms were cultured to baseline in 
15(71%) patients. Of these, 6 isolated a PPM while 9 continued to have only mixed 
upper respiratory tract flora in their sputa.  A different or entirely new PPM was 
isolated in the sputa of 5 patients. An additional organism to their baseline isolate was 
found in one patient. Two patients who had mixed upper respiratory tract flora at base 
line converted to PPM at Day 1. (1 Streptococcus pneumoniae; 1 with Haemophilus 
influenzae and Staphylococcus aureus).  
The total number of patients isolating a PPM in sputum at reduced from 12 at Day 1 to 
7 at Day 7. Overall microbial clearance was achieved in 7 patients. Out of five patients 
who isolated Pseudomonas aeruginosa at Day 1, microbial clearance was achieved in 
two patients. However, interestingly, 2 patients had isolated a new PPM having had 
only upper respiratory tract flora at Day 1 in their sputa. 
At Day 14, seven patients had achieved microbial clearance. However 4 patients had 
isolated a new PPM in their sputa (1 Pseudomonas aeruginosa, 2 Stenotrophomonas 
maltophilia, 1 Coliform organism). Of the 3 patients with Pseudomonas aeruginosa at 
Day 1, only one had achieved microbial clearance.  
On recovery from the exacerbation, Day 42, only 14 sputum samples were analysed. 
Four patients did not attend the final visit (2 still hospitalised, 1 further exacerbation, 
1unable to attend). A further four patients were not able to expectorate sputum at the 
time for analysis.  Eight of these patients had returned to the baseline profile of 
sputum. Of the remaining 6, 2 patients had lost the PPM and isolated only mixed upper 
respiratory tract flora. The remaining 4 patients had acquired a new PPM (3 patients 
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isolated Pseudomonas aeruginosa, 1 Stenotrophomonas maltophilia and one a 
Coliform species).  
Table 8.2 lists the PPM isolated in sputa at baseline and at Day 1 of the exacerbation 
for the cohort followed through an exacerbation. 
Table 8.3 lists the PPM isolated or the lack of it in sputa during the course of the 
exacerbation at each visit. If no sputum sample was obtained, the numerical 10 has 
been used and UA has been used if patients were unable to attend. Table 8.4 is the key 
to Table 8.3. 
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Table 8.2: Microorganisms isolated in sputa at baseline (steady state) and at onset of 
symptoms (Day 1) in patients followed through an exacerbation of bronchiectasis. 
 Organism isolated in stable state Organism isolated at Day 1 
1 Pseudomonas aeruginosa Pseudomonas aeruginosa 
2 Mixed upper respiratory tract flora Mixed upper respiratory tract flora 
3 Mixed upper respiratory tract flora Mixed upper respiratory tract flora 
4 Mixed upper respiratory tract flora Mixed upper respiratory tract flora 
5 Pseudomonas aeruginosa Haemophilus influenzae 
6 Pseudomonas aeruginosa Pseudomonas aeruginosa 
7 Pseudomonas aeruginosa, Achromobacter 
xylosoxidans 
Pseudomonas aeruginosa, Achromobacter 
xylosoxidans 
8 Mixed upper respiratory tract flora Mixed upper respiratory tract flora 
9 Mixed upper respiratory tract flora Mixed upper respiratory tract flora 
10 Mixed upper respiratory tract flora Mixed upper respiratory tract flora 
11 Mixed upper respiratory tract flora Mixed upper respiratory tract flora 
12 No sputum Pseudomonas aeruginosa 
13 
Streptococcus pneumoniae Streptococcus pneumoniae, Staphylococcus 
aureus 
14 Staphylococcus aureus Staphylococcus aureus 
15 
Mixed upper respiratory tract flora Staphylococcus aureus, Haemophilus 
influenzae 
16 Streptococcus pneumoniae Mixed upper respiratory tract flora 
17 Mixed upper respiratory tract flora Mixed upper respiratory tract flora 
18 Mixed upper respiratory tract flora Streptococcus pneumoniae 
19 Pseudomonas aeruginosa Haemophilus influenzae 
20 Mixed upper respiratory tract flora Mixed upper respiratory tract flora 
21 Haemophilus influenzae Haemophilus influenzae, Pseudomonas 
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aeruginosa 
22 Haemophilus influenzae Moraxella Catarrhalis 
Table 8.3: Microorganisms isolated during the course of and on recovery from an 
exacerbation of bronchiectasis. 
Baseline E1D1 D7 D14 D42 
     1b, 1c 1c,1d 1c, 1d 8 1c 
8 8 8 5 8 
8 8 1a 8 8 
8 8 8 8 10 
1c 3 8 8 1c 
1c, 1a 1c,1a 1a 1c,1a UA 
1a, 1b, 7 1a,7 1a,1b 1a,1b 1a,1b,7 
8 8 10 8 8 
8 8 8 8 8 
8 8 8 8 11 
8 8 8 8 10 
11 1c 8 8 10 
2 2,6 8 5 1c,5 
6 6 6 6 11 
8 3,6 8 8 11 
2 8 8 1c,1d 1a 
8 8 9 9 9 
8 2 8 2 8 
1c 3 8 8 8 
8 8 8 8 10 
3 3,1a 7 8 1b 
3 4 8 8 8 
 
Table 8.4: Key to Table 8.3 
 
1a Pseudomonas aeruginosa - mucoid 
 1b Pseudomonas aeruginosa - dwarf 
1c Pseudomonas aeruginosa - rough 
1d Pseudomonas aeruginosa - small 
2 Streptococcus pneumoniae 
3 Haemophilus influenzae 
4 Moraxella catarrhalis 
5 Stenotrophomonas maltophila 
6 Staphylococcus aureus 
7 Achromobacter xylosoxidans 
8 Mixed upper respiratory tract flora 
9 Coliform sp. 
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8.4.4 Antibiotic prophylaxis and microbiological profile of the study cohort  
 
In our stable cohort of fifty seven patients, thirty eight (67%) were on prophylactic oral 
antibiotics. Fourteen (25%) patients were on aerosolised antibiotics. Eight patients 
were on more than one antibiotic prophylactically. One patient with end stage 
bronchiectasis was on four antibiotics at the same time.  
In the cohort of 22 patients followed through an exacerbation, 15 (68%) were on 
prophylactic antibiotics. Being on prophylactic antibiotic did not affect the isolation of 
a PPM in sputum.  
Table 8.5 lists the relationship between isolation of or lack of a PPM in sputum with 
the use of prophylactic antibiotic. 
Table 8.6 lists the antibiotic prophylaxis prescribed to patients and the microbiological 
profile of the study cohort followed through an exacerbation.  
 
 
Table 8.5: Relationship between isolation of or lack of a PPM in sputum with the use 
of prophylactic antibiotic. 
 On Prophylactic Antibiotic Not on prophylactic 
Antibiotic 
10 No Sputum 
11 Unable to attend 
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PPM in sputa 17 9 
No PPM in sputa 21 8 
Chi square test χ2  =0.371, p=0.573 
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Table 8.6: Antibiotic prophylaxis prescribed to patients and the microbiological profile 
of the study cohort followed through an exacerbation. The column on the left lists the 
sputum microbiological profile at baseline and the column on the right lists the profile 
at onset of an exacerbation. The column in the centre lists the prophylactic antibiotic 
prescribed to the patient. 
Baseline 
Antibiotic 
Prophylaxis Day 1 
Pseudomonas aeruginosa  Pseudomonas aeruginosa  
Mixed upper respiratory tract flora Azithromycin Mixed upper respiratory tract flora  
Mixed upper respiratory tract flora 
Doxycycline 
& aerosolised 
Colomycin Mixed upper respiratory tract flora  
Mixed upper respiratory tract flora  Mixed upper respiratory tract flora  
Pseudomonas aeruginosa  Haemophilus influenzae  
Pseudomonas aeruginosa 
Aerosolised 
Gentamicin Pseudomonas aeruginosa  
Pseudomonas aeruginosa &  
Achromobacter xylosoxidans 
Azithromycin Pseudomonas aeruginosa & 
Achromobacter xylosoxidans 
Mixed upper respiratory tract flora  
Azithromycin 
& aerosolised 
Colomycin Mixed upper respiratory tract flora  
Mixed upper respiratory tract flora  Azithromycin Mixed upper respiratory tract flora 
Mixed upper respiratory tract flora  Doxycycline Mixed upper respiratory tract flora  
Mixed upper respiratory tract flora  Trimethoprim Mixed upper respiratory tract flora  
No sputum sample  Pseudomonas aeruginosa  
Streptococcus pneumoniae 
 Streptococcus pneumoniae & 
Staphylococcus aureus  
Staphylococcus aureus Doxycycline Staphylococcus aureus  
Mixed upper respiratory tract flora  
Doxycycline Haemophilus influenzae & 
Staphylococcus aureus 
Streptococcus pneumoniae   Mixed upper respiratory tract flora  
Mixed upper respiratory tract flora  Trimethoprim Mixed upper respiratory tract flora  
Mixed upper respiratory tract flora   Streptococcus pneumoniae 
Pseudomonas aeruginosa  Amoxicillin Haemophilus influenzae 
Mixed upper respiratory tract flora  
Azithromycin 
& aerosolised 
Colomycin Mixed upper respiratory tract flora  
Haemophilus influenzae Azithromycin Pseudomonas aeruginosa  
Haemophilus influenzae  Amoxicillin Moraxella Caterrhalis  
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8.4.5 Quantitative data 
 
The mean (SEM) log10 total bacterial count of the PPMs isolated from 26 of 56 patients 
sampled at steady state (baseline) – not the smaller cohort followed through an 
exacerbation at  was 7.17(0.19), n=26. 
Table 8.7 describes the mean (SEM) log10 total bacterial count in sputa on all patients 
followed through an exacerbation.  
 
Table 8.7: Mean (SEM) log10 total bacterial counts in sputa for all patients followed 
through an exacerbation of bronchiectasis. 
 Baseline Day 1 Day 7 Day 14 Day 42 
Number of 
patients 21 22 21 22 14 
Mean 4.51 5.43 3.13 3.90 4.13 
Standard 
error of 
mean 
0.60 0.68 0.40 0.57 0.64 
 
 
In thirteen of the 22 patients, samples of sputa were obtained at all visits. When no 
PPM was isolated in sputum a minimum value of 102cfu/ml has been substituted for 
the purpose of calculation as this was below our leve0ls of detection. There was no 
significant change in the log10 total bacterial counts during the course of an 
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exacerbation. Using a Global test (repeated measures ANOVA) the p-value over all 
time points was 0.132 (n=13). Figure 8.6 is an interval plot demonstrating change in 
the mean log10 total bacterial counts (PPM) during the course of an exacerbation in the 
study cohort. 
The total bacterial count at baseline was 0.5 units lower on the log scale                             
(95%CI -1.9, 0.3) than at Day 1 (n=21, p=0.167).  Counts at Day 1 were 1.4 units 
higher on the log scale than at Day 7 (95%CI 0.96, 3.9, n=21, p=0.003). Counts at   
Day 14 were 1.5 units lower on the log scale than at Day 1 (95%CI -0.186, 3.3.24, 
n=20, p=0.078) There was no significant difference in the bacterial counts between 
baseline and Day 42 (n=14, p=0.171). 
The mean total bacterial count at baseline was poorly correlated with systemic markers 
of inflammation CRP (r=0.15) and ESR (r=0.041). [Method explained in Chapter 10] 
 
8.4.6 Chronic bacterial colonisation of lower airways in stable state bronchiectasis 
 
In the stable cohort of 57 patients, 20 (35%) patients were colonised by a PPM:  
Pseudomonas aeruginosa 17(30%); Haemophilus influenzae 2(3%);                  
Streptococcus pneumoniae 1(2%) 
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Figure 8.3: Interval plot [95% CI] demonstrating change in the mean bacterial count 
during the course of an exacerbation of bronchiectasis in the COBEX study. The 
variables on the x-axis are the time points during the study when total bacterial count 
in sputa was measured i.e. baseline, Day 1, Day 7, Day 14 and Day 42. The y-axis 
variables are the mean and 95%CI log10 total bacterial count in sputa. There was no 
significant change in the total bacterial count during the exacerbation, p=0.132 
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8.5 Discussion 
 
Clinically stable patients with bronchiectasis have a high prevalence of bronchial 
colonisation by potentially pathogenic microorganisms [108]. This damages the 
mucociliary escalator preventing bacterial clearance and allowing the persistence of 
pro-inflammatory mediators [244]. The prevalence of chronic colonisation in our series 
was only 35%.  Rates of chronic colonisation in our cohort is higher than some reports 
of 16% [17] but well below most others 48% [46] , and 54% [61, 127]. It is known that 
when given antibiotics prophylactically this colonisation rate falls. This may explain 
why the lower rate of colonisation within our cohort [17]. Up to 66% of our cohort was 
treated with antibiotics prophylactically. This would have been based on previous 
chronic colonisation data and therefore our current estimate may not be accurate for 
this population. 
Two thirds of our patients were on prophylactic antibiotics and a third of patients 
isolated no pathogenic microorganism at baseline. We think this to be to the patient’s 
advantage as higher colonisation rates are associated with frequent exacerbations [17]. 
However statistically we were unable to prove a significant difference in the isolation 
rates between those on and those without prophylactic antibiotics. 
We found no significant relationship between serum inflammatory markers (ESR & 
CRP) and the total bacterial load at baseline. Patients who are colonised with a PPM 
are known to have significantly higher levels of neutrophils, elastase, MPO, and IL-8 
levels in bronchoalveolar lavage fluid.  It is possible that in stable state this 
inflammation remains local and may only spill over during an exacerbation [127]. 
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Appearance and colour of sputum can predict bacterial colonisation [159]. We were 
able to validate the utility of sputum based on appearance alone. Most patients have 
mucopurulent sputa in stable state but this appearance significantly changed to 
purulence during an exacerbation. In our study, this appearance was described by a 
single investigator. A doctor patient correlation of describing sputum appearance is 
proven [159]. Seventy two per cent of our patients had mucopurulent sputum at 
baseline. Other groups report higher levels of purulence, in some cases up to 57% [71]. 
Our cohort may have milder disease and antibiotic prophylaxis may be a confounding 
factor in the outcome. 
Eighty per cent of patients are known to have a more than fifty per cent fall in 24 hour 
sputum volume at the end of an exacerbation [80]. We were unable to confirm this in 
our study. Our mean daily sputum weight was less than 10gs. Mean daily sputum 
volume has been variously reported as 10mls [71], 30mls [80], 35mls [17, 27].  There 
are many confounding factors to this volume collection. As volume varies everyday an 
average of a 3 day collection may be more accurate. Compliance and sputum 
swallowing also remains a problem. Collection of this volume from hospital in patients 
may be easier. Office goers in our study cited an accurate collection as being difficult. 
Again nocturnal volumes may go unmeasured. We certainly found a trend with 
increased sputum volume at the onset of the exacerbation and this was reversed by   
Day 7. Perhaps the small number of patient in ours study may have reduced the power 
of detecting the significance in this trend. Patients with Pseudomonas aeruginosa 
produce more sputum than those with other or no pathogens in their sputa [17]. While 
this was true in our cohort the result was not statistically significant. 
Microbial clearance as an end point in an exacerbation would seem logical. We noticed 
an increase in the isolation of a PPM at the onset of an exacerbation. By Day 7 this was 
189 
 
reduced and fell further by Day 14.  Qualitative bacterial clearance can be achieved in 
up to 78%of patients [80]. We achieved microbial clearance in 31% of patients. 
However we also isolated new PPM in the sputa of some patients indicating an altered 
microbial balance within the airways. Antibiotic prophylaxis could once again be 
responsible for the lower isolation rates seen in our study.  
As in most series, no pathogens are isolated in a large proportion of patients. 
Commensals or upper respiratory tract flora are seen in the majority of patient          
[71, 245]. There may be many reasons for this. The gold standard for collection of 
specimens remains a bronchoscopic lavage. Induced sputum may also give a better 
yield. Most studies, like ours, use spontaneously expectorated samples. Our 
methodology did not allow us to detect a bacterial count of less than 102cfu/ml. 
Isolating a new organism at Day 1 having isolated only mixed upper respiratory tract 
flora before, could mean that these organisms were already present in undetectable 
numbers previously (less than 102cfu/ml). We assume that a count lower than this is of 
no clinical significance. Other techniques such as polymerase chain reaction may 
increase the yield [17]. 
Pseudomonas aeruginosa is the most commonly isolated pathogen followed by 
Haemophilus influenzae [5, 71]. Pseudomonas aeruginosa was the most commonly 
isolated pathogen in our cohort too. Streptococcus pneumonia was however the second 
most common followed by Haemophilus influenzae. Our antibiotic prophylaxis policy 
may again be responsible for this change in balance. Other antibiotic naive populations 
report a higher incidence of Haemophilus influenzae isolates. The low incidence of 
Staphylococcus aureus in our group is in keeping with other series. [149]. 
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Microbial clearance is certainly possible for most species but may be less likely if 
patients are infected with mucoid strains of Pseudomonas aeruginosa [80]. 
We found no significant increase in the quantitative bacterial load between baseline 
and Day 1- onset of the exacerbation. There was a significant fall in total bacterial 
counts between Day 1 and Day 7 suggesting effectiveness of antimicrobial treatment. 
There was no significant difference in total bacterial counts during the course of an 
exacerbation in our cohort. 
A slighter lower yield in our study is also caused by our strict requirement of sputum 
sample to be expectorated within two hours of the analysis during the scheduled visit. 
All patients were not able to provide this easily. Bacterial density of spontaneous 
sputum is affected by the time and mode of sample storage. It can be stored for up to 
6h following expectoration at 25 degrees C; beyond this it is associated with a 
significant increase in bacterial load [246]. 
We find that sputum appearance is the only useful markers of infection that could be 
used as endpoint in future therapeutic trials. While 24 hour sputum weight, microbial 
clearance and total bacterial counts show promise, larger studies would be required to 
confirm our findings.  
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Chapter 9 
Anti-pseudomonal antibodies and bronchiectasis in the COBEX study 
 
9.1 Background 
Specific serum antibodies could be helpful in defining the status of bacterial infection 
as well as the response to early treatment in patients. It may also confirm protection 
following vaccination. However antibodies induced by disease do not seem to offer 
protection in Cystic fibrosis [12]. The antibody response against Pseudomonas 
aeruginosa in CF is a marker of chronicity of infection and of inflammation and tissue 
damage. Some patients with non-cystic fibrosis bronchiectasis when infected with 
mucoid strains of Pseudomonas aeruginosa have high levels of antipseudomonal 
antibodies. It is not known if information from CF can be extrapolated to non CF 
bronchiectasis [162]. 
Immunoglobulin G (IgG) antibodies to Psa surface antigens in serum can be estimated 
by enzyme-linked immunosorbent assay (ELISA). Antibodies to Psa can be directed 
against alkaline protease (AP), elastase (ELA), exotoxin A (ExoA) or whole cell    
[153, 163]. The secretory IgA is the initial humoral response to infection in the lungs. 
While antibodies to IgG are commonly measured, it is possible that at the onset of 
infection an increase in specific serum IgA antibodies may occur before an increase in 
serum IgG antibodies [164]. 
In CF, the  Pseudomonas aeruginosa antibody response is related to the degree of 
inflammation and lung tissue damage [162]. Therefore it is postulated that it may help 
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differentiate between chronic and intermittent infect [155]. Specific serum IgG to 
whole–cell  Pseudomonas aeruginosa has been measured in CF patients with chronic 
infection (>50% positive cultures of Pseudomonas aeruginosa  in previous 12 months), 
intermittent infection (≤50% positive cultures) and those never infected. Antibody 
levels are significantly higher in patients with chronic infection and very low in those 
never infected. A sputum culture positive for Pseudomonas aeruginosa with a negative 
antibody titre suggests early superficial infection rather than advanced chronic 
infection [153]. Antibody titres measured in patients undergoing antibiotic treatment 
for eradication of Pseudomonas aeruginosa are significantly higher in patients 
chronically infected compared to those with negative cultures [153]. The duration of 
infection with Pseudomonas aeruginosa and the total number of days patients were 
treated with intravenous antibiotics also correlates with the antibody levels [155].The 
Pseudomonas aeruginosa antibody level can be followed up to evaluate success of 
anti-pseudomonas treatment [247]. 
In CF, longitudinal assessment of antibody titres assessed before and after inhaled 
antibiotic therapy in patients with first Pseudomonas aeruginosa isolation showed a 
significant decrease in antibody titres against AP and ExoA in patients clearing Psa 
infection, whereas titres increase in patients in whom antibiotic therapy fails to 
eradicate the organism [153]. 
Eradication of bacteria is more likely after early antibiotic treatment of pulmonary 
infection, given the problem of poor antibiotic access from serum to the 
intrapulmonary cavity, which is compounded by the tissue damage that occurs during 
infection. Alternatively, a defective IgA response may be present in some patients, 
which contributes to pulmonary infection. The ratio of IgA and IgG concentrations 
may provide an indication of the depth of pulmonary infection, and also an insight into 
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the reasons for the observed differences in prognosis of different patients with Psa 
infection [164]. 
Variability between patients is considerable, and whether treatment decisions should be 
based on Pseudomonas aeruginosa antibody levels alone remains controversial. While 
some suggest it may not be ideal [153] others report benefit. Patients with high serum 
IgG titres against Psa when treated with antipseudomonal treatment at intervals of four 
months until the serum IgG titre return to the control range, show improvement in the 
frequency of Psa isolation when compared with an observation only group [164]. 
High titres of serum IgG antibodies are associated with a poor clinical state, while low 
titres are associated with a better clinical state in both chronic and intermittently 
infected patients with CF [165]. Information on antipseudomonal antibody levels in 
patients with non-CF bronchiectasis remains limited. No study has previously 
described change in anti-pseudomonal antibody titres in exacerbations of 
bronchiectasis. 
 
9.2 Aims 
1. To investigate the prevalence of antipseudomonal antibody titres within this 
study cohort 
2. To study the prevalence of antipseudomonal antibody in patients in whom we 
did not isolate Pseudomonas aeruginosa from corresponding sputa sample 
3. To study variation in anti-pseudomonal antibodies titres during the course of 
an exacerbation of bronchiectasis. 
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9.3 Methods 
 
Ten ml sample of venous blood was collected into a sterile vacutainer, centrifuged and 
the serum stored at -70oC. Serum samples obtained from patients were sent to the 
Respiratory and Systemic Infection Laboratory (HPA, Colindale, London NW9 5HT) 
for analysis of antipseudomonal antibodies. Antibodies to A-band lipopolysaccharide 
antigen were analysed in this study. 
 
Data was analysed using SPSS statistical software. Data are expressed as mean ± 
Standard deviation (SD). Comparison between different timepoints was made using the 
unpaired t test. Correlation between groups was determined by nonparametric 
Spearman correlation analysis. Significance was defined as a value of p < 0.05. 
 
9.4 Results 
 
Thirty one patients had antipseudomonal antibodies measured at baseline. Twenty of 
these patients had negative titres (below 0.99).Six patients had slightly elevated levels 
(0.99-1.49), 4 had clearly elevated levels (1.49-1.99) and only one patient has 
significantly elevated level (>2). Titres of antipseudomonal antibodies at baseline are 
listed in Table 9.1. Table 9.2 indicates when titres were slightly, clearly or grossly 
elevated and is a key to Table 9.1. 
Seven patients had elevated titres of antipseudomonal antibodies despite not having 
isolated Pseudomonas aeruginosa in corresponding sputum samples. Three of these 
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seven patients had clearly elevated titres. Two of these patients were previously 
colonised with Pseudomonas aeruginosa and were already on regular antibiotic 
prophylaxis (oral Azithromycin + oral Doxycycline and nebulised Colomycin). One of 
these patients isolated Pseudomonas aeruginosa  in sputum during the course of an 
exacerbation. Only one patient was neither colonised nor on antibiotic prophylaxis. 
This patient did not subsequently isolate Pseudomonas aeruginosa at baseline and had 
no further samples of sputum analysed during this study. 
Ten patients had anti-pseudomonal antibodies measured at all visits during the course 
of an exacerbation. Whilst there was a trend with increased titres at the onset of an 
exacerbation, there was no significant change during the course of the exacerbation, 
p=0.996. There was no significant change between baseline and Day 1 either p=0.756.  
Pseudomonas aeruginosa antibody titres were higher at the onset of exacerbation in 
our patient cohort however this was not statistically significant (mean baseline - 0.793 
ѵ Day 1- 0.873, p=0.672, n=11). The titres fell after 7 & 14 days of treatment with 
antibiotics but this fall was not statistically significant (mean Day 1- 0.874 ѵ Day 7 – 
0.853, p=0.884, n=21). There was no significant change in antibody titres over the 
course of the exacerbation (p=0.996). 
 
Table 9.3 lists the mean (SD) antibody titres at all visits during the course of an 
exacerbation in our patient cohort.  
Figure 9.1 is an interval plot demonstrating change in the mean anti-pseudomonal 
antibody titres during the course of an exacerbation.  
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Table 9.1: Anti-pseudomonal antibody titres in steady state bronchiectasis 
Patient number 
Anti-pseudomonal 
antibody titres 
1 1.386** 
2 0.711 
3 0.937 
4 1.281** 
5 1.762*** 
6 0.454 
7 0.729 
8 1.343** 
9 1.169** 
10 1.641*** 
11 0.249 
12 0.751 
13 1.731*** 
14 1.183** 
15 0.599 
16 1.704*** 
17 0.525 
18 0.471 
19 0.561 
 
Patient number 
Anti-pseudomonal 
antibody titres 
20 0.244 
21 0.906 
22 0.804 
23 0.366 
24 1.108** 
25 0.546 
26 2.197*^ 
27 0.526 
28 0.839 
29 0.488 
30 0.822 
31 0.699 
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Table 9.2: key to Table 9.1 
 
Interpretation   
      Negative 0.00 - 0.99 
**= Slightly elevated 1.0 - 1.49 
*** = Clearly elevated 1.5 - 1.99 
*^ = Grossly elevated 2.0 + 
 
 
 
Table 9.3: Mean (SD) anti-pseudomonal antibody titres during the course of an 
exacerbation, n=10. 
 
 Mean Standard deviation 
Baseline 0.811 0.408 
Day 1 0.867 0.488 
Day 7 0.854 0.453 
Day 14 0.811 0.454 
Day 42 0.815 0.417 
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Figure 9.1: Interval plots showing change in anti-pseudomonal antibody titres in serum 
during the course of an exacerbation. Variables on the x-axis are the visits during the 
study when anti-pseudomonal antibodies were measured i.e. baseline, Day 1,7,14 and 
Day 42. The y axis variable is the mean (95%CI) anti-pseudomonal antibody titre. 
There was no significant change in the anti-pseudomonal titres during the course of the 
exacerbation, n=10 p=0.996. 
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9.5 Discussion 
 
The purpose of this study was to investigate the prevalence of antipseudomonal 
antibody titres in the study cohort and measure change in their levels during the course 
of an exacerbation. 
At baseline, in stable state bronchiectasis, eleven out of 31 patients (35%) had elevated 
antipseudomonal antibody titres. Our cohort was relatively stable clinically. This may 
explain the infrequent need for antibiotic treatment and hospital admissions in the 
preceding year. Eight patients had elevated levels of antibodies despite not having 
isolated Pseudomonas aeruginosa in the corresponding sputum sample. Two patients 
had Pseudomonas aeruginosa in sputum with negative antibody titres. Indeed during 
the course of the exacerbation, Pseudomonas aeruginosa was cleared by day 7 of 
antibiotic treatment in both patients. This indicates possible early infection. Others 
continued to isolate Pseudomonas aeruginosa despite antibiotic treatment. Whilst one 
of these patients was on oral Amoxicillin as antibiotic prophylaxis, the other was 
antibiotic free. Positive IgG antibody titres may predate isolation of P aeruginosa, but 
in some patients are present soon after acquisition of infection. A positive titre 
indicates significant exposure to P aeruginosa and could be used to detect infection in 
patients unable to produce sputum. The presence of a systemic immune response above 
the control range indicates tissue invasion and hence infection [163]. 
Antipseudomonal antibody titres were not significantly higher at the onset of an 
exacerbation in our patient cohort. There was no significant change in antibody titres 
over the course of the exacerbation (p=0.996).  This may be due to the small number of 
patients in our study. 
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Detection of anti pseudomonal antibodies at an early stage, in non-CF bronchiectasis 
may help in differentiating between early infection and harmless colonization. It may 
also be a useful monitor of the progress of infection and the response to antibiotic 
treatment in the early stages of infection.  
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Chapter 10 
 
Serum Inflammatory markers and 
Capillary blood gas analysis in bronchiectasis – the COBEX study 
 
 
10.1 Introduction 
 
Systemic markers of inflammation are raised in bronchiectasis and correlate with 
disease severity. The level of inflammation determines disease progression and health 
status [181]. In Cystic fibrosis and community acquired pneumonia serum 
inflammatory markers rise during an exacerbation and fall on treatment with antibiotics 
[181, 248, 249]. The persistent local inflammation in patients with bronchiectasis and 
the host response may be reflected in systemic markers of inflammation. Some markers 
correlate closely with the anatomical extent of the disease while others correlate more 
closely with the lung function. No significant difference has been found in the levels of 
systemic inflammatory markers between patients who are on long term prophylactic 
antibiotics (either oral or nebulised) and those who are not on any antibiotics [181].  
In respiratory conditions such as Chronic obstructive pulmonary disease (COPD), 
systemic inflammation is raised in stable state [250]. In exacerbations of COPD, 
systemic biomarkers are not useful in predicting the severity of exacerbations [81].   
Plasma biomarkers are easily accessible. While absolute values may be less important, 
change in values may be useful in predicting onset of an exacerbation and recovery 
therefrom. 
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10.1.1 C-reactive protein (CRP) and bronchiectasis 
 
C reactive protein is an acute phase pentameric protein produced by the liver in 
response to IL-6 stimulation. It is thought to help in removing autogenous and 
exogenous material from the circulation. This may be its main role in infection, when it 
acts by recognising products of pathogenic microorganisms. A raised concentration of 
this protein is considered to be evidence of active tissue destruction [251, 252]. 
Relevance in a particular disease is less well defined [81]. 
 
In patients with stable COPD, frequent exacerbators (> or = 3/year) are 
indistinguishable from infrequent (< or =2/year) exacerbators in terms of serum levels 
of C reactive protein [253]. In exacerbations of COPD, plasma CRP alone has not been 
found to be a useful biomarker. CRP in the presence of a major exacerbation symptom 
has been found to be useful in the confirmation of COPD exacerbations. When 
measured with a major symptom, CRP becomes 95% specific in predicting an 
exacerbation [81]. 
High CRP values are frequently found in patients with bacterial respiratory infection 
but may also be seen in viral illness. In a prospective study of patients with upper 
respiratory tract infections, higher CRP values were found in those infected with 
influenza A and B [254]. 
In stable bronchiectasis, CRP remains high signifying persistent 
infection/inflammation. In one cohort the CRP was raised above normal levels in 30% 
of patients whilst in stable state [181]. In another study measurement of the C-reactive 
protein (CRP) in patients suffering from bronchiectasis, clinically judged to be in 
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remission, showed a major on-going acute phase response. Such a response could 
predispose these patients to the development of reactive secondary amyloidosis [255]. 
In an exacerbation of bronchiectasis, the CRP is raised and decreases significantly on 
treatment with antibiotics [83]. In a prospective study of exacerbation in bronchiectasis 
more than 2/3 of patients had a raised CRP  and 75% improved on completion of 
treatment [80]. 
The CRP also correlates significantly with the extent of bronchiectasis as measured by 
a HRCT score. This would signify local inflammation that could be measured 
systemically [181]. Impaired activity and morbidity are central issues in the lives of 
patients with bronchiectasis. CRP is significantly correlated with the activity and total 
scores of the St Georges Respiratory questionnaire [181]. Finally the CRP is thought to 
be an independent predictor of hospitalisation and mortality in patients with end stage 
respiratory failure [256]. 
 
10.1.2 Erythrocyte sedimentation rate  and bronchiectasis 
 
The ESR is a nonspecific measure of inflammation used commonly in clinically 
practise. Of little use in diagnosis, it often helps to monitor disease progress or 
treatment. Its major impact lies in its ability to help reinforce or lessen diagnostic 
probabilities [257]. 
In stable state bronchiectasis, when compared to healthy controls the ESR is 
significantly raised [258] . In one cohort, up to 33% of patients had a raised ESR when 
in stable state [181].   
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In exacerbations of bronchiectasis, the ESR has been shown to fall significantly 
following a two week course of intravenous antibiotics. However this was a modest 
improvement and fell only 1.8 fold [80]. 
The ESR correlates significantly with the severity of bronchiectasis as defined by an 
HRCT score and also the activity score as measured on the St Georges respiratory 
questionnaire [181]. The ESR also correlates significantly with measures of lung 
function including forced vital capacity (FVC), peak expiratory flow rate (PEFR), 
alveolar volume and the transfer 
factor of lung for carbon monoxide [181]. 
Colonisation with bacteria is common in bronchiectasis. There is conflicting evidence 
with regards to ESR and CRP when different pathogenic microorganisms are isolated 
in the sputum. Some reports suggest no difference in the levels of these inflammatory 
markers in different groups [181]. Others suggest a significant association with the 
ESR when patients are chronically colonised with P aeruginosa [258]. 
 
10.1.3 Total White cell count and bronchiectasis 
 
In stable state bronchiectasis, the total white cell count (WCC) is elevated above 
normal levels in up to 15% of patients [181, 259]. While neutrophils are mostly 
reported, a differential white cell count shows that the elevation is distributed in most 
cell types [259].  
In exacerbations of bronchiectasis the total white cell count is raised. The mean white 
cell count was significantly reduced on treatment with antibiotics. Some report a 
significant fall in the WCC while others suggest a smaller difference of 1.5 fold 
decrease that is thought to be less relevant than other markers of inflammation [80, 83].  
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The total white cell and the neutrophil count are significantly correlated to disease 
severity as measured by an HRCT score, activity and total scores of the St George’s 
Respiratory Questionnaire [181]. 
Lung function measures are correlated to the WCC [181]. An inverse correlation 
between the peripheral WCC and FEV1 percentage predicted has also been reported. 
This may suggest that the host peripheral leukocyte response may be a factor in the 
determination of lung function [121, 259]. 
 
10.1.4 Albumin and bronchiectasis 
 
Protein in the plasma is made up of albumin and globulin. Serum albumin is the most 
abundant and comprises about half of the blood serum protein. It is produced in the 
liver and is soluble and monomeric. It has a half-life of approximately 20 days. 
Albumin has a number of essential physiologic effects necessary for normal health 
such as vasodilatation, inhibition of endothelial cell apoptosis, antioxidant effects and 
reduced platelet aggregation. The causes of hypoalbuminemia are malnutrition, 
reduced synthesis by the liver, renal losses, and chronic inflammation 
In stable state bronchiectasis, serum albumin levels are lower than age matched 
controls [259]. In lung disease, the acute phase response starts with a local reaction at 
the site of injury characterized by activation of granulocytes and mononuclear cells, 
which in turn release acute phase cytokines (interleukin-1 [IL-1], interleukin-6 [IL-6], 
tumour necrosis factor-alpha [TNF-α], and interferons). IL-6 acts via specific hepatic 
receptors and inhibits the synthesis of albumin [260, 261]. Hypoalbuminemia is thus a 
marker of on-going inflammation. 
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A graded relationship between albumin and mortality is described. Reductions as little 
as 0.5g/dL in serum albumin concentration has been associated with a 54% increase in 
mortality rate [261]. Administering albumin to patients with hypoalbuminemia has not 
been shown to improve survival or reduce morbidity, suggesting that the underlying 
cause of hypoalbuminemia, rather than low albumin levels per se, is responsible for the 
increased mortality [261-263]. 
Albumin enters the lung by passive diffusion and can be measured in sputum and 
bronchial secretions. Since albumin in the sputum is derived from the blood plasma by 
diffusion alone, it is also a relatively sensitive marker of lung inflammation. A ratio of 
sputum to serum albumin is a guide to transudation into the lung. Levels of this ratio 
fall with treatment and rise again on cessation of treatment [264, 265]. Bronchial 
secretions in patients with Haemophilus influenzae secretions have higher albumin 
levels, indicating active local inflammation [266]. .Multivariate analysis has indicated 
that lower serum albumin is significantly associated with worse lung function. 
Persistent inflammation plays an important role in the deterioration of lung function in 
bronchiectasis [121]. 
 
10.1.5 Capillary blood gas and bronchiectasis 
 
Impaired gas exchange in bronchiectasis causes hypoxemia and occasionally 
hypercapnia. In stable state bronchiectasis, Oxygen saturations as measured by a digital 
pulse oximeter shows reduced levels when compared to control subjects [258]. The 
cause of this is multifactorial. 
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In Cystic fibrosis, impaired pulmonary gas exchange is seen as measured using the 
multiple inert gas elimination technique. Improvement in this gas exchange is seen 
post treatment with intravenous antibiotics. This could be secondary to improvement in 
mucus plugging of small airways [267]. Airway clearance techniques (ACTs) also 
significantly improves mucociliary clearance and thus gas exchange [268]. In 
asthmatic patients who die of ventilatory failure, profound mucous plugging has been 
found on autopsy [269].  
Significant arterial hypoxemia occasionally present in patients with extensive 
bronchiectasis is thought to be due to V/Q abnormalities. Right-to-left shunts are 
increased but contribute to a smaller extent to hypoxemia. Perfusion of unventilated 
alveoli is thought to be partly responsible for the intrapulmonary right-to-left shunts 
observed. New vascular communications in the bronchial wall and granulation tissue 
might shunt blood from the pulmonary arterioles to pulmonary veins. These shunts 
have been described previously by Liebow, Hales, and Lindskog in 1949 [56, 270]. 
 
Bronchiectasis is commonly disabling but a rarely fatal disease. However hypoxemia 
and hypercapnia are closely related to the mortality and described as significant risk 
factors [21]. This may reflect the severity of disease in these patients. Little is known 
about gas exchange in acute exacerbations of bronchiectasis.  
Gas exchange can be measured in different ways such as arterial blood sampling or 
ventilation perfusion imaging. Arterial blood sampling is painful, and even with local 
anaesthesia the procedure causes more pain than sampling from the ear lobe [55]. 
Capillary blood gas (CBG) samples may be used in place of samples from arterial 
punctures to estimate adequacy of ventilation. A puncture is made with a lancet into 
the cutaneous layer of the skin at a highly vascularised area (heel, finger and toe).   
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10.2 Aims  
 
The aim of this study was to establish the level of systemic markers of inflammation in 
stable state bronchiectasis and measure change during an acute exacerbation. We 
wished to define clear end points towards which future interventions can be directed. 
 
10.3 Methods 
 
Samples for venous and capillary blood were taken at each visit.  
 
10.3.1  Venous blood 
Two ten ml samples of venous blood were collected in sterile vacutainers 
One sample was centrifuged and the serum stored at -70oC for analysis of 
inflammatory mediators later.  
The other was used to measure markers of systemic inflammation on the same day:    
C-reactive protein (CRP), Erythrocyte sedimentation rate, total white cell count and 
serum albumin.  
 
10.3.2  Capillary blood 
A capillary blood sample was used for blood gas analysis. A proprietary rubefacient 
[Transvasin- Hexyl Nicotinate (2%w/w), Ethyl Nictotinate (2%w/w), 
Tetrahydrofurfuryl Salicylate (14%w/w)] was rubbed on the ear lobe of each patient 
ten minutes prior to the procedure. A stab was made with the point of a lancet 
(2x1.5mm) in the fleshy part of the ear lobe. We collected the blood in a heparinised 
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capillary tube held horizontally against the puncture site. The blood gas analysis was 
analysed immediately (i-STAT® handheld system). Gases were measured while 
breathing room air with the patient at rest and in sitting at least 10 min before 
extraction.  
 
10.3.3  Statistical analysis. 
 
Variables are expressed as Mean (Standard Deviation) when distribution was normal 
and Median (Interquartile range) for non-parametric data. A global test for repeated 
measures (ANNOVA) has been used to measure change over time and paired t-test to 
make within group comparisons. A significant result was inferred when p≤ 0.05. 
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10.4 Results  
 
Stable state bronchiectasis 
 
Normal ranges of each of the systemic markers of inflammation along with median 
measurement values (interquartile range) for the study population in stable state is 
summarised in Table 10.1.  
Table 10.1: Systemic markers of inflammation in stable state bronchiectasis.  
    Values are median (Inter quartile range). 
 
Bronchiectasis 
patients Reference ranges 
Number of 
patients 
CRP mg.L-1 3(2) 0-10 53 
Total white cell count 
x109.L-1 6.20(5.4) 4-11 54 
ESR mm.h-1 14(6) 1-15 49 
Albumin 39(37) 30 to 50 55 
PaO2  kPa 10.8(9.9) 9.3-13.3 45 
PaCO2  kPa 4.5(4.1) 4.7-6.0 45 
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In stable state, correlation between all measured markers of inflammation and 
spirometric indices FEV1 % predicted and FVC % predicted was sought. Only partial 
pressure of Oxygen while breathing room air was significantly correlated to FEV1 % 
predicted (p=0.023) and FVC % predicted (p=0.000). Table 10.2 lists the Pearson’s 
correlation coefficient for each of these comparisons. 
 
 
Table 10.2: Pearson’s correlation coefficients between lung function measures and 
systemic markers of inflammation of patients with stable state bronchiectasis.  
 FEV1 % predicted FVC % predicted 
CRP (mg/L) -0.017 0.080 
ESR (mm/hour) 0.001 0.257 
WCC (x109/L) 0.044 0.060              
PaO2  (kPa) 0.339** 0.371**            
PaCO2 (kPa) -0.108 -0.140 
 
FEV1: forced expiratory volume in one second; FVC: forced vital capacity; ** p<0.01. 
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10.4.1  C-reactive protein 
 
The CRP increased significantly between baseline and Day 1 (p= 0.025). This trend 
was reversed by the end of treatment at Day 14 (Baseline ѵ Day 14 p= 0.584, n=20).                                           
The CRP varied significantly during the course of an exacerbation (n= 20, p=0.008). 
Table 10.3 lists the median (interquartile range) values of CRP at all visits during the 
study. Figure 10.1 is a box plot demonstrating change in the median CRP levels during 
the course of an exacerbation. 
Table 10.3: CRP levels during the course of an exacerbation of bronchiectasis.  
Values are Median (inter quartile range). All values are expressed as mg.L-1. 
 
Baseline Day 1 Day 7 
Day 14 
 
Day 42 
Number of 
patients 21 21 20 21 17 
Median 3.00 9.00 3.50 3.00 3.00 
IQR 2.00 16.00 4.50 3.00 9.50 
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Figure 10.1:  Box plot demonstrating change in median (IQR) C-reactive protein levels 
during the course of an exacerbation. Variables on the x-axis are the time points during 
the exacerbation when CRP was measured i.e. baseline, Day 1, 7 and 14 during the 
exacerbation and Day 42 on recovery from the exacerbation. Variable on the y-axis is 
CRP levels in mg/L. Extreme outliers are marked with an asterisk. There was a 
statistically significant change over time, p=0.008. 
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10.4.2  Erythrocyte sedimentation rate 
 
There was a significant increase in the ESR between baseline and Day 1 (p= 0.017, 
n=14). This trend was reversed at the end of treatment at Day 14 (n=11, p=0.08). 
However there was no significant change in the ESR during the course of an 
exacerbation (p=0.227). Table 10.4 lists the median (interquartile range) values of ESR 
at all visits during the study. Figure 10.2 is a box plot demonstrating change in the 
median ESR levels during the course of an exacerbation. 
Table 10.4: ESR during the course of an exacerbation of bronchiectasis.  
Values are Median (inter-quartile range). All values are expressed as mm/hour. 
 
Baseline Day 1 Day 7 Day 14 Day 42 
Number 16 18 19 17 14 
Median 13.5 17 16 13 15 
IQR 10 18.5 24 16 22.2 
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Figure 10.2:  Box plot demonstrating change in median (IQR) ESR levels during the 
course of an exacerbation. Variables on the x-axis are the time points during the 
exacerbation when ESR was measured i.e. baseline, Day 1, 7 and 14 during the 
exacerbation and Day 42 on recovery from the exacerbation. Variable on the y-axis is 
ESR levels in mm/hr. Extreme outliers are marked with an asterisk. There was no 
significant change over time, p=0.227. 
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10.4.3 Serum albumin 
 
There was a significant fall in serum albumin levels between baseline and Day 1 
(n=21, p=0.026). This fall was sustained and did not recover even by Day 42, recovery 
from the exacerbation (p=0.022). The Body mass index (BMI) and serum albumin 
levels were not significantly correlated (p=0.07). The serum albumin levels did not 
correlate significantly with number of exacerbations that patients had suffered in the 
preceding year (r=0.18). Table 10.5 lists the median (interquartile range) values of 
serum albumin at all visits during the study. Figure 10.3 is a box plot demonstrating 
change in the median serum albumin levels during the course of an exacerbation. 
 
Table 10.5: Serum albumin levels during the course of an exacerbation of 
bronchiectasis. Values are median (inter quartile range) in g/L. 
 Baseline Day 1 Day 7 Day 14 Day 42 
Median 41 38 37 37.5 37 
Inter quartile 
range (IQR) 4.0 5.2 3.7 5 3 
Number 21 22 20 22 19 
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Figure 10.3: Box plot demonstrating change in median (IQR) serum albumin levels 
during the course of an exacerbation. Variables on the x-axis are the time points during 
the exacerbation when serum albumin was measured i.e. baseline, Day 1, 7 and 14 
during the exacerbation and Day 42 on recovery from the exacerbation. Variable on the 
y-axis are serum albumin levels in mg/L. Extreme outliers are marked with an asterisk. 
There was significant change in serum albumin levels during the course of an 
exacerbation, p=0.022. 
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10.4.4 Total White cell count 
 
The white cell count was higher at the onset of the exacerbation but this was not 
statistically significant (n= 20, p= 0.533). The white cell count did not vary 
significantly during the course of an exacerbation (n=15, p=0.845). Table 10.6 lists the 
median (interquartile range) values of total white cell counts at all visits during the 
study. Figure 10.4 is a box plot demonstrating change in the median total white cell 
counts during the course of an exacerbation. 
 
Table 10.6: Total white cell counts during the course of an exacerbation of 
bronchiectasis. Values are Median (inter quartile range). All values are expressed        
as x109.L-1. 
 Baseline Day 1 Day 7 Day 14 Day 42 
Median 5.8 6.7 6.3 6.3 6.0 
Inter quartile 
range (IQR) 1.95 3.30 3.25 2.75 1.90 
Number 21 21 21 22 17 
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Figure 10.4: Box plot demonstrating change in Median (IQR) total white cell counts 
during the course of an exacerbation. Variables on the x-axis are the time points during 
the exacerbation when total white cell counts in blood were measured i.e. baseline, 
Day 1, 7 and 14 during the exacerbation and Day 42 on recovery from the 
exacerbation. Variable on the y-axis are total white cell counts (x109). Extreme outliers 
are marked with an asterisk. There was no significant change in total white cell counts 
during the course of an exacerbation, p=0.845. 
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10.4.5  Capillary blood gas 
 
10.4.5.1 PaO2 - Partial pressure of Oxygen in capillary blood 
 
The PaO2 did not vary significantly between baseline and Day 1 (p= 0.158, n=16) or 
during the course of an exacerbation (p=0.229). However there was a trend with the 
PaO2 falling from baseline to Day 1 but recovered by Day 7. Table 10.7 lists the mean 
(SD) values of PaO2 at all visits during the study. Figure 10.5 is an interval plot 
demonstrating change in the mean PaO2 during the course of an exacerbation. 
 
Table 10.7: Capillary blood PaO2 levels during the course of an exacerbation of 
bronchiectasis. Values are mean (Standard deviation) in kPa. 
 
 
Baseline Day 1 Day 7 Day 14 Day 42 
Mean PaO2 10.8 10.3 11.5 11.4 12.2 
Standard 
Deviation 2.657184 3.272743 3.206107 2.05669 2.815402 
Number 16 22 19 20 19 
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Figure 10.5: Interval plot demonstrating change in mean (95% CI) PaO2 during the 
course of an exacerbation. Variables on the x-axis are the time points during the 
exacerbation when PaO2 in capillary blood was measured i.e. baseline, Day 1, 7 and 14 
during the exacerbation and Day 42 on recovery from the exacerbation. Variable on the 
y-axis is PaO2 in kPa. Extreme outliers are marked with an asterisk. There was no 
significant change in PaO2 during the course of an exacerbation, p=0.288. 
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10.4.5.2 PaCO2 - Partial pressure of Carbon dioxide in capillary blood 
 
The PaCO2 did not vary significantly between baseline and Day 1 (p= 0.754, n=16) or 
during the course of an exacerbation (p=0.288).  
 
 
Table 10.8: Capillary blood PaCO2 levels during the course of an exacerbation of 
bronchiectasis. Values are Mean (Standard deviation) in kPa. 
 
 
Baseline Day 1 Day 7 Day 14 Day 42 
Number 16 21 20 20 19 
Mean PaCO2 
kPa 4.7 4.6 5.8 4.8 4.6 
Standard 
Deviation 0.614783 0.67637 4.018693 0.475616 0.452414 
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Figure 10.6: Interval plot demonstrating change in mean (95% CI) PaCO2 during the 
course of an exacerbation. Variables on the x-axis are the time points during the 
exacerbation when PaCO2 in capillary blood was measured i.e. baseline, Day 1, 7 and 
14 during the exacerbation and Day 42 on recovery from the exacerbation. Variable on 
the y-axis is PaCO2 in kPa. There was no significant change in PaCO2 during the 
course of an exacerbation, p=0.229. 
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10.5 Discussion 
 
We hypothesised that markers of inflammation within serum increase during an 
exacerbation and may be used as biomarkers of disease. There are currently no 
validated markers in bronchiectasis to assess response to treatment [80, 98]. 
CRP has previously been shown to be high at the onset of an exacerbation and 
reversing on treatment within 14 days [80, 83]. This fall on treatment was very 
significant (9 fold) [80]. The median CRP at the onset of exacerbation in our cohort 
was 9mg/L which is lower than that reported by Murray et al of 67mg/L [80]. However 
patients in Murray et al cohort had failed a course of oral antibiotics and were likely to 
be a sicker cohort. Most other reports have studied patients requiring hospital 
admission whilst ours was a purely outpatient study. Our patients may have had milder 
disease as we have identified a bias in recruitment. Sixteen per cent of patients in our 
study showed no improvement in CRP  after treatment as compared to 9% of patients 
in other reports [80]. The purpose of our study was to validate the change in CRP 
during an exacerbation and we were able to do this. The CRP increased significantly 
between baseline and the onset of an exacerbation. This trend was reversed on 
treatment with antibiotics. The CRP also does not correlate to lung function parameters 
[181] . We were able to confirm this in our cohort (r= 0.125 and p=0.437). 
The mean ESR in our cohort was 58mm/hr at the start of an exacerbation and this is 
comparable to other reports of 40mm/hr [80]. The ESR increased significantly at the 
onset of the exacerbation and reversed on treatment. Fifty three per cent of patients had 
improved their ESR by Day 7 of treatment and this rose significantly to 86% of 
patients by Day 14. We were unable to show a significant correlation between ESR and 
spirometric indices. 
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Serum albumin levels have not previously been assessed in the setting of an acute 
exacerbation of bronchiectasis. We were able to demonstrate a significant fall in serum 
albumin levels at the onset of an exacerbation. However treatment did not reverse this 
effect. Recovery from exacerbation is thought to occur by 4 weeks. The serum albumin 
levels had not yet recovered at this time. Serum albumin levels may reflect local 
inflammation in lungs and it is possible that this inflammation takes longer to recover 
to normal levels. While elevated markers of inflammation are reduced on treatment 
with antibiotics they are clearly inadequate in dealing with persistent airway 
inflammation [181, 248, 249]. Presence of elevated systemic markers of inflammation 
is independent of the presence of infected sputum [181]. 
The mean total white cell count was 6.7(x109/L) in our study. This is lower than other 
reports of 10.8±7.1(x109/L). The white cell count is above normal limits in only 0.03% 
of patients in stable state. [80]. We found that all our patients had a total WCC within 
normal limits at baseline. Other workers have also acknowledged the change in WCC 
to be marginal although significant [80]. We confirm this in our study. While noting a 
trend of increased WCC at the start of an exacerbation and a fall on treatment we were 
unable to prove statistical significance. The WCC has also been shown to be 
significantly correlated to lung function parameters but this was not true in our cohort 
[181]. 
The PaO2 was within normal limits for 80% and PaCO2 was within normal limits in all 
our patients. This is comparable to other reports wherein the PaO2 was below normal 
limits in 15% of patients while the PaCO2 was above normal limits in 0.02% of 
patients while in stable state [181]. Again the mean PaO2 in our cohort is comparable 
to other reports of 10±6 kPa [181]. The PaO2 and PaCO2 in our study did not vary 
significantly during the course of the exacerbation.  
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In steady state patients colonized by Pseudomonas have significantly lower PaO2 than 
patients not colonized [109]. There was no significant difference in our cohort between 
patients carrying Pseudomonas and those that were not (p=0.617). Perhaps the number 
of patients in our study was too small to make this comparison. 
CRP and ESR are robust markers of inflammation in blood and can be used as 
biomarkers in therapeutic trials. Serum albumin, WCC, PaO2 and PaCO2 are not useful 
parameters to predict the onset of an exacerbation or thereafter measure response to 
treatment. 
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Chapter 11 
 
Cytokines in sputa and sera of patients with bronchiectasis in the COBEX 
study 
 
 
11.1 Introduction 
 
 
The pathogenesis of bronchiectasis remains poorly understood. Three distinct 
pathogenic elements, namely infection, inflammation and enzymatic actions, interact 
with each other and have been implicated in the pathophysiology of bronchiectasis . 
When exposed to bacterial endotoxin, bronchial epithelial cells release inflammatory 
mediators  Some of these mediators are proinflammatory and others anti-inflammatory. 
Among the proinflammatory mediators involved, IL-8, IL-1β, and TNF-α play a role 
favouring the trafficking of activated neutrophils through the bronchial wall into the 
bronchial lumen. The anti-inflammatory mediators IL-6 and IL-10 act as a counterpart 
of proinflammatory mediators by promoting the synthesis of natural antagonists  IL-1β 
and TNF-α  [127]. Intense neutrophil infiltration into the tracheo-bronchial tree occurs 
as a result which further aggravates the release of inflammatory mediators. Human 
airway epithelial cells also produce   ET-1, which promotes neutrophil adhesion to 
endothelial cells [166]. 
Airway inflammatory response triggered by bacterial stimulation may be excessive in 
relation to the bacterial burden indicating. It continues to reverberate even after the 
infection is controlled. The altered homeostasis of airway inflammatory response to 
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bacterial infection in the dynamic process of host–pathogen interaction dictates the 
clinical manifestations of the lung disease [166, 167]. 
 Finally neutrophil toxic products impair the structure and functioning of the airway 
mucosa by digesting airway elastin, basement membrane collagen and proteoglycan, 
contributing in this way to the progression of the disease. 
 
11.2  Tumour necrosis factor (TNF α) and Interferon γ (IF γ) in bronchiectasis. 
 
TNF-α is a proinflammatory cytokine synthesized and secreted by monocytes and 
macrophages. It has a range of properties, such as chemo attraction of neutrophils at 
the site of inflammation and up regulation of the expression of other chemokines with 
a function similar to that of IL-8.It is generally accepted that TNF-α is an essential 
mediator in the inflammatory cascade of a range of lung diseases and that it is able to 
serve as a marker of progression or prognosis in certain diseases such as pneumonia 
and cystic fibrosis [258, 271-274]. In steady state bronchiectasis, sputum neutrophil 
elastase levels correlate with the per centage of neutrophils, TNF-α  and 24-h sputum 
volume that is a marker of disease activity [166, 169]. Neutrophilic infiltration into 
bronchiectatic airways is also mediated by tumour necrosis factor –α [6, 172]. This 
causes release of toxic products such as neutrophil elastase (NE), metalloproteases and 
reactive oxygen species. Because of the large number of neutrophils present, lung 
defences are overwhelmed [2, 172, 173]. Patients with more advanced disease have 
more inflammation within the airway. Levels of TNF-α are higher in broncho-alveolar 
lavage fluid of these patients [127]. 
IFN-γ is a cytokine that is critical for innate and adaptive immunity against viral and 
intracellular bacterial infections. Aberrant IFN-γ expression is associated with a 
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number of auto inflammatory diseases. The importance of IFN-γ in the immune system 
stems in part from its ability to inhibit viral replication directly and most importantly 
from its immunostimulatory and immunomodulatory effects. IFN-γ is produced 
predominantly by natural killer (NK) and natural killer T (NKT) cells as part of the 
innate immune response, and by cytotoxic T lymphocyte cells once antigen-specific 
immunity develops. Non-typable Haemophilus influenzae is a major cause of 
respiratory tract infection especially in chronic obstructive pulmonary disease and 
bronchiectasis. The primary factor that determines whether clinical disease occurs or 
not is the nature of the lymphocyte response. When challenged with non-typable H. 
influenzae patients with bronchiectasis put out lower levels of IF γ levels, suggesting 
that CTL and NK cell responses are important in preventing disease from non-typable 
H. influenzae infection [275]. Interferon-gamma “trafficking" is also thought to play a 
central role in non-tuberculous mycobacterial infection associated with bronchiectasis 
[276]. 
 
11.3 IL-1β, IL-6, IL-8, IL-10, IL-17 and bronchiectasis 
 
Interleukin-1β (IL-1β) is a cytokine produced by activated macrophages as a 
proprotein, and is an important mediator of the inflammatory response involved in a 
variety of cellular activities, including cell proliferation, differentiation, and apoptosis.  
 
Interleukin-6 (IL-6) is an interleukin that acts as both a pro-inflammatory and anti-
inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune 
response to inflammation. In terms of host response to a foreign pathogen, IL-6 has 
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been shown, in mice, to be required for resistance against Streptococcus pneumoniae 
[277]. 
Interleukin-8 (IL-8) is a cytokine produced by macrophages and other cell types such 
as epithelial cells. Its primary function is the induction of chemotaxis in its target cells 
(e.g. neutrophil granulocytes). 
Interleukin-10 (IL-10) is an anti-inflammatory cytokine. It is produced primarily by 
monocytes and to a lesser extent by lymphocytes. This cytokine has pleiotropic effects 
in immunoregulation and inflammation. It enhances B cell survival, proliferation, and 
antibody production. It is capable of inhibiting synthesis of pro-inflammatory 
cytokines like IFN-γ, IL-2, IL-3, TNFα and GM-CSF made by cells such as 
macrophages and regulatory T-cells. IL-10 also displays potent abilities to suppress the 
antigen presentation capacity of antigen presenting cells. 
Interleukin 17 (IL-17) is a cytokine that acts as a potent mediator in delayed – type 
reactions by increasing cytokine production in various tissues to recruit monocytes and 
neutrophils to the site of inflammation, similar to Interferon gamma. IL- 17 is 
produced by T helper cells. IL-17 functions as a proinflammatory cytokine that 
responds to the invasion of the immune system by extracellular pathogens and induces 
destruction of the pathogen’s cellular matrix. IL-17 acts synergistically with tumour 
necrosis factor α and Interleukin-1. 
Neutrophilic infiltration into bronchiectatic airways is mediated by various agents  
such as host complement factor 5a (C5a), leukotriene B4 (LTB4), IL-8 and IL1, tumour 
necrosis factor –α and leukotriene (LT) B4 [6, 172]. These cause release of toxic 
products such as neutrophil elastase (NE), metalloproteases and reactive oxygen 
species. Because of the large number of neutrophils present, lung defences are 
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overwhelmed [2, 172, 173]. Activated neutrophils do not differentiate between bacteria 
and bystander lung tissue. While individual cytokines have different actions, there may 
well be an overlap in function. IL-8 is one of the most potent chemoattractants which 
also degranulates neutrophils in bronchiectatic airways [71].  TNF-α  and IL-1  have 
been shown to induce the breakdown of tight junctions in the blood/brain barrier in 
vivo [174]. A combination of anti-TNF and anti-IL-1 antibodies completely neutralized 
cell separation in the vascular endothelium that is induced by Streptococcus 
pneumoniae [175]. 
Exacerbations are associated with elevated inflammation in the form of augmented 
cytokine expression, cellular infiltrate, adhesion molecule expression, loss of lung 
function and symptomatic deterioration [177]. in exacerbations of (COPD), the 
systemic inflammatory response is proportional to that occurring in the lower airways 
and greater in the presence of a bacterial pathogen. In particular serum IL-6 is 
correlated significantly to sputum IL-8 [179]. This has not previously been studied 
formally in bronchiectasis. Most studies have evaluated these mediators in stable state 
disease. Investigating these biomarkers has the potential to yield information about 
underlying mechanisms of disease and aid development of therapeutic strategies      
[71, 81]. 
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11.4 Aims 
 
 
We wished to investigate the interrelationship between concentrations of serum and 
sputum inflammatory markers in steady state bronchiectasis. 
The following markers were studied: IFN-γ, TNF-α IL-6, IL-8, IL-10, IL-17 and IL-1β. 
We hypothesised that the inflammatory burden would increase at exacerbation and 
wished to follow the inflammatory markers longitudinally through the exacerbation.  
 
 
11.5 Methods 
 
Serum and sputum samples were collected at the same time during the visit. Not all 
patients were able to provide sputa at the time of their study visit. When provided, 
samples were not always adequate for microbiological and cytokine analysis. Samples 
analysis is described in Appendix iv.  
Supernatant cytokine was analyzed with the Bioplex Protein Array system using beads 
specific for IFN-γ, TNF-α IL-6, IL-8, IL-10, IL-17 and IL-1β according to the 
manufacturer’s instructions. The detection limit for IL1B, 6, 8, 10, 17 and TNF-α was 
1pg/ml. This was kindly done for us by Mrs Karen Brown at the Immunology 
Department laboratory at Papworth Hospital. 
The limits of detection were 0.7pg/ml (IL-6), 10pg/ml (IL-8), 3.9 pg/ml IL-Iβ, and         
15.7 pg/ml TNF-α. 
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11.6 Statistical analysis 
 
Normally distributed data is presented as mean ± standard deviation, whilst non-
parametric data were expressed as median and inter quartile ranges. Normally 
distributed continuous variables were compared by t test; otherwise the differences 
were assessed by the Mann-Whitney U test. Variance was measured using ANOVAs 
and general linear model. Correlation was analysed using Spearman’s Rho. Analysis 
was performed using SPSS and Minitab 15 software. Significance was assumed if 
p<0.05. 
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11.7 Results  
 
Stable state bronchiectasis 
 
Thirty six patients had sputa analysed while only 30 patients had simultaneous serum 
samples analysed in stable state.  
We investigated the interrelationship between serum inflammatory markers using 
Spearman rank correlations, corrected for multiple comparisons. This resulted in a 
matrix of 135 correlations. 
Sputum IL-1β was significantly correlated to the ESR (r= 0.525, p=0.004) and CRP 
(r=0.680, p=0.000). We were unable to obtain any other significant relationship 
between sputum and serum inflammatory markers.  
There was a significant interrelationship between many serum inflammatory markers. 
TNF-α was significantly correlated to serum IL-8 (r=0.375, p=0.045), IL-6 (r=0.946, 
p=0.000) and IL-1β (r=0.366, p=0.047).  
Serum IL-8 was also significantly correlated to IL-6 (r=0.506, p=0.005) and               
IL-17 (r=0.605, p=0.001). 
Serum IFN-γ was significantly correlated to serum IL-17 (r=0.725, p=0.000) 
There was a significant interrelationship between many sputum inflammatory markers. 
Sputum IL-8 was significantly correlated to sputum TNF-α (r=0.339, p=0.043), IL-10 
(r=0.471, p=0.004) and IL-1β (r=0.432, p=0.009) 
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Sputum TNF-α was significantly correlated to sputum IL-6 (r=0.479, p=0.003),         
IL-10 (r=0.473, p=0.004), and IL-1β (r=0.457, p=0.005). 
Sputum IL-6 and IL-10 were significantly correlated (r=0.346, p=0.039). 
In particular EBC pH did not significantly correlate to any marker of inflammation. 
Sputum IL-10 was significantly correlated to PaO2 at room air (r=0.388, p=0.042). 
 
Acute exacerbation of bronchiectasis 
 
Twenty-two of these patients were screened at the time of an acute exacerbation. No 
significant change was noted in any of the inflammatory markers in serum globally 
during the exacerbation. 
Table 11.1 summarises the change in soluble markers of inflammation in serum during 
the course of the exacerbation - IFN-γ; TNF-α; IL-6; IL-8; IL-10; IL-17; IL-1β. 
TNF-α, IL-8 and IL-1β levels in sputum significantly changed during the course of the 
exacerbation. Levels of these markers increased at Day 1 and fell to normal levels only 
by Day 14 on completion of treatment. 
Table 11.2 summarises the change in markers of inflammation in sputum during the 
course of the exacerbation - IFN-γ; TNF-α; IL-6; IL-8; IL-10; IL-17; IL-1β. 
There was no significant correlation between markers of inflammation is serum and 
sputum either in stable state or during the exacerbation. Table 11.3 lists the Spearman’s 
correlation coefficient and significance levels for each of the measured inflammatory 
markers in serum and sputum. 
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Table 11.1: Changes in median (IQR) levels of cytokines in serum during an 
exacerbation of bronchiectasis. Bioplex (pg/ml). 
 
Cytokine 
 
 
Baseline 
 
Day 1 
 
Day 7 
 
Day 14 
 
Day 42 p value 
 Median (Interquartile range)  
Number of 
patients 
11 20 20 20 19  
Interferon-
γ 
1(7) 2(8.75) 2(2) 1(3.25) 2(9) 0.992 
       
Number of 
patients 11 20 20 20 19 
 
TNF-α 7(1) 8[261] 8(1) 7(1.75) 8(2) 0.668 
       
Number of 
patients 11 20 20 20 19 
 
IL-1β 1(0) 1(0.75) 1(0) 1(0) 1(0) NA 
       
Number of 
patients 11 20 20 20 19 
 
IL-6 3(9) 7(18.25) 4(4.75) 3(4) 4(4) 0.181 
       
Number of 
patients 
10 20 20 20 19  
IL-8 12(11.5) 15(20.2) 15(14.2) 10(7.2) 12(2) 0.067 
       
Number of 
patients 
11 20 20 20 19  
IL-10 5[261] 5.5(12.5) 5(3.75) 5(2) 5(4) 0.184 
       
Number of 
patients 
11 20 20 20 18  
IL-17 1(4) 2(3.75) 1.5(3.5) 1(4.25) 1(6.75) 0.989 
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Table 11.2: Change in median levels of cytokines in sputum during the course of an 
exacerbation. [Bioplex (pg/ml)]. NA- not applicable 
 
 
Cytokine 
 
 
Baseline 
 
Day 1 
 
Day 7 
 
Day 14 
 
Day 42 
p 
value 
 Median (Interquartile range)  
Number of 
patients 17 20 18 19 15  
Interferon-
γ 
1(0) 1(0) 1(0) 1(0) 1(0) NA 
       
Number of 
patients 17 20 18 19 15 
 
TNF-α 8(20) 23(93.8) 4.5(16.75) 2(9) 6(30) 0.004 
       
Number of 
patients 17 20 18 19 15 
 
IL-1β 8(23.5) 44(134) 11(25) 6(22) 12(46) 0.030 
       
Number of 
patients 17 20 18 19 15 
 
IL-6 47(279) 181(308) 97(168) 114(138) 88(237) 0.649 
       
Number of 
patients 
17 20 18 19 15  
IL-8 10814 
(9902) 
16319 
(15888) 
12714 
(16110) 
6590 
(13480) 
16400 
(14393) 
0.040 
       
Number of 
patients 
17 20 18 19 15  
IL-10 1(1.5) 1(9.8) 1(0) 1(0) 1(0) 0.472 
       
Number of 
patients 
17 20 18 18 15  
IL-17 1(0) 1(0) 1(0) 1(0) 1(0) NA 
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Table 11.3: Pearson’s correlation coefficient and significance levels for sputum and 
serum cytokines. 
 
Cytokine 
 
Baseline Day 1 Day 7 Day 14 Day 42 
Interferon-γ      
Correlation 
coefficient ‘r’ * -0.091 * * * 
p value * 0.704 * * * 
      
TNF-α      
Correlation 
coefficient ‘r’ 0.498 0.042 0.474 0.450 0.240 
p value 0.143 0.862 0.047 0.053 0.390 
      
IL-1B      
Correlation 
coefficient ‘r’ -0.157 -0.013 -0.042 0.257 * 
p value 0.664 0.958 0.869 0.288 * 
      
IL-6      
Correlation 
coefficient ‘r’ 0.185 -0.164 -0.291 0.045 -0.177 
p value 0.610 0.490 0.242 0.855 0.529 
      
IL-8      
Correlation 
coefficient ‘r’ 0.286 0.068 0.229 -0.097 -0.238 
p value 0.456 0.776 0.362 0.692 0.393 
 
     
IL-10      
Correlation 
coefficient ‘r’ -0.121 -0.029 -0.227 -0.038 -0.087 
p value 0.740 0.902 0.366 0.877 0.758 
      
IL-17      
Correlation 
coefficient ‘r’ * -0.051 -0.078 -0.147 * 
p value * 0.830 0.757 0.562 * 
*Values identical (not detectable <1pg/ml) and Pearson’s correlation co-efficient not 
valid 
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11.8 Discussion 
 
Patients with bronchiectasis show a minimal systemic inflammatory response, with 
poor correlations between systemic and bronchial inflammatory mediators. This 
suggests that the inflammatory process is mostly compartmentalized [127]. Our study 
was able to confirm this. We studied 7 inflammatory markers in sputa and serum. Only         
sputum IL-1β was significantly correlated to CRP and ESR. We found no correlation 
between any of the other measured individual markers in sputum and serum. In COPD 
the systemic inflammatory response is proportional to that occurring in the lower 
airways. In particular serum IL8 is significantly correlated to sputum IL-8 [179]. 
Although there is similar neutrophilic inflammation in bronchiectasis, we were unable 
to find a significant correlation between serum and sputum IL-8; r= 0.133 and                 
p = 0.577. Also at the onset of an exacerbation in COPD Serum IL-6 has been shown 
to be significantly correlated to CRP [179]. We did not find this to be true in our cohort 
(r=0.072, p=0.720).  
The pro and anti-inflammatory mediators showed a significant correlation within 
compartments. The IL-6 and IL-10 were significantly correlated as would be expected. 
The TNF-α, IL-1β and IL-8 were significantly correlated to each other. 
Serum levels of most inflammatory markers other than IL-8 remained low at all times. 
This is in keeping with other reports [178]. During the exacerbation we found no 
significant change in any of the measured inflammatory markers. 
Most importantly, all the 7 measured markers of inflammation in sputa - IFN-γ, TNF-α 
IL-6, IL-8, IL-10, IL-17 and IL-1β increased from baseline to Day 1 and fell on 
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treatment. However only TNF-α, IL-8, and IL-1β changed significantly during the 
course of the exacerbation.  
We had also hypothesised that exhaled breath condensate pH may worsen during an 
exacerbation and may be correlated to markers of inflammation. We were unable to 
find a significant correlation between exhaled breath condensate pH and either sputum 
or serum inflammatory markers. 
Inflammation in the airways that is exaggerated by the presence of PPM, and the 
higher the bacterial load the more intense the inflammation [127]. The number of 
patients in our study was unfortunately too small to detect change in levels between 
patients colonised with PPMs and those without and to compare markers to the total 
bacterial load. 
Sputum TNF-α, IL-8, and IL-1β are important mediators of inflammation and change 
significantly during the course of an exacerbation. We would recommend their use as 
biomarkers in future therapeutic trials. 
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Chapter 12 
 
Summary and Discussion for future work 
 
12.1 Summary 
 
This study was designed to allow identification of the key outcome measures in acute 
exacerbations and provide critical endpoint data for the powering future interventional 
studies.  
Symptoms of cough, breathlessness, chest pain, chest discomfort, volume of sputum, 
colour of sputum and fatigue when measured on a visual analogue scale vary 
significantly during the course of an exacerbation. A simple Modified Borgs’ 
breathlessness score was equally effective in predicting change at this time. Either or 
both these would be effective tools in any therapeutic trial 
HR-QoL as measured by the Euroqol questionnaire is useful in predicting the onset of 
an exacerbation and improvement from thereof. It is time consuming but will be a very 
useful marker in any interventional study. 
In steady state bronchiectasis Impulse Oscillometry is at least as effective as 
conventional spirometry and is likely to cause less distress to the patient. Forced vital 
capacity actual is the only spirometric index likely to be of use in the trail setting. 
Sputum appearance alone changes significantly from mucoid or mucopurulent to 
purulent at the onset of an exacerbation. Identification of a new PPM is common and 
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can predict the onset of an exacerbation. Microbial clearance in sputum occurs on 
appropriate treatment.  
 C-reactive protein has once again proven itself to be a useful marker of disease. It 
remains an essential tool in any therapeutic challenge. ESR and serum albumin can 
predict the onset of an exacerbation but are not of use in assessing improvement. 
Sputum levels of TNF-α, IL-8 and IL-1β are effective indicators and can be 
recommended for use as end points in therapeutic interventional trials. 
 
12.2 Discussion for future work 
 
Several studies have investigated markers of inflammation in the blood as indicators of 
the intensity of the host response to pulmonary infections and have used them to 
evaluate the efficacy of antibiotic treatment in suppurative lung disease [246, 249, 265, 
278, 279]. These markers are shown to correlate to disease severity. Other studies have 
assessed response of clinical parameters to treatment with antibiotics [80, 83].  
However there remains paucity in the literature of studies validating end points prior to 
engaging in a trial of therapy.  
It would be prudent to start by defining the clinical state that needs investigation. 
Currently stable state bronchiectasis, which would be the baseline for all valedictory 
studies, remains poorly defined. Some authors use a six week infection free period as a 
definition [181] while others prefer non specific descriptions such as “ less than 20% 
volume change in sputum in the last 24 hours with lack of decline in lung volumes and 
clinical parameters” [71]. Some fail to specify criteria altogether [27]. We have used a 
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4 week infection free period as stable state within this study. A similar ambiguity 
exists in defining an exacerbation of bronchiectasis. As previously described in 
Chapter 1 there is no standard definition to proceed on. A consensus must be reached 
on defining the clinical state, so trialling therapy does not fall prey to confounding 
factors. 
Simple bedside evaluations of symptoms in our study have provided very significant 
results. Most studies so far have used either spirometric indices or more complicated 
inflammatory markers in blood to assess disease and change therein. Perhaps looking 
out for simpler techniques may continue to give us adequate answers in the future. We 
would recommend that the visual analogue score for clinical symptoms as described in 
Chapter 3 and a modified Borg’s breathlessness score be used in all future studies 
looking at therapeutic interventions. 
No validated HR-QoL questionnaire is currently available for exacerbations of 
bronchiectasis. It is assumed that a questionnaire validated for stable state disease 
would be useful in exacerbations. Various questionnaires have been employed in 
therapeutic trials. These include the chronic respiratory disease questionnaire [83]. 
and the St Georges respiratory questionnaire [80] A formal validation of a HR-QoL in 
exacerbations of bronchiectasis is desirable. 
In Chapter 6, we were surprised to find that FEV1 and FEV1 % predicted were 
unchanged at the time of an exacerbation. Only FVC absolute was affected by the 
exacerbation. We feel that the small number of patients in our study might have 
hindered a more meaningful response. We would like to see a larger study in a similar 
fashion prior to accepting this result finally.  
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Impulse Oscillometry is new on the horizon and is not widely used as yet. Clearly the 
first step would be to promote familiarity with the test itself. We have shown that it 
significantly correlates to spirometric indices in stable disease. We have not validated 
this formally in the exacerbation cohort. But as patient comfort is very important, use 
of IOS frequently in the research setting is to be encouraged. 
Exhaled breath condensate pH failed to prove useful in our hands. However having 
demonstrated a difference between the study cohort and healthy individuals, it 
continues to hold promise. Our methodology may have been inadequate and  numbers 
small, we would therefore like to see a similar study with a larger population. We also 
await further analysis of the stored condensate in the hope that it may yield a 
thumbprint for bronchiectasis. 
Microbial prevalence and clearance is central to bronchiectasis [17, 80]. However most 
descriptions are of bacterial disease and within this group of potentially pathogenic 
micro-organisms. There is very limited mention of commensals or upper respiratory 
tract flora. It is uncertain if this would add to the bacterial load quantitatively and 
hence to pathogenesis. The microbial balance within the lung milieu is unexplained. 
Also there is very little evidence of viral infections in bronchiectasis. Significant 
morbidity has previously been described when patients with bronchiectasis are exposed 
to Rhinovirus, Corona virus and Respiratory syncytial virus infections. Transmission 
from close contacts is well documented. Respiratory tract symptoms following 
exposure to the virus is comparatively severe in these patients [280]. 
The epithelium of the respiratory tract forms a large surface area that maintains 
intimate contact with the environment. In response to these challenges many strategies 
have evolved to protect the host. These include the barrier functions of the epithelium, 
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cough, mucociliary clearance, resident professional phagocytes, and the secretion of a 
number of proteins and peptides with host defence functions. The surface and sub 
mucosal gland epithelium of the conducting airways is a constitutive primary 
participant in innate immunity. In the near future, more research is required to better 
understand the signalling mechanisms for innate immune responses and the nature of 
any deficiencies in innate immunity associated with bronchiectasis. The capacity of 
cytokines to precisely control the movement of inflammatory cells into inflamed 
airways suggests that cytokines and their receptors might provide targets for 
therapeutic treatment to modulate airway inflammation, in order to prevent further 
deterioration in lung function and to better control symptoms [166, 281]. 
The presumed triggering events of bronchiectasis are more common than 
bronchiectasis itself. It is therefore important to understand why some individuals 
exposed to a triggering event develop permanent damage leading to bronchiectasis 
while others do not. Similarly, identification of risk factors related to disease 
progression, particularly in children, is of particular clinical importance since this can 
allow for early intervention and so minimise long-term morbidity and mortality [166]. 
Therapeutic policy at our centre includes the administration of prophylactic antibiotics. 
This may have interfered with some of our results particularly in the microbiological 
aspects of our study. Perhaps a naive population may yield different or more powerful 
results than ours. It would be sensible for future studies to set this out in the inclusion 
criteria. 
We acknowledge a bias in our study cohort. We think that the patients we have 
recruited may not be very ‘sick’ and hence our results may be underestimating the 
reality. We also note the small number of patients that were followed through the 
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exacerbation (n=22). A larger study with a mixed cohort of severe and less severe 
would be useful to validate our results. Also most studies are done on local populations 
[3, 27, 71]. However the audience remains international. It would be useful to set up a 
task force to facilitate multicentre studies. This will also ensure that efficacy is 
standard across populations. 
Finally, an effort at new strategies in the management of bronchiectasis is constantly 
on [282]. We hope to have provided important information in establishing an effective 
foundation on which therapeutic trails can be built. 
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Appendix iv 
 
Methodology of analysis of sputa 
 
Sputum samples were collected at each visit. The specimen was then divided into three 
parts – Two samples were a hundred microlitre aliquot each (Samples A&B) and the 
third was a three hundred microlitre aliquot (Sample C). 
Sample A 
A 100 micro litre aliquot of sputum was taken from the fresh sample. Three volumes of 
phosphate buffered saline were added to these aliquot. This mixture was gently mixed 
using a pipette. The sample was ultra-centrifuged at 50,000rpm for 90 min at 40C in a 
Beckman JA 25.50 fused angle rotor centrifuge (Beckman Instrument Inc., USA). The 
sol phase was removed with a pipette and stored at -800C. {Aliquots of the 
homogenized sputum were added to an equal volume of glycerol broth (20% glycerol 
in nutrient broth) and stored at –80°C for future use}.   
 
Sample B 
A further 100 micro litre aliquot was homogenised with an equal volume of 0.1% 
dithiothreitol (DTT, Pro-Lab Diagnostics, Neston, UK). This sample was vortexed for 
5-10 seconds and then stood for 30 minutes at 37oC. It was then vortexed again for 5-
10 seconds. Using a 10 micro litre loop, a direct smear of sputum was made on a glass 
slide, allowed to dry and fixed in methanol for later staining and reading. 
Ten microliters of sample B was then used to inoculate a Sabouraud agar. This was 
incubated in an atmosphere of air at 370C. This was read at 24 and 48 hours and then in 
3 days. The homogenized specimen was further diluted to 1 in 100 in sterile distilled 
water (SDW). It was then inoculated by hand onto Blood Agar, Chocolate Agar, Cled 
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medium (Cysteine Lactose Electrolyte Deficient agar) and MSA (Mannitol Salt agar) 
plates each.  
Identification of bacteria was done using standard methods including the 20NE test, 
the Oxidase test , the catalase test, tributrin test, Coagulase test, procedure for X and V 
factors, the optochin and bacitracin tests.  Four colonies of each organism identified 
were selected and each individual colony was subcultured on HBA, suspended in 
glycerol broth and stored on sterile glass beads at –80°C. Bacteriological media were 
provided by Oxoid Ltd, Basingstoke, UK and the API NE used for the identification of 
P.aeruginosa was from Biomerieux, Basingstoke, UK. 
Microorganisms with potential pathogenicity described include Pseudomonas 
aeruginosa, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella 
catarrhalis, Stenotrophomonas maltophila, Staphylococcus aureus, Achromobacter 
xylosoxidans and Coliform species.  
The homogenized specimen was further diluted 1 in 200 and 1 in 20000 in sterile 
distilled water (SDW) for quantitative studies. Twenty microlitres of each dilution was 
then inoculated by hand onto Blood agar, Chocolate agar, PCFC and MSA plates using 
a hockey stick to spread the inoculums. Blood and Chocolate Agar were incubated for 
48 hours in an atmosphere of air + 5%CO2 at 37°C and the Cled, PCFC and MSA in 
an atmosphere of air at 37degrees centigrade. These plates were read at 24 and 48 
hours.  
Total viable counts of bacteria were calculated from the growth on these plates. Results 
were expressed in colony forming units per millilitre (cfu/ml). Only pathogens with 
count ≥103cfu/ml were regarded as significant.  
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Sample C 
Three hundred microlitres of sputum was homogenised with 4 volumes of 0.1% DTT. 
The sample was gently mixed with a pipette. It was then left to stand for 15 minutes at 
37 °C. Four volumes of Phosphate buffered saline were then added to this mixture. The 
sample was gently mixed again. The mixture was filtered through 60 micrometer nylon 
gauze. The solution was then centrifuged at 1800rpm for 10 minutes in a Heraeus 
Biofuge fresco centrifuge [DJB labcare UK]. Two hundred microlitre aliquots of the 
supernatant were then aspirated. Inhibitors were added to samples before freezing at -
80°C. For Neutrophil elatase assay:  To each eppendorf a 8µl of freshly prepared 
mixture of Nα-p-Tosyl-L-lysine chloromethyl ketone hydrochloride (TLCK) which 
inhibits trypsin-like activity  and ethylene diamine tetra-acetic acid (EDTA) to inhibit 
metalloprotease activity and 3µl of z-phe-diphenlyphosphonate (inhibits chymotrypsin-
like activity) was added. For Cytokine Assay: To each eppendorf a 6µl of freshly 
prepared mixture of TLCK and EDTA (1:1 ratio by volume), 2µl z-phe-
diphenlyphosphonate and 2µl methoxysuccinylAAPV-CMK (neutrophil elastase 
inhibitor) was added.  
 
